var title_f12_40_12928="Cutaneous leishmaniasis";
var content_f12_40_12928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous leishmaniasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 245px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodular lesion with central ulceration found on the arm of a patient with cutaneous leishmaniasis. Fever is typically absent and a history of travel can usually be obtained.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12928=[""].join("\n");
var outline_f12_40_12928=null;
var title_f12_40_12929="Embedded earring with infection";
var content_f12_40_12929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Embedded earring with infection after helical piercing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4ATUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5zkTJGKrSA9xVs/L1qCcggY61zxLZVIzTO9SDvmmMccCtSRjcGmqetKxxnPWmqeaYhBycdqHGDQcZoPJwelMBq0dT7UvekIxQAgoBwaSigB/TpSqw6NwaaOR702gB5A6Dg0wg07rwfzo5U80AN5zTgxHNKNp68UMMUACvyM9aVwB7ZpnFSBlKhSOnSgBMEp7imcdxzTwNpODkelJxyMUDEAXPNOwvrQNoFGB+FAD0gLjhh+dKbWQLnH5VGMU4OQOM0XAb5T9ccUpjIp4kfBAzQCzdT0pXCwwLTjGewwKfjAyQOakVWYYAzQOxD5fc08KVIxWhb6fLLtwhwe+K1rbRYMHzZQOM88Ueoehzgj38gc1MtpK3Pltj2FdRb/2ZbIwZPMYcHsKLe+ypjhjVYA3+s25I9qnnjstSrMwYdNZ1JyAB1BpY7SPcAu5z6YrqGeCLZNJGzMGyVPAf/Corq6huTJJbWqwgHOXIGBSc11EkzDXT5mLDYBgflTG08hSZZVT0APWrb6nOYntk4DccDqPrUNrbzTTFVhZmXu38qOZtXSCy2uVUtQxYRQmUL1Y96K31W8kRTFcQQAcFBjiine//AA6DlOfnYuemMVTcnPtVmRzt6AVVYE5NRBAyMtxUZPNPJx1qFjk1qSIeTSjAIoAHWk70xA33jTT0pWpO1CAUH16UhyKDS7uMEcUAJkGgikIwKP60AAHNBHej2pxztFADTxTgexptIOKAHle46Uh+tIrHNP4bpwfSgBvB6il2jPymmmg0APIPBOcilODj1NNDHbincMg7GkMYRjrTgRRtYDpkUoUHp19KYCDGacDgdqVInJqZbY7uhpAQgk8Y/KrKRkr0wO+a0bPTpLgD7PExJ7kVppodxAP3qqPx5qW7amiiY9vp005Uqpwe54FbtnZeQmPJDt3JPSp47csAHlVO2Cc1qJAqoYxcNtI7YArNzvoVyWKElrKsW8S/Ofuqq8VWuba8kjUkNLjr83Aras7aKbhnZZEP3ic5HsK0I4ILBSu2dt3PoKFZ6sHdHKHTXMQHlovqTyTUFzHd2sWwf6l/TIrrfsombbGGiQ85JqVtMtl2l/MmccbmyeaenURyFvY3VwkapMCOoyOBW9a+Fredl+03avLgN8p4+lXzamO5VCFTf/ETgH8Kq3Gi3IDPbzPJ5ZyPLGGXNOOnwpBvuy9b2FtbSI1zHEFPyrNkkZ/pTmtLBy4Zd02T9wHn3zWA099YSbrmF5LZhu+c9/p0qWLUbi+DR2cSrgfwn7vuPSpdWa0aEoLdC32i4kDwXHlB+qmis97K+cAySNI3OcHpRRab6ILxWlzlmGeGPeo5GCgikkkLOTVeU81UUQ2MY7jTWFL3FBrQkaT6UlLikPSmAH7optPXkEUz1oATvR2oFKiF2CqMmgABweKnitZZSPLUnNdDo3h/O2S6HXnb6100FhAYygjGO2BWU60Y6G9OhKWrOJj0G6bGQBn1px0G4UEV36272qDzcyQ9Q4HK/X/GrSWqSDeMMp6Ec5rJYh9jf6tE8tn0a6jGdmfpWe8bKSGUgivXpLAHnjFZmoaHFOCGQcjqBWsaye5nLDdmeZdKD1zXQap4dmttzxAug646isFlIcgjBrW99TncXF2Y7IYfNj2NMZSPp60N/KhWIGO3pQIT0p6DMb08Ir/d4b0NWILSRkYkECgEirGW6Ak+1XYbYMMyjYOxq3a2yhgscZd/YZrTt9IuJj84UD+71rNy7GsYW3MyOMfdiH1JrVthCqxsFaSQe2R+ValvoqK484n6f/Wrb0+yER2w245/ibism/M2SXYwrNNQecRwxqu87l7AeuK1n06RuLiSSInvjk/jWk2nPMApKxuvKlR39KupBazWyl/M3rwVL9/eobRVmc9LpdmsO9bjLj9a1tNtIJotssMjy44T1qzHplvgFkPP3R6VfgsllAKSSB1+Xk8cUJ21uJxuZ80G0qIbVIZU7ucZ9q0bKdLpAJ2hjPQgDJqYQgx7JYN56ZVs5/CobizspFOVe2fv1Gaad9bkuJck0dXiDW9ywYdOgB9s1REUUm63nRRL/tMeaBb3MK7rVxNGP4d5B/Ks271ywLGC+ge3nX7pfOPwNVzvr+BPKg1AXEB2Rxxkr8yHgHils/EkfmFZY3RmxnI496q3GrWTwGOM73J4H8YP9RWSm4zrDeuqRS9wOfp7Go5k9Uw5X1NfVpXvdw0+LerffVh8p9x71zs+mS2UzmEvDKfmaPHBrtbNLW2jRHHlj+F0bGferV9p0d3EoiczEj5SR0/EVpFKRLbRwi30qopk3RORyHQkH3BFFbK6RqVpJJGFhlTOQG/h9cUUclt1+QX/AK1PKmQqxHpUL4zxVqQcZqs2K2TMiMjBHrSY55p/1phz6UxB3ph604DnmmtTAQHBocYNITS9U9xQIaK6PwxYqzefKuQD8o9a51BlgO1d5pMYis4lHYZrGtPkjob4eHNLU1YFYgk9a0IE244yaqW4zg569q1LdORtrgXmemok9udw+YYpfsOzL2vyN1aM/db/AAq0kHTjBq1HGVGCOlWtCuUzkKSZRkMcwPKNwf8A6496VoQTgg46Vdu4ElUCRfoRwV+h7VEkc0CjGLiPHphx/Q1pHyJatuZl1ao0b5GOK4zxVoA80SWifvMFio7j1r0cGC4QojgMezDBFZkUIlgaR/4+B9Bx/PNaxlZmNSkpI8VKMrlXBB6EU5Eywz0rtvEvh8mYzW6/MThlFUbHR4kkT7WSAx24HUHtW/MrXOCVJp2MuzsfMdSilq3YdLdwd+QvYCtmz08W45QBB2HWtaJY9uIwq1jKpqaxhZGPZaY0IwsXyjqw6/l1retLaDy927d6jpRESo7ZFPdo3XLrye68GsnO5ooFh4lXaUUKaFk+bDdarh5FUFXDAdA3Wq8l2F+Z8r9ahtvUtK2hrpKqHLdKheF2kF1Fyw5MZ/jHr9azIp3nO/8A5Zg/nWpBKW77f6VPMVa5ds51ulDJ0B5xV2CJixkjO31HasoRshee1xvJyyE4D/4Gr1lqEbKSW2MOGRhgrSbsNK5oSQNjOQc9cVXkdEBVmLRt37qfeonvo42IWTIP40sdvLd/PDE+e7ONq/l3qotvYmSS3KTzxNJsMahuzngEVWuLEXQLHA46t0I9s1rvoKSNuupSwPQIPlH4Gqr6b9ncbX83sokY8fStE2tmZuN+hzraVYSMdsMqSA4yFI59iOKytT0PUVQv9oWZVO5cjLD612U2ozWDH7VCxhbjIXIFMu7mxuY0mhKgN1KnGD71fMvtfiRytbM4uz1541jhlt2kfOGRm4+q+h9jXS2XiyONWt5VdFXhCVxisfVtLgkZpYjuU8464P1qnqWlXlrbiQSJPbnHyyHBX6Gly3Xusn1Oim8RQXMhYRu2ONyg4NFcPZu6GVJpo4tp48wE5+mKKNVow0OduTmQgdKiKfJk1fWFXjLnqD0qrPlsgDiuhdjCxVPSmtUjDA96YQAKoQzJNMfqBT29BTSKYhmKdGcGlxS460AKAEkBPTrXdadIGhQg8EVwq/MuD1FdJpVw0dtHuPHSubEJuNzqwztKx1sJGRxzW1ZjKjnkVz9jIJVVlPWuisQeK4ktT0omtCoKjPBqyE29efcVFbjag4/OrRBKD3q0a2IJVD4x3o8orhv4asKq7yCOBT1G0kc1aHYztRt43tWLxqznhTjByeBzVCezlteIG3oAMJJ19+f8a3Jv3k1vHjoS7fgOP1NR3aArg8EVonfcxlA5aeQMMTxPET3I4/Osm7tow+4YJbgkdv8A69dXLHtJXHH6VjazbKYzIiAOOcrxTt0MakOpFbSFh+8/1q/K49fQ/jT5IzndHhTnOPWsySYxFJYW3lVwwPcf/WqcXe4Bjkqe46VmZJE32gq+HyCKdJcrgYPNQuytuOVYL19qi+0w7hsQv/urmpsWiwZjIm1QT9BT4IV3AynJHbtVcyykZASNf9o8/kKjJUkb5nc56L8tLYdrmnKbYL8+1e3BxUDXDK6i2ErL0yV4/Oi1TcT5MAH+0w/xq/FbEkPNJn2oab3El2IYLm7c4zGg6epqylnNdRt56eaw+7IG2EfT/wCvVy2tkSYMi9fXmtRNqrn160rJFctyjbrcWkeGtfOUDjC7CPw71ej8SRQbRdxSwEjGGQ4zVuLJLMvpU5TzolA+9+dJtPcFBrYg/tC3uIxJFOg9s1Tvb2yMWTdRK4564rTjjVVKTxJz0JQc0rW9rGfOeOBR0LbF4oVluws7bHNNq9rcxNHCJLhyPuJGT/SqM9s05Kpp0kLkcmQhRn+ddXdXOxg1irSHoSgwh+pqBmN23+lMkTY5RByfx/wrWLSMpJs4W90aW0Bf7ckZcYMancD+dYV9JqdgQbuJpg33WYlto+leqXOiQXColvGiKefM6kGqMmn28P7ieNuMEtnr75rVKL1MWmjzBp7eTEivHGzfeVh3orr9T8O/vsi3LKckFOB+VFaWfch2POg3zbQcLVaYgbh/k0Kx3c0ssR4NPYz1ZTPUU2QcmpNp34BpXXjpVklfbmgjrUhXFMbrRcQ09Kae9KePrTSKYACQeOtblqSluAeh5rDAywrfhG6CMe3FY19jfDq8jpPDuTb89M12WnqMLjHPSuK0WT7PCA4Jj/i45jP+BrttMUFVYjg8giuJ/EerTV0bMKkrgdauIo28/iKhgUBcHAU96s7eOOeKZukM2qeQM+1SAbos49qWJcID2qR1Cr04NUirFHaftcgAzsiA/EnP9KjmBYA44zU0RJnunB6lF/Jf/r0OMZPY1og5TOuYvk69KyZxv3Ie4xW9cLkdKw7tdkoPoeabMpw0OQmt7qOWRQoGCcZPaq6wzoQrswiz/D2rqrnAmPemoqOCGAIPBocY9jh1TsYNvalCWIJOOpzmrNvBOvyruAPbtWoIzCAH5jJwrHt7GrawhRnHWpGjL+yhiBIoP0OKsQ28MfKQgHuc1caPbxjNLHHg49aXM9h8pBySNobHer0Ryo+V8Y9KRYQDjAFW4EAIBHGO1IrlI45yjfLFKcDstXYJGzzbzf8AfNAXIG39auwAgDPPFQ7JlpPuNtWnaTHkN+JAq1ALvzwuIY+f4m3fyp0CFXyOh9+lWnXEiyDqp7VGgWY9rN5FInuG/wB1FAH51HDptshUBDvzwzEt/OtFTuUE96a/yqenHekpPoK19yKSxAXCucen/wBasu+01ZEYEbiOhU4raMpyAOppsS7mbdVKfUlx0OfgDWmDGS8fdZCcirizrPOQFTLJgqavz2qS5PRuh44P1rBuoXs5YtkQuHYssUQOCx/oPetYvsYyiUdTu4bO48phcGXqyRc7R2J9M8/lRVuKyEa77hJZLqT5pZAM7j6D2HQUVpb+rGR4I2Fc9OadgstNI+XnrS78DA4rWRhEgcbXXAobkUkp5BpjsQKu1xbEbselRk08jqTTSO4qkS2MpOopxGc8UBTTENH3hW/a8RR1hovzDNdDYgExA9O9c9d6I6cMveZ11tD5pjZTsnCgKccEehHcVuaSsse4W8WJFGXtS3/j0Z/p0rL0wZlHbiukgiSZAGykicpIvVT/AJ7Vyp33PThF20NfT5I7uESRNkDhgeCpHYjsatBeDmsiASrciTetvfEY3EZiuR7+h/Ue9aAugmFu4zbyt03HKn6N0qkjeLuWYVHkZz3zinOGYqOKSKVfLXjkelWI2hkjfd8ko5U9jTjY0sZcP+vuyc/6zkf8BFSMckHFIkbRX10vchHH5EH+VD7huyM1ZSWhBPkAjOQKyL2LcprXfBGKpXUZ2H09qCJpWMjaCygjNPNvt+YdKY6sJAR1H61fhXfFg007qx58o2kVsK4KsAQex70ka+Q4WQ/uWOEc9Qf7p/pVw23A7GnGDKOjqCjDBB7ikWokPljoacIuAcj2pYswssUxyh4jkP8AI+9WNgLYPQVI7FdU9asQIenNO2jPTj1qaMYxipHYfGMH6dqtQL0OKYqg9uasQjanNSwRPDGclv4e1WkHbHJFNhYFT+dK0mcEViwHQsQSp429KUljknv2oUhzkDkdaeB8hY9ulSFrBCSEyRk1MuCAyj6imwqGQjnjriqhu2llktrAK0iHEkrfci+vq3t+dV5Esfd3SwsEjQy3EnKRDgn3PoPeoLKBY5i8ziW5diHcdMEfdX0FOgtVgncoWeR1y8j/AHnP9Pp0oiOJQcciQZq4ysRKN0TfvIvk2mRQeD3opJ7lbS4k3sdrncporTmMeU+Z5SEYg4yaqMxBNTXEnnPnpUJU5Oa7IrqziYxjux7UnGORTyg4xTWXAqtAIm+Y4HSmkHNOGVJxSnk8/pTFuMzjOaQEkU4rShcigQ1R05re0xT+5J4G4DmshEAFbGkn5kUjOWGAaxrO6OihpI73TYh94dAcV0dlGdynAyecGsbTE3EKOg9K6W3jTKcc1yo9ansTMqyxFJVDKeqnvTmMsKbSrXNsRggjLKPcfxD9amgUZbI49atxRq2cHGapG5mW0G3bLp0ihc8xtyh+ndTStdIkmyYNbuf4X6H6HoasfYwJZHiYxSdyvRv94d6jnnCR+XeRgDs2Mo3+H41ViloR7sajG+eJImQH3BDfyJqd1zkg8+lULuAQQLNavtEbhwp+ZQOjcfQ1N9peKQLeR+WM4Ei/Mh/Ht+NNdx3s9dBzIdvtVaRDsJ7e9aMpwhOPxqtKQY+MdKtIiTMCRPnNWrIZ+UVC4DTg881YiiKvxQzkavItMCq5AyFqVU3qD60Rcrg1NEpYZ64qC7FaS3VlZXUMh6g1XjQwyLFMSUb/AFch7/7J9/51sFABj17VG8EbxtHMNyMOn+ehpCt1RTEWRj0qRVIPoOlJE5ikEE5y/wDBJ08wf4+oqVcseake+pKg45PPanR5U57+9QqTke1Wo13EHpis2FizGpYjBqUIGyAOlEIAAx+NE0kcKl5ZURPVjis33BkiqA3FJeXMMChpW2rnAHUk+gHeqwuJZlBs4+D/AMtZQVT8upqSG0SJ/OcmW4Y8yv1HsB2FFrbkAiXF1uErNbQnny1P7xvqe30HNWIoooEaOBFjjXoqjAp6nDtxTJGwGalfohW1HgDfx0FU79SEJHByBn0q1ACxz3pJo/NgkTqSCR9aaBodGvmoA5wy8HiipYJLdbaI3EkasRxvYCiquu5HyPlIckc09RmlCcZ4xUqFQprvvY81RuRmIk8U1kIPPNW1CsM9KimJIoctdBqJQkXn5aYelWWXPfikKAccVXMRykCknrUir6Cn7AOgpwTik5DSFQZrV0lcXMYx3HWqEaHitPS1zdICOc1hN3OiEbM9A0UHPByDXW2kfQchq5jQo+F5wM111spHJrJOx6sNiSKIeYQWwAK0ooVCKgAB61Wij81jkHPWtS1t98GApMm4Y9a1irmjehSv7SSJRKqkKevvWXMNxLL90jBB6VuX5MaNGjnAPzDOR9aygiyM4BwCM03a5dO9rsznttufKbyw4wykZUg8dKjsrl1tgLiHmPMTlTuGV45HX0P41pSISoBHyqOKzLlTBeYztE65H++P8R/Klew5Ec7x7HNpNtJ52k5X8u1UZdR8mJluAEbjkHINLqaKI9zr84/iHBrlrmd95G8uD2b/ABrnqV+VmLXY6ZCruhBBB5BFXo8bh1FcVb3stk5ebd5Q5O0/rXU6Xdx3KiWK4R0YcBhjn61tGakkzC92zXjxt5qzEcduPSqto28/6vvgYYEfWpRI7PgQv+lNmitYtFcmmlSTtOKYTcbwEiTb6s+P0pWjumPMsSY/uKWP60rMQlxbLPCYpAcdQRwQfUHsahtQ6zfZ7gjzUG4N0Ei+o/rUxs3Jy9zO30IX+VRTaXb3KqHV8jlXLElT/nt3peTE0+gs0tvC372WNWJ4BNKLsvgW0Esvvjav5mooQlu6xzQQxSk4WRV+V/oex9q0CCyYY81ErdSldjB9rZcM8UCn+58zfn0p8Nnbod5Qyy95JTvY/wCH4U5AfuY/GpDwOOO1ZttD5SdXDDJyT6mjr9KiSaAcGRSc4wvP8qeruy/ureRgem/CD9aSTIdkWYRkkEe9OKqI33gYOearJHcuPmljhB67BuP5nipBYwugM5edhyPNbOPoOlFrEsijuIyQsG6dwOREu7H1PShUu55lQ7LZD12nc/8AgP1rSQbFCIABjgAYpGHlzIxHNO6sLUj0uxhgheOOFHYMdzSDcxPuTRVq2LJJN7kGir533Znyo+UIo2BwRxUhgJ5XinjenVTxT4nZic8V0uTucKXQiWEjvSyL8pDDn6VdjQkAqATUF5uHWp5ne4cqZmuu1uKjwamfFRjdnNaJ3JtYF6c1MijHvTFUnrViNcdKmTKSHRJitDTxi7iJH8QPHpVJRx1rQ05DLdwqvUnFYPVmySR6RpAwQwGVPSuptANoLdOgrB0iDcvOQAa6ezhQou7jtil1PVgrRLVlHuY88DmuvtbdbbTzctJvAKhlHDKeoOKw9Mt3nukWOIMwXcVU4OB1ra1qG2htolilZldd24jlH9K6oJpXMKju1EwdbCC/kAAO4biQeGz3rBIO4qnP6ZrQvi4kVJMDbwreorMvCwEZAxyckVlJvqdlJWSQmduefrWdqZ87CA7JFOVY/wAJHQ1ejZSoJbkmqmqFgwZlwWHpione10ElfRmVqc4uLPcVCSDhl/ukdRXOxWsU1ysQdjcSDIAHC/U10B0ya8laSNjkjDIP4wO/1H603xBov9h3mmx29w1wLyMSMyjjHbFZcl/ekjkm7PkMU27TKlrPHiRiVxWzaxW+hW0EN3cQwhj8yOfuk+ldp4f8Dveadp9843S6grmFs/dCtjmuj174RQan4dnvrpHF5CuVgQ8EDr+NdlDDNrR2POrYr2T7nAW0Fu2WRI3U85Xofyq3FaQtyplU9wrnFYfhu2GmTzWyCY2+/aPM7V08ICyMFIx2FTO8XZnfQqKrHmRXeBlGI7iQA9AQGpyrc7MCaJv95SD+lS2TyapePa6PZ3Op3ana0Nmm/Yf9t+Ej/wCBMKd4/wDDureGPDlte69rFho017cx29vbwsHYA/M7PK+FXCK3CqfmKjdzQqcpa2CdenDS+pF/pRyNsDZ9GIqMPdZOII+n/PT/AOtVEeJdDBONb03H/X2n+NJ/wkuh5/5DOmc/9PSf41nbyNE49/yLMyXEyFZIYCp6hnJz+lRFLq1XdJOn2bPLBSzRjtnPUe9M/wCEk0I4/wCJzpn/AIFp/jUsXiHRZpkii1fTpXkIRUW5RixPAAGefpUteQXXRlyOBmwTcSsD/dIUfpVn7LCpH7oO3qxLVShIsZBuz9hY8E/8sSf/AGX+VauCBuGMY9aybZViSFEVRtATthRintHjqeKjX7i461OpL4OOKm4nGwwNh8FamyD179fakYdSAKYq/N833TQ/ITRZRlJ3Z6dKJ/nkjHTnmmxx/OSp+gqQqGYeoPJoM2hWZgAUI5z1oqRWUDpu/pRT5iLHzBvWXsNppGhQHOR9as/ZecoKSS1bvkfhXRscQgwkWFIJrPumYdsmtBodg5Ws+5m6jaPyp9Q1RRYEdeT7UgBPAp5yx5pVGOlXcmwsa4qZQAcUxQfWpkArOTNIoeB+daOhIWvIz3Diszdz6Guh8MRebdAFsHGR71K3NEtkemaMndz1rpbdeAT271gaTEQIw/pXTW6tgLU9T0tkdN4YmNtKZ1tlZlXq44+lP8WMk8vnQBVjKAtCrZCt3xU2kRRR2Inmnk3EFY40GMNnjd7Vj60kkF5NJLsXe2Cqdjiuy9o2ORJSqXOfvgDLnJ2gZAJrPuopomKzoUcqGAYdVPQir7D5m8wHGKgv5ZZLaOe4cyYAgUsckBRwPwFYtdT0ItqxnFQHAQ9s1eeSO7tLlr2IyTlVWGReAhHqO/FVrdXMkkiJuEaEtjsPU0IzlMHOM5ppdQmrkmoafcabFBKu1mkhFxFsPO3OPzqC+kiZbeRwRbRASkP/AMsWP/spP5H61N9pMEyO/Ixg/Sqt5qulXemXcTx3Av5CFRwPkRc8k+vFRJXaR59S8ZXZd0vxY9hogxNMRaBvskbkYQO2WA79f/rUmk/EfxRcLfxQyS+TdHAUoOMjHynt74rkI1SCKWCSMSW2cJMScxj/AAratTbhkhtfNCjhiT/KrhaOkv8AI554WVV3joTlpZMidERy2WC0tzYQ6nZNb3DSqjd43Knjp06j2OQfSryQReWVB+b070qBV4A4HWnNtu53UKMacOQ6zwj8QNW8M2cNhc6ZZajpsQwn2GNLOZB7RjETn6eWK2/GfxajXQra78IX2mpeLcxx3lpqttIJoo3+UOse9CwDlASCy4bOeK883AnABAqvf2VtqEHk3sEU8XXbIoI+v196pV2tznngIN3jodZ/wszxx2m8NH/uGT//ACTSj4l+OMZ8/wANf+Cyf/5Jrm1T5cd6RlIHNR7afc2+p0P5fxZ0q/ErxwRnz/DYx1/4lc//AMk1k+I/FvirxTpB0zVrjRFsXngmkNtp8qSHypklADNOwGSgHQ8Gqnl9PTFIYGBwp+Wk607WuJYSindL8xCAEIYAr6EdqhRXtCBGGltOuzq0f09V9u1WUTLAelTqmD8vIrmZ0MI5EliEkLB0PRhSo7HgHmq5tvLcyWjiN2PzDGVf6j+opy3CxNi5TyT0DdUb6N/jUtBoXSS4GODTlBAye1Qq2FBHI/nUuTI4Gce1JaktFiIbl3A4PoKkjjCly3XFRRswkxwatKeMgU0Yy0GLtCjPcZoqZEVlBIFFOyIufMwu8kgcLS/aCc4qpDBIcY/lVuK1bJ3Hit+VHJcbK7OnHU1l3KY5PNb8sKLEcHHH5VhXeBJ0NDetkCKO3J6Gl2gdacSewxSHkc1dxWHLzgZqVQOtQoO/erCjiokWhhA3V2PhOD94jrg4XFcjtw1dn4PUs2R1GBil0Lpq80em6bEyrHtxnr7V0NmNxBIGR1FYelHaqo+MH9K6HSome9jCAMSelKKuzuk7I6zSYoktTcajzDGflUDn6Gub8ROt7etLDbtCu3lT1+prtbO7S30ueCdZFlBwCg3bh6D6Vw2rTSvNKZiUYsQcjr9a7JaKyOahdzbMGYO+UPXsapJErqWmLZwSMdyKt3A2uFBzzwaWIxgESghVPKjr9RXO0rnpLRFSKSSFJ/JJCTp5bY9D2pkjMdofggY6dBWgfMh03eyYW5fcp7Hbx/OqDkkAE8dapCvcqXZygzzg1lSKquxHU1o3xLBl4xVAqc/yq0YTjdjRDuypPynqD6VYtrOSxi8yE7oB/wAsxyyj29R7VLAinkjkVetggfa2Tkce1TKN9S4xLFmBdAfZnG5vu89asXMckTbJECOow2Oc1R+yFQ88Enlz559G+o/rUj3JTYZ1KMerM2VJ+v8AjSuVbUmRSQdp564pFPIBPPvU42rhl5LDNLJGFkBzuyM5HaoYwRcc5pXAxlqkQ5wOrUP83y+nSkS9yMHJBU9PWlLkqBjkGmDiT0FSYG3tn1rJsLERJD55zU6EkA55PWgAbM96jXKk4BzUsknAUDPpUn3o8Yyh4wR1qFV4yx+bNSIXJz/B2FS7hYheyCj/AER/JPUpjKH8O34VGt0UcJcoYsceYOU/Pt+NXSuQcsQaW3RSpxz6k0XvuHQdCwBLKwKnoR0NW0Y7sf5FUntYWyVUxN6xnaPy6VKkc6gbJVfH/PRcfqKSRm7dS/ExxjBGKKrrLIgAkhbPqjBhRVXtoZWPAYrYHgYyKsfZ406nJ70DCDAwKbJIOcZroucJXvyixnjHFcxduC5xW9egtkYJGO9Yc0YDGpWjLW2hWBYjApMYyc5qXaFpnU89Ku5IsY5z0qYHHaox04FSx8HkZ9qllIFGT1ruvBSEQ7uMluMelcVGoZsKD1r0PwjCYolwBtB6+tI1pK80egWIUxbsEFe1b+mOFeOZBwpHBrAtsZTqMiuj0eLdIIpvkz83zdPpV01qdk9jr7W4s7WGWaaG43RkSRrznPqPauG127k1G8e6dQpdskAYA/CuzutTkC21ptPyDbluRtPriuGvRnUJVL74wxyQMZroqa7GOGXvOTM6ePHU8dQar3hdXUkk7hx/Src6kuQo+U8e1Pnm82RJXVNyqE2jpwKxep3KRUnkkmEKygYiTAI4685qo7HvVmdmc7ieTxVOc7c00HQqS4aTHfvUYjG49anRQ3PO4nrTtu0k/gasz3YIpwCKtxIoClRzjnNRQIdwwa0BAoVCAG9QDUlrQTypVhEzAeX7U1AMPlSY26CpQXZHVdwjHY1bjtmFq4QgzRDcq/3gaTVx3S3K0VvDGEay3RkD54yNyN+Hb8KFkZWZpkKKBncg3r/iKeIngRWONrDtViJQFZlHHc1D8yXpsVrYiX5kdST6GpvKKnDYNFzYxTBXlVXfGc9D+YqHyZIstFK+OmyX5x+B60mTccybT64pqJ8ys3Q9qbuugxDQI59Ukx+hpjXagL5yyxMDj5k4/MVLQXLoUH7wpvHIz19KjEiyANHIjHOOGBqXaV4IPPrWTYrChQjAoMrijJXBznPUUuSowenrTgoAzgetQAh+bl+DUke0KOOKjGSNzn6UqZK4HDHpQwZPwD83CmpRtVxzx+lUwp34kP1FTkF1A5K+1IhosF0z6jtRUewRgAMo+pxRTuybHhrMCpxjPaqu4l8D86c7ZG1R8x/Sgr5a57966Lnn7EF7xF8v5+tYNxhTW1ePlMDtWHcY3ZNLeRS0RWY5JJ6UnUgClb5jgdKAgJrQRIgxx3NPHv1pEHHWl6DrioZRYsgWmTHrXo3hfctvCMZB/wAa8/0xS10oHU5Ar0jwypVY/MH3VFCNaHxnaaeOF3YKnofSuis5ldVSQEsvAb27CuYtyNvGa6DSlVwCd2ela01dnTU2N6fXBaWFxbiwZ7qVdvn5wAD7Vy9zGUZFYBARu4OfzrV1ESLsjhbeSOc/w1iSZjLLjJbgmtZX6ioxS1QjyLkcYxyB71VKrtJ568VOwAQqvX6U2Vg8IjJGUGazbOhaFKducY4zwaoyc9qvT84x9KpPy2M8ChFdByRkpgDpQUIxgVLHlV4qSNctzVMhBCpz0FaQtAY98RIlXkpnnFV1QJJ8w5NWUfJBGfMxjOe1LTqN36CshnXKfdUYbH9agiSW2KyjcFIODVm3cCJlPGcg+9XSjyR2xUDZtIj9/XNLRkuVg0uCKYqlzhXxuBfoy04W0cnmNkgIc7R3GatwWcU3FvLl1iztcfdOelIlv5UEspcrL9119aprTyMXO7dirc24F2ViDJHxjd1qs8e3eQwYoe9arJMUhlVhI7ggA9QB60w2kMMdm0o3SzSbmHYD3rNrqNTMmVMtlRhsdBTFhZQBjDdSc1pXDrFqUrkKQpKgDpVZiGUnHU9azk7Fp3RVe2gORLHGfqoqE2VvuBWIhQOzEf1q1JlpFUd6Qn59qDgdaybZSRWNkh2lZJ1yegkNSfZvmG64uBjj/WdKsmPdyDinRoD8x4x2qGwZWNi5P/H1PjtyP8KJLQZU/abhvfcOP0q3tIbO7G7tRtUIQFO6i5JSe0AwzTXTNnOTIasR2kbg7vMb2aRqsc8HA47VMg3EHuO1CZLZWNlBFwYU/wCBDP8AOirnlh+dxP40Vdn3IueAqgUk5ziq9xJlgOMU6R8IBVQbpH4PtV3ucOxDcsegOcdazJ1ycmtmeMJGKyJwSxov7xSKuOTj86E6896lIGMU3H51dxXsKAKd3FAH1zThz0FSwLumAfa4iSAAetem6LlUCt+JrzjRohLcqp79jXpeixgxL1z3pxOjD/EzpraPKKycgjkV0WlNHIyRSHbkAFvauft2Ctt5AxWxp7lVLRbfMByue/tW9N2N5rQ09dWC1UpZXPmRso5JyQe4z6VkOojC7iSxGSDT5ZAQzSxnzTxg9qiJbfuyWbjk+lNu7CEeVEMi/Mm4gZ/QVUuG3TORjBOMCrM2S7EnNVWjbcM8dxWbbN0RsvymqKrufpjFXpRhOOarxKSapATAcD8qmiUABsU1ADjnBq2ke0DbyDyTTEMU5bDDIPrTvs7eSZEbKKfm9qYeWHIOf0qwkoi3rKvyOu0kUaMHfoMZdoXAwyEEj+8KvLCfsyvGxAzvUelQ2+wgBsMSMBqsWheO3lXeMOduPahLuRJs0NHu41uiLobQUJJA9KtXQimikmiVllUb+RwVrNtV2v5iASHoVPp61YmBZVNlKSETDBv5Vd3YwklzXRFAY2kMinrwMH1otV827jjCkheWz6CqtxIySrIi+VKSCMdKt2kiTXiSytiNiBJt61l1NGtLlXCyXcrBMr8xx6VFglAOCGqwhRZrsIGaJdxTHX2qIL5Z3ckbOp9azltoUmVQGLsM9O9ChQQMncfSrDo6RZYYwuKihwQWwcdMmsX3LTuPwhxnv3qSRACAvOKhZioBZeOgxUsPI4bDD1qBPuOA2nGM5/SnKMZ9ulQsy5wDhjSueQAwx3pCsKvytuyM1KrIxOOD0qJ2VVAAJJ7CnKyMOhA9KaJauWEAReWyT6GiocA87vwNFUZ2PnybA4JJ4qW2h2Lvbqaqxg3Nxk/dU1qlflPoOvvW2tjhZnXuNpPGawpWG/j1rdvvlQ5POKwZepIqOti1oiP+LpSj6UgBzkdaeB2IqmITBzgZ5pyj86Mc+1OAJ6daTYza0MK1wWUdunvXomjEMq9QwHWvPvDyfv8A5Rk+tei6QgSNWPJIq1sjow63Z0Fpndjg5wMmtaCNo2bgZBxWPbcsMmthY5Yo1mkAZTwAOue1aLRHQwlDFj5gyeoqBmJ5Y59h2qyyP5oVx5bns/GB71Xx8pAwDnJJoKiRngHtjk02TDAZHzY609nJjCEAjOc45pGGBjocUKw2UZ/TFRxrippep9qSIAnmn1GhVUD734mtKGD/AEbdvBycYHaoLSEtI4IJAUkirESGO3ZTnK/NTBsqbQjEqMg9fapGwIgXHzDj61Iw3P5g4p0z7oShOcHIpaA2NjURMCufm5A9qtyMNjsqqMHoazt7KQRnjpntU+9ZSfMchmI6U0S0a2nXkFmRPGhkmKkMp7E1NcM0kYEcQgk8vd7NVCIRRzSqvz4XnHerczXMdosbx5VhlWPUVV3axi4q5FPNCqQsib2A5DdjT7eYQrIDEpMg/KqU7ux+dAABzjvU00Y8lX3E8jbzWTk+hbiupG8BC3Dq54wcDvQ4KiFS3LjjntUrQtDGpYEq5zgd6jn2hlVVIdBg5rOQJ3GzODw5wAcGowx8wRjAWnbQ4GTjHP1qMozNj161kykLcIxfCn7h5pYWJBLKMVKYxtOOCKQoSBgcGpaHciGTMSFzQ6AKcMN3pTnRw2VwMVGoXIwcsetKwxVXy4wwbLHrU8Cgx561HDBvckvhfSpwpJ2ouR7d6BSYrheMECiiREyAOD3oouyLHz/aRbAAMVfbhPSoIQOD6cUs0jbTjrW9zzTK1FskqPrWRIOa2blDyeM1j3ACt15qVuWiIdBTwcZ9aYgzzmnkdOuKbBCjn2I9akhIEqkk4zUYHWnxryPakNnR+H4nSZiCML/KvRdLRDGhP5Vw2goAwLgjOBXd6YqqBnt05rXY6cPrE2rVEBHOTnitaIXEjKsHz7eQD0FY0R2kE59q3EYi0lNs7bGUCUDgAZ/xq1sayKsjyO7mbO4HDZNImX+YDAHSkL7lCYyRwc1PHjywD8vqTQkW9EQupIIYAEdcd6rTOD0qxKRvYgjFU5e5x1oKSK0vJ5qaFSCuarnO8Y5rcitEWwSQsd7NgqfSmvMUpWH6fL9nFwvl7vMUAE9hTrmLYzqzfMBgD1qOZv3T4XnI59KS8nNxK8hBBKgfiKbl0JSu7kfBOM8AU1hiMgjPP3hTdzFFGOc5zSszFSOgqEy2iEqSR81WIUUyAM2ABnOOtRRkdDg5qzbqVb5zyBxTTFJkcbP5jgIVUnDADtXQbb25tAykMsX3UxzgVnQSgFVZhtJ3E4q2b2ZJTKjDcBgAdCKpNGM229CTUY/LsbV5EjZpMuGQ9B6GqBA3AR8jaWKntU7wiN0dZQyyc49DUM5JZpIyB8uOKiWu4R0HIs80aqpJCJuX2FVmcOrFwc9S1S2pOxyrN8seDg9KYMwxsjMGRhmsZIpaMN2LZvlBBIIapAoDbQQeM1TEgVRlCATk+9WIZCu5oyMuNuD6VPqDRKF4bbwO1Jg5GTgU2NgQVLcZp1xEfMC8lAuamwLzITucHnAB496aY/KlGE3M3vU22NUKhsgcg0jHJA6N2qWUmMDfPgrgD9asxFcHOB75qGYYGON2M9acYyIkbcPn9DQJ6on2xn73I7Giox8iKMgfU0VRnY8Gi+WLg+9RkZJPenM2Bhc1NBCdhLHt0rRK5wNlG4ACnPWsK5X5zzmuiu0wvtWDdD5jSbsVAqD5acBmjGTQBQUOHTFSRrhhimgelWLUZOCOBzUiZ02iMzgKM44Ga7mxBCrt+9iuI8Orv2EAjJrurJCFHcnpitUdeHXumrEu4KSK0VibAZQ2z+L0FUrQ4dW4OO1aIZt21SUDDBGeMVppaxs2xI42IL4wPekJJXDHj9KkkkaRQMKu3uDTUXClmGc9AaBp9WQOAAAMZ61FOfl5PNT7Oecbu+KgmXJx1plEenKrXsRk+4GGa3ruNNx8uTKDJA9KyLMeUykgZxWhDOu7DcDParvZWMpXbuQzSF/LXHbnFRcFuPoRUjqR8ytz3NMbrxge9Zs0RHjqCfzocfeB6VIQOTjpTG5PFFxjI1GTxVqLGPQnoahRDgADmr8KbVBI5prUiTH2+1NxIDLjGT2q1LBBIClvIA6gbf8AaqE243ZZ1Py7sCmShfMIQ4A6exp7aGS1ZIgiZ4yUY7R8w96rCTBb5RsLYJPpVy0MON0rMNoO4jvVCRg8AABIySfeok9ClvYqyGVVkKNhN2MgcH2pgkPleW3J96trxCUDYQvyh61XMSs7EnG09KzdjRBIpGyPIbIyCO1PEfIwck84pgwi/MMlqUZ3kjO31qGwsTov7z+9H61bmZnAk3dBtqlCygcMQo6+9Wrtllji8lSo5znvSXUiW43yQyocHCjLAVBE2Seueefap5JQFRWGCBjjvTJEw+fu5pPUafcgwZlfBK+9PEaqyeWxyO9PaE5yp+Udx0qaPZHIMff9e1J6FOQyYFmyw5opXUyMX8zaD0FFF2QjwSE7n56Cr8Z59BVeBAcnoTUzttTjrW2x5pU1BlCkDpXPXI+b1rduRkc1kXK4YmokXAp44NA5xSmlxxxRcoAM9avWDBJfm+6eDmqi9KtWkZc4Aqb6ks63w8mwBSM88V3OmqrJiuL0CJhDEW9Ofau10tPlGfwrex20fgRtPbPE8PmBf3ih1ZTnINPuMho1k6Z4FRgMkC45weOaknjkjkCTptcYbHX6VfQtXuTxqp3LjntRJwoyQSOMURsTjaMButPkXGcgYHcUIfqVDnkeveoZAM46VZkHGRVf7zU0UPt1JUg9qlOFOMc+tR5IU4xj1pyMQvz9SKZI5uc4weaRcYxgYpgY84/A0mQWHHB71LKsS/KqnnioVyWyOg70FuvY9PrTUznrikNKxcg+Y8VcjBOQpINVLcYOc1pQxK0fmHOBxmnExm7MHhYIpPyydc44NVmyVkOCeeT71qyqCFV5csCNvHaqrhhI24AhvyokiIyK0vMEbSDGTjjpVd2xJtjIfBBU9qttkWoQ4ILcCqiTBPMBQYY8eoqGzVakMsjPI7MBuzk47U1T8irjcAck1P8AJsk3DceNrDtTFTKs33T2rN9ykQuzbsjoOgqJ5WOAfu+gqWReBg/WneUnmopU7G7+tIq5JZfvkeCNFJI3biemKTeGwsTEr3J7UkUTJKQhC7T+Yp2xELZ+7nkCgh7iqDuXOcZ61YUAFt3ze5qJ2IKo44A4xT4BhiZD07ZpWWxNxxAaFVjyCD+lMCbnCgcEZyPSkeQhWI4x0plqxMO4KAxPNSw6XJoSzAlB8ueKKzLmO5u5Ctld+RDEdpbGd7d/wH+NFUkK6PIYiF4HPrTXbr3NRIfT+VTRjHJrTc84hnHy5PWsW8+8a27lSenSsi9GW7VEyoszm68d+tKBxSnr9KUDnpxU3LFUZIA61dsSfMCqec8fWqY4IPpV2wQvMpAOAeT6UK7egpaI7TR96uCeQ3Wuu0/A2nkVy2iA5Gema7CyVR1Gcdq2Wp201aJpLllAyMZyRToyNzdyemeadBAPKYso5GQ2aIQxlCqNxz8oFXcpPsW4QSAMHpzTmUCPAqRUDxLiOZJQSrlj8p/Coym3dxkihCuVZF5wSfwqNgVORjIFXsZBIxxVWQ5bBwB2Iq0PmIY9xOD1HrQzHfjtSDPPNMXIOaTKQ9iMHsT3pg757UEk5HWgcZzx2qS0L1HrT0QlxxSIvFTIhx1oE2WEyGATFaEGOIyCM8n0qCxtJJ8suCBxzxmtKSKNQm87m7gdqqKsrnNOSvYHHy8jcBxmq8uVA2nPt6U55HjBXJWM9j1pAuCCGJyKl7iSKkkLtKqgcnkAGqskeSygYZOtXkAKearESI3Q96gceZJI33Wzn61mzVMr+UVyjEEe1MlQog5P1FWlyu7d0PtUGVPHtUMpMrqxZj6VJgyAYJIHeg/KPk4PrUiyfLtX5d3HNJlMcgRCGY7uOnpSMQBhcMXHI9Kc4VBlgCy9h3pI48NnbjnOaFoSRlgsmGyewpjnqDn1z7VYdnDmQqM9uOtQMwZckgHvikFhsxyqbTwxwR3FJeloUSKBiZZG2rj9T+Aqa3EYXOCXbIOagtx80l0RnB8uMf7Pc/iaq1xN20LNtCBEI7eN/LTgf4mipolZYVeIkB8kg9jRRysm54XbRZXkZ9anKc479TUMLFcY6VazgZ7+taI80iuFHl8Vz9+RuPFdFLgp74rndSHz5FRMcdzPHJpwx6UgHOadnk1mzYAOOtatjkGJVBAI5IrMU9Ce9bdg4eRdgwoHP1qobky1sjrdHyIwQOBXX2GGO89TXOaIo8oAjJbiultyIoV45x19PatL2O6O1jVjZgQAodR29auIkIfzCzJMpBVAOCO9Z9sSy/K2CvJ96skZweOKXMPlL9vITEzEltrZAzxzUTlTyO/anRFVi2qqhcfU1DIwXNaJ9yLakMx54OBVaUjGAetOlcZGTjNc/q+tQ2ZClt8hOAq9apDvY2CwwcUnf3rEstQeWUpIjRvgHa3p61rI4YccE+tNp9RxlfVDmYY9DSqxP3hUbKemKmiQ4BJqbGt1YljJJqzGhkYL0GecVAuB71qWAZAGCck8ZppGUpGhaiOKABfnHp3FNuCcbdu0H86sbAxXaP3h684FVpHzKRNwfWnI51q7kZBYAElmqN9ylgy5KDk56U87Q6kHPOahlLbHOPvHPWs2zVEL5YqT0FLuDyMScZ6UjA59DTyVLcrzjtWfUsjZmIOcH1qvOPlJGB6CrL4H3f1qs2SQOpqWVEIgpTk4brTwASBjketNVeRk1NnavrnvSuMaQFjJwMn9KkgBk4OAoFDpljggr1oVQpOM59KQhsgBQgk9MAE1C4BCqEx61MGOAGAx2NEi4UMxwM8Y9aARBdKEh2AkSuQq/j1P5UToqIqLyigKKG3faoyRnapYe/anO3GcZH0p3EWFZo0UL869uaKrJHgnDMoPPNFaqZm4njUKcHj8aee49KZEdowPxqU560zz2MZRtOT0rntSz5hFdJLjyz61zeosC5xnIqKmxUdyhjnNJ3px5pAPmrI1HDFbWhoSSwBrE5HQV0mkxmNEx1PJNXBdRrVnW6a4gEbqa6O1mMwGRtXOeO9c5aKGEQAA7810diGWM/KMA1UtztilY1Y2B5U4JH4Vbg8so3VieDVGCTjj71XAACCV25HQGku42WdykKANo9KhlyoOOlSoPmB/u1BduMEkVsjJvUwtduzBbkRgmZztRQMliegArj9R0J44o5JDdLqxmBeB1+Vk79eQRXfeAtTsx8ULI3/k/Z40dUaVgAkhHBGeM9R+Nd1rVlp95p/ibXb4wLeeY9nbbZQyK3GCD3JJ59MV10Yw5by3PKxmJnGfKtjxe31RElEUtvvWMbUlzzmugtJVlUEOG+lcZNaXSSukSNIkZwzoNwB9SRVi0/tCx1CP7VG8aSfdJUj8azactUjahiIR91s7lRkA/wA6lVevWoLeRmQGQYfvVm3HnSAE4Udaysd/NdEtsmZAOua3IVCRhiwIHGO9UkWGJw0K4OMZ9aUSM7NkfLRexDbkWHZA53EnJ42npVcyEN82cZ4JqNmAbjgelJu349fSobGlYmBOcAbqWXP3eD9KiLENwKfkDDchu1S2OwwjrkE9vpTSQpLegoZ2Vic5JqCV9wIA61Ny0EkwY8fLmpEVQp5qGNARjqferQQYUDPNRqynZaDVQYz0HpUm3I6ZA70RhVY9yO1RySYGFoJ6jlwCxwCBQC/JHWnRDK5OeOOPWpAABnHzDrSsO9isqGQ/IMEdcmm3EeQFLE7euKs7niBZRkEdSKhV/mbA3HqRQ9ATI2H7yJl56qT7VIIk2KMfVvWq91MI4SzsEjJ49SfYd6hW9uWbZDYvtI4aZwn4jvTWomXJXYEKOVXgYFFVYJL4p/x724xx/rj/AIUVWorI8fUbewqUNxz2qPLAjsPWoZ5wg4NXc80W9m2RHkc1zNy+9yelW9Qui5xms4sSR6+1ZSd2awVhOTzT1BJ9qEXeav2Vo0rcjgUkruwyO1t8uCe9dJYoNyjpVKG3KSKewrWtImDjjH0rRLoaQWp0mnosgG4gEdPet20bEbccg5xXP2bhJEOTwOa6W1KyhCTgAYHHI+tDWp1bE3mbmLNhWPpxVuDDICSc9jVJELMQvOOlXI+Ixxj6ULUb2LLOT0b8KzNRkKxHnnFXGfpg81QvAGUhiK0T1M2ea3Ecl3fzRQqZJXZiqccn8a0dL8QwaHp0WjazE9xaxku0ecBXPU8d60Lrw9FcXiT5ZSpJBU4OalPhy2eVpXQlmXaVPIPvW9k42va55tWjKVS50Hgm/wBDtbyPUPDWrmHawa406++ZZF7gN1H611fjLxz4b8T28FktpIzBwzSAAMmOwIrxu98EQzyb7WR7Z8/wHrWr4a8LjTCcztIzdWNKjKdO95X+X5mMsI5NJxt/XTqdKjLJK5iyYc4XPXFadoiqMgc1BFAkEQAxgVLGcEEHIrOUrHqRWliz5oJwTikLgfMTzVRo57psLKIYh02jLH8aT+zI9oMzSyn/AGmNZu7KViY3Uaud8iAe7Co5b+2zkzxA+maethaRo3+jpu7cZpRGgbIiQcdQoqS7jE1ezwA11FgdMmrC3VvKu6K4hf2VwTVd9o4KKQf9kVSuLe0kH7y1gb/gAH8qegkjUlcbSf5VAgIIJPBrM+wW5/1BmgP/AEylI/Spo7e8Vf3N9vHYTxA/qMVFvMtaI10xkHt61NkhMAgrWYkuoRD9/ZxzAfxW0nP/AHy1WYdRs5GSNmaCfH+rnUxsfz4P4UWaJumWAhyWVhn3pSm4Z796lCAAFgfoKe/+rVSoBz96k9g5iLbgoqEDvgUsiNv46dakKDzMd+xFOAJOD26UrXFchZ90W0ZXHU1AikIXHGO9WJwC5zyentVeY7bSRi2SFIofYadlcdZxJLILh8tM4IAPRB7VMywsmxgTIWxUaIVWNA2MAYJqOWRnmwf4eNwFO9iUiB3jVyoVyV4NFTLIkDt5mCzc0UF3PD55O3+TWPezfM3zVavpNgxmsKaQmQ5pyd9EefFdQkbnmmjJxz3powamg+8ARmp2NLmjY2nmDJOG7V0dlaKiAYwTUGiWYZQSOTXVW1ntYHGfwrRIcI31ZhPbFTkg1YtU5AbjNatzbZ56e9QQRrkhuCKatc3jEs20YBy2eK2rIbsMDjHH1rOtVABBHNXojsPXjpVX1NjVDkAcYFCvsPX8KrLIR1YYxQz9MZJ9aQiw8q8461Xdsr+tV5pcZ5x9aYkobPPNCE7FtcAYpWfAx3qJSzDhcYFWIkG4FhVXZi7EaRl2z29av20Kqrc89qIwgb0FOMig4AovYV7isnGG4z6UkO1QQacJSOMU2Rc/NnH0qGzSK7j7SUKrIc5DECrCEknHQetUo1xcZ7MP1q1uwO1K4Eh3bc44qJ3wBnihpM8ZNVJ5Ocd6AQTSDJAPWogjP9KiKlnByauQqMf40mabCRwjFTBdvqB6UqAA+uKnbDLwM+ppbkuQkc2SSOvpUrqtxE0cyLIv91wDxUOxVww696XAU5UkjvSvYTSZCLSW2O7TZ/KUf8sJcvEfp3X8KdNqL27BdRhe1J5En34j/wACHT8cUr3MC/LI4Hfjmk/tCPptmIxziMkfjRe4bF+1njkCvuDx5yGQ5BH1qYkfMw6k8VzM39mKWkjjuLOUnJkt1aMn8Bwfyqe2v32sP7TtZtoyEuYzGx/4EvH6UCfc22Ks4LjjHT1NZ98wFnLhcFiAMfWqaa9ubEls31hkWUD8iD+lJ/aVncWePtccblxgS/uyOf8AaxUN6j2RrFdw+ckMoyc1WeUNmK15k6n0X6/4VBcXj3zOukxy3mfvXMePKX2DdzT7S2u/s4iEkdrznEQ3N+LGmkwuWVEij51DMerMOtFQpp1o2TND5792mck/zop38xX8j551OTc3HXFZbH5qs38oL8c1Tzk5q99TlWiHqTxitHTIhLKq9CaoIOldH4att0m89qS1Yb6HYaPbBY1OOOldJFbgqABzVHS4f3K9a3II/lqm7HSkkjPltiFORkdKyZ7dojuAyPWutEG45IyMVTubPcrKynFBSZjWzfLnbj6VdV+OOTjpTPsjRkkdBT4wq5yOaZVyTBZfmOMVBPPswEzu9alyzHBHNNKYPzCrUbkSqW2Kj73bcx47mpUYAjFSNAxQqKVbfaAec0NW2Iu3uSpN8pyelTwygkE5xVdISTnqDU6Jn+Hj2pFWLauNx7j0NSb89AM+tVo89BU4jJwO1S2CVhytkksaXk05YQQDkg1IUCnBPFKw7kT5wrjnaamLAD3qu42grn5TUMcj42n7y/yosNK5OWy2B1ppX5s/hSRoc5qZgAMd6V7FWsRiPvUsS4xRj5cA80+Iccdalh0H8twKcrlFwOpGKRVPPoKaPkDP1PYHvRqiR7SCMjKlj/dXqaVIDJjzD8h52L2+tNgQh97H526+3tVnJV+OPpQhCxQpEcRovHtT0fa5cAYzyp6UpkOMnpTHfK5GCKGxJENxtYkg4Pp2qB4hIAGTJ7cVaSLcTjrTJgzgRRMA3V2/urUlXsZU9pGZTFFbQySD7zMo2J9fWqk2hWlzbyfbFEoVgfM5wTnoo6KPet9EXOyNdkGMf71FzHmCVFUYAypHb8KrmaehLs1qY58M2I2taG6snQcNbTtH+nT9Ksy2t9bxHytYctjC/aolf9Rg1q7C6g7iBgcDiovKEb8FWyOp5pNt7ha2xkRnxCRxZ2V0O0kRKg/gxyKK3DK0YCQ5GOvvRTvDqvzJvPo/yPlq74cntUSct6VLeffNRRZxV9DAsQ/eA967fw1b7EXOCCciuKiX51z0Nei+H4/9HiIUYxSjbUcNZo63TVxEo71vQLhQTz71k6dGOD0rajIGBnqKnc6miQQ5HykYqN4scAE1cjwF45454pWT0/KqsQY00OWqjcBYQOBn1rbmUDORWLe5eXnoKcXqMjRc4FPZcsCB7UsSkcnp9KnVN3IFbXIsRouTUwhGORTokHUdamVcjHpUSY0iDyeQFNTxxFFIPJNTiPIGR0p8aBiAeDUXGQxQc5xj6VOkfqM/SpVQdOKlVMdGpoVyq0RXnoKaU3c9BVltuSCcntUbYBIzx7d6TsCKnlkghh+NRtEQQ45ZecetXTwBjp3ph5J45pXLTI1wyB14B/SmODnpxTmUxktk4PUVJjIGOfpUlJjFXjgHmpF+XHqeaXGAMUHtxzSd0FwlOOM8mmOd8yKeiDJ+tK+Wlyf0pbXmSRm5+bFAWLCNhegxUhGYxyOvWo2GDgdO1GTx0xQSK5+QDpUKn59vb0pxcnOTxRGAAGNS9StibzBHGzN0UUllEzxs752lssf7x/wqEhJ7lUYFoI/mY5++3pj0rSVwPu/XFXsZyYxwm7GOKrXB2q2w53KePSrLcsQMcd6pyN8wA6Gk2NEsG1rRBj58cnNNyqnA5OKUbfmaLhQuB7H0qsrkOpH3v60noC1JGnCcA59aKbGgQtvxuJyaKVh2R8yXi/OfWok+X1zV2/hIlPGBVTGK0v0OZEsJy6Z7GvTNAI2Rhh/COleYxnDCvRPDcuYYvYU49iqfxHfWONg61rW4BxkVi2D4APeteObaAQBSejOkvRgk8Y+hqVl2pk4HpUMMvOQOKd5m4HIwKaIepWnGc1h3vyyKT3Nb8nSsm/g3HNUtGMZCpbtxVyOMAAEce9Q20bBQavIucdqtO5LCOFcFsc0pi53DpU8S5HFSBOvHFEiUyttwvFPjjBwe4p5QbSQcU6M4OKj1KE2d+nvTQdrcjqanZvlIH51V39iDupNpCWoOfmIYcCkMZ4GfrUg2sRk/WlVWLHuO1K9xkBQqeelPEZyc9ak2HPGMUkjEMT+lKw7lSQDOD0NMUMpCnp2qYAM+T1FSMFc46ZFIoj7fNSLyfm6UoPzbW7d6eUUKDzmluIifhsng021cKrEcjdUkqErntUNquGkDdjkUhlotk0jdRtPFKq5P9KVnWPt+Hc0xXIGYAAE4HrSzEiPd/wAsx27se1NMXmPvft0X0p0sfmSQp77j9BQgbLdrbssSBjlzyx9asgAA549TUW8Fc5PHpSPKuMDJ+tVdGeo6SQJ0zg9qznfdKMcDPSrLfM3BOKg2Yc7RkdvU1Luy46DLcNiVWJBDfpTr6WKMhkD84AXqzH2qBZ2a7mS3xI4xvJ+6n+J9qe6bTuON56sepoasJbjfnkO5y6Z7K386Kkj6HdnNFJSZVkeF6va5Xdj9K52UYOK7m5jEqHgEdK5nUbTy2Jxx9K0krO6OSL6MzUrsfDNxmJVBHBrkNnzCtfQLkw3G3GVPWlF6l7O56vpk4ZRurdtzn3FcdpdwNqntXR21wAuBTaOpO6ubcT4+tShs4ziqMLZAOc1cQgnNCRIrj5M4qu6buoq2ajKCmxEAQDp0qWLqKcU49aVRjmmmItRKME9qdtIHpTIMd1O3vUsmOcdKpmZXbOcD8aaqEincAkkn3pVO0Zzx7VJoNLFRUGCSSBxUxIZjjOPeggKQORU7gtBgHTirDMAFCLt9aiUc44+lTRr97J5oExhPpUco+UkrmpW4PB4x2qBz8vNFxojQDk9MUdR70m7aSTg/SkWQDmoKFlj+Tk8+o7U2Fjna/X1p+dxA65pWh3E45FIBSMqR3qGEbblv9od6ejhWKNlmHYd6iuIm82OQ/cBwVFAiwznOIcFv0pojAJaT53PerGFC7UUAVE4THzU9hIbGQHzkCmO2253A8hMU04YkKc+lRctcOD2ApLYqxZRjux61Z2qcHkH0qCEAk7gakllRELOcAce5PoKCWMlYKrbyAgGSegFUgr3CsVZorc8Ajhn/AMB+tTbDKA9yoxnKxjkD3PqaV9yjJ5z6072ArJiKZYlQIgTgLUpYO3OcimSYW5UgZ+TmkY4X/aPpSY0OYgHknNFMRkA+cZNFTYDzGNARxiqN/bCVTxVwOQoANOVdy+9dL1Rx2OPvLUxMeD7EVBbv5Uysc4zXWXdoJYzwM/SsC6snj5xxWMouOqLjK+jOs0S+SVFI4PSurspRgY715do87QzhWJC13Gl3YYDawOK0i+ZGsJW0Oyt5BxzV+NuAawLSbOOlasUvHJoNGaO7gEH8KcDkjNVVkyAOKkjkwfagRZAGKa2M+9JvFMZxnqKZJbgOUIbIp0jbcAjiq6yDGB0p8hLqScjjtVMSWo1mBJx0NOb7uKiA5FPUnJHas7lixpzwMmiX7wx+VBbBABqJ85560rjQ5Dg/WpywAAB6VUHDDPAPvUqgDODimmJoGfGSOaikkypwO9NOdx5zTS23g44qbjQ0uRyAKaWO08ZpjMzE7R+J4FNPI+bnPYUiyaKTAwFLN7VOiu2Nx2g/wio4gAgx09qkBGaCGSeWoXgY+lNkG+N1wM1E8vzDnjpS+b6Ac96LhYWGTMXJO4cUrfM2SKrF/LmB/hb+dWmw205wfSpAi2FZB2FIAPPc9eBnFSyFcDGdwqpNK6TqqqC7L90H9TRbsHqS3EwhUHBZ2OFQdW/z60JHtYTTuHmPCjsg9B/jUbLsyzsWkI5b+g9qEkyDx145pha5MzM3C/nUZOSAASB+tMJIUYzkU8Ockn8Kla6AMdt9wQqYAWmHauD1Peomkbc7ls5OBSKVUdCTimBJIys3Pb0opbZG2k8cnvRRdjseYKOnvU69MCos/MAMVYiUck103OSwsSBvfBqC+tVlBGKsxEAlqUAu3TihO4rHOy6W2crxirdhLJbHa6kjPX0rcMQB4HFOa2UjO3r1qVGz0HqTWV6gVcP+dbVreb1wG5rnDp54K9Kcizwv8pNVZlqfc7KK5Ax3NTxz/N1/OuUguHAySc1YXUJE5INLlL5kdQ1wFHJ4qq1585ANctLf3EjnBIHp61e06UyYMgyaTQ00zqLaUsAAf1q6rYUHPNZlq649zWgvIBzgVIyU5UDPQ0in5s03du6nimk5Py8UrjQ4fMTg4xSPnjd9aaxINI5PGTUjGyfKQV5HrTULfNk9Ke+MYyKaOBz09KAAv+7CgEN601oweScn3pQ3IwMkVJK27jbg0AV2yOq8Y6UmAV6Zp+MgZpzYCZ4FG47ioMYGetOJ/wD1VFGw25B/GpxjvTE2V5QSPr6UqKccHr2qVgSQFxilxjIbqKQ7ldoy4wfvfyp8Vy0gMbffX26+9SIpzx+dVJleZt1scBThnH8XsP8AGkhMnkJ5WIZb+Juy/wD16SKCNSrhiWP3mPU/WiCRfK2ou0DqvoacjDZnrg01YTGzxswJ606KPjnGAKmkZXI8sY+lRMpwQOM+9JpBfQCEHTk9qhlP3gOvrUmAEOT0qBgc98GkCISgUHOKYWPCkHLdKkLxq2D8xP6VBIzbwVJ46UFLUvISqANwaKgSTeMtnPtRS+YrM8wibzJBzxmrrnaoFULY4f0Jq833hmt1qjmRMoAQetOhX58c0xDlsE1YjwCc9aYyVQBnd1qRW5GcGq8+eoqWzy/LdaNSrF1FytIyAMd3epEAEfrTZV3D2obCw14lGCMHNKYQU6c1Ki/LzzikyTnBpphYqCIBzwKt2pAbkDPSoRncQOaniGBmk2aJGvbMBg5q+jccHiseF9p781oRuNnTmsyrFwNgZBqRHwvzVSEnTmplfdipQWLBcEDvimyMuOuT6VCWBYKO3WnMOODz60XCwr/MM9/Smh/Wk3dcc1CTtHtQUkTk4GRTtx43ZBPSq4b5c9qN/TNCYWJy3IppbCnuageQhwF5p6ZIJbGDQgsOjJ2npipUlJ69KrDIIwamjRWBOeRRvsJomyPMGGp7sAGdsDHXPaoGIjUyN0HH/wBamKGl+eQYGflT09z70ySYL52CRiFv4ehb6+1Sthegx6Ck3EcelIxzKAOcd6T2AhuFLSAxYVx+tOt7vZId+EkAxnsalO0ds5qIp8+CvXrmhdxD0YYJHXuRTGYMTggH3pohjVm2luecCovKOd2OAaBIfIPlG3k1Xd2HBqSV3AO48dqqTzYbHB7UFIUseijAPehssQAPlHWo2mkKjJ+UdqkhkLDHHPUmgolt13hiFJop6vtRVTjHqKKCTymP5WJ5xVtSSucmiitFqc6J7c5YCrYAzz6UUVb0KWwjA7farFkQvX8aKKCkX4yM0pJyR2ooqOoxwJweKTIIPaiin1BDIwRkdwalUEn3oopdDRE8R7nP4VbglHU0UVBRMG34xU0b4xnpRRSAfkHJU/MO9KHymSefSiilcQm3bhgetNfGeM5FFFNjTEkbGM9fampkjPr60UUDF28k0RoxDDPFFFAX0JI8GP3qVWVIWLnCg5A9TRRQJggLqJJeoPCf3f8A69PH38AY70UUMgd8quQTnPeljKrn1PAoopMBgyZME496fzhsnvx70UUCYTFWxgBSB+dQTMQoGeBRRTBFbcxGOoB71Edi9Rk0UUdCkRA54HC09WBIC9upoopMC1GCRkruJ70UUVNxH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note crusted discharge and surrounding erythema and swelling at the piercing through the upper portion of the helix (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12929=[""].join("\n");
var outline_f12_40_12929=null;
var title_f12_40_12930="Living donor transplantation";
var content_f12_40_12930=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right lobe liver transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cartoon depicting the anastamoses in the recipient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Amadeo Marcos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12930=[""].join("\n");
var outline_f12_40_12930=null;
var title_f12_40_12931="Cystoscopic view bladder tumor";
var content_f12_40_12931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cystoscopic view of a bladder cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cystoscopic view of a bladder tumor. Note the calcification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcus L Quek, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12931=[""].join("\n");
var outline_f12_40_12931=null;
var title_f12_40_12932="Cevimeline: Drug information";
var content_f12_40_12932=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cevimeline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/60/7108?source=see_link\">",
"    see \"Cevimeline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Evoxac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Evoxac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Cholinergic Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Xerostomia (in Sj&ouml;gren's syndrome): Oral: 30 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No specific dosage adjustment is recommended; however, use caution when initiating due to potential for increased sensitivity.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2930034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2930035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Evoxac&reg;: 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9460385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptoms of dry mouth in patients with Sj&ouml;gren's syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cevimeline may be confused with Savella&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Evoxac&reg; may be confused with Eurax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (12%), rhinitis (11%), upper respiratory infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, palpitation, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (3%), insomnia (2%), depression, fever, hypoesthesia, migraine, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythematous rash, pruritus, skin disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (8%), vomiting (5%), excessive salivation (2%), amylase increased, anorexia, constipation, eructation, flatulence, gastroesophageal reflux, salivary gland pain, sialoadenitis, toothache, ulcerative stomatitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (6%), cystitis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (5%), arthralgia (4%), skeletal pain (3%), weakness (1%), hypertonia, hyporeflexia, leg cramps, myalgia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision, eye abnormality, eye infection, eye pain, xerophthalmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Earache, otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Coughing (6%), bronchitis (4%), epistaxis, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergy, flu-like syndrome, fungal infection, hiccups, infection, moniliasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal ECG, abnormal hepatic function, abnormal renal function, aggravated multiple sclerosis, aggressive behavior, alopecia, angina, anterior chamber hemorrhage, aphasia, apnea, arrhythmia, arthropathy, avascular necrosis (femoral head), bronchospasm, bullous eruption, bundle branch block, cholecystitis, cholelithiasis, cholinergic syndrome, deafness, dehydration, delirium, dementia, depersonalization, diabetes mellitus, dyskinesia, emotional lability, eosinophilia, esophageal stricture, esophagitis, extrasystoles, facial edema, gastric ulcer, gastrointestinal hemorrhage, gingival hyperplasia, glaucoma, granulocytopenia, hallucination, heart disorder, hematoma, hematuria, hyperkalemia, hypo/hyperglycemia, hypo/hypertension, hypothyroidism, ileus, impotence, intestinal obstruction, irritable bowel syndrome, leukopenia, liver enzymes (elevated), lymphocytosis, manic reaction, menstrual disorder, MI, micturition disorder, neuropathy, paralysis, paranoia, paresthesia, peptic ulcer, pericarditis, peripheral ischemia, photosensitivity reaction, pleural effusion, pulmonary embolism, pulmonary fibrosis, rectal disorder, renal calculus, seizure, sepsis, supraventricular tachycardia, syncope, systemic lupus erythematosus, tachycardia, tenosynovitis, thrombocytopenia, thrombocytopenic purpura, thrombophlebitis, T-wave inversion, ulcerative colitis, urinary retention, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cevimeline or any component of the formulation; uncontrolled asthma; narrow-angle glaucoma; acute iritis; other conditions where miosis is undesirable",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parasympathomimetic effects: May cause a variety of parasympathomimetic effects, which may be particularly dangerous in elderly patients; excessive sweating may lead to dehydration in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual effects: May cause decreased visual acuity (particularly at night and in patients with central lens changes) and impaired depth perception. Patients should be cautioned about driving at night or performing hazardous activities in reduced lighting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary stones: Use with caution in patients with a history of biliary stones; may induce smooth muscle spasms, precipitating cholangitis, cholecystitis, or biliary obstruction in susceptible patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with significant cardiovascular disease (including angina, myocardial infarction, or conduction disturbances); may alter cardiac conduction and/or heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrolithiasis: Use with caution in patients with a history of nephrolithiasis; may induce smooth muscle spasms, precipitating renal colic or ureteral reflux in susceptible patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with controlled asthma, COPD, or chronic bronchitis; may increase bronchial smooth muscle tone, airway resistance, and bronchial secretions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients with CYP2D6 deficiency: Patients with a known or suspected deficiency of CYP2D6 may be at higher risk of adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F149154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F149122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F149132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F149130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Cevimeline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $348.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Evoxac Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $387.60",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Evoxac (JP, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to muscarinic (cholinergic) receptors, causing an increase in secretion of exocrine glands (including salivary glands)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2D6 and CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites and unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8884 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5CA193EFE4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12932=[""].join("\n");
var outline_f12_40_12932=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149142\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149143\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149160\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149146\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149147\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930034\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930035\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149125\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149111\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460385\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149126\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149167\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149158\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149129\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149115\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149154\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149120\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149122\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149131\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149149\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149132\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149130\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149133\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149114\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149128\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8884\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8884|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/60/7108?source=related_link\">",
"      Cevimeline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_40_12933="Bezafibrate: Drug information";
var content_f12_40_12933=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bezafibrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/44/31428?source=see_link\">",
"    see \"Bezafibrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bezalip&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, Fibric Acid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Dyslipidemia:",
"     </b>",
"     Oral: 400 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12617470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Dyslipidemia:",
"     </b>",
"     Oral: Children &ge;20 kg: 10-20 mg/kg/day (maximum: 400 mg).",
"     <b>",
"      Note:",
"     </b>",
"     Limited experience available; use caution.  Based on child&rsquo;s weight, dosing may not be possible as the manufacturer recommends administering the sustained release tablet whole.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2649926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dyslipidemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients &lt;70 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients &gt;70 years: Manufacturer labeling recommends avoiding use in patients &gt;70 years due to declining renal function and the likelihood of Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute in this population.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F141146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute",
"     <b>",
"      or",
"     </b>",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.5 mg/dL: Use is contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12617466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bezalip&reg; SR: 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F141120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Do not crush or chew; tablet should be swallowed whole with sufficient fluid. Take in morning or evening with or after meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F141119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to diet and other therapeutic measures for treatment of type IIa and IIb mixed hyperlipidemia, to regulate lipid and apoprotein levels (reduce serum TG, LDL-cholesterol, and apolipoprotein B, increase HDL-cholesterol and apolipoprotein A); treatment of adult patients with high to very high triglyceride levels (Fredrickson classification type IV and V hyperlipidemias) who are at high risk of sequelae and complications from their dyslipidemia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F141179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (4%), dizziness (2%), insomnia (1%), migraine (1%), pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus (3%), eczema (1%), erythema, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Gastritis (6%), flatulence (5%), dyspepsia (3%), constipation, diarrhea, epigastric distress, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, cholelithiasis, creatinine increased, hypersensitivity, myopathy, pancytopenia, rhabdomyolysis, rhabdomyolysis, Stevens-Johnson syndrome, thrombocytopenia purpura, toxic epidermal necrolysis, WBC decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F141123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bezafibrate, fibrates, or any component of the formulation; photoallergic or phototoxic reactions to fibrates; hepatic impairment; primary biliary cirrhosis; renal impairment (serum creatinine &gt;1.5 mg/dL, Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute, or patients undergoing dialysis); pre-existing gallbladder disease; concomitant use with HMG CoA reductase inhibitors in patients predisposed to myopathy (eg, preexisting renal impairment, hormonal or electrolyte imbalance, severe infection, trauma, surgery); pregnancy or breast-feeding; not indicated for the treatment of type I hyperlipoproteinemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F141106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Mild decreases in WBCs, platelets, and hemoglobin may occur following initiation of therapy; levels tend to stabilize with prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Has been shown to be hepatotoxic; discontinue therapy if response is not obtained in 3 months. Use with caution in patients with history of jaundice or hepatic disorder. Abnormal liver function tests have been observed; discontinue therapy if abnormalities persist (reversible when discontinued). May increase risk for cholelithiasis; discontinue therapy in patients diagnosed with cholelithiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Has been associated with rare myositis or rhabdomyolysis (usually with renal impairment); monitor closely. Instruct patients to report unexplained muscle pain, tenderness, weakness, or brown urine. Evaluate creatine phosphokinase (CPK) levels with signs/symptoms of myotoxicity; discontinue therapy with marked elevation of CPK (10 x ULN) or diagnosis of myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumorigenic: Has been shown to be possibly tumorigenic (animal models); discontinue if response is not obtained in 3 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HMG-CoA reductase inhibitors: Use caution with HMG-CoA reductase inhibitors; may lead to myopathy, rhabdomyolysis. Monitor closely and discontinue immediately if patient presents with signs/symptoms of myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Warfarin: Use with caution; warfarin dose adjustments may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Due to the likelihood of renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute) in patients &gt;70 years of age, use is not recommended in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Limited experience is available in children; therefore, caution should be used when treating children. Accurate dosing may not be achievable as sustained release tablet should be administered whole and not cut.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F141177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Fibric Acid Derivatives. Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any fibric acid derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic). Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: Fibric Acid Derivatives may increase the serum concentration of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Bezafibrate may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin  Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Fibric Acid Derivatives may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fibric Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F141126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in pregnant women. Embryotoxicity has occurred in animals at toxic doses. Therapy should be discontinued in women who become pregnant during therapy. Women planning pregnancy should discontinue bezafibrate several months before conception and women of childbearing potential should employ effective birth control methods.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F141149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F141127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use during lactation due to absence of data concerning the presence of bezafibrate in human breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F141128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with or after meals. Before initiation of therapy, patients should be placed on a standard lipid-lowering diet for 6 weeks and the diet should be continued during drug therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F141115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic evaluation of serum lipids, cholesterol, and triglycerides (especially in the first few months of therapy). LFTs after 3-6 months; then at least annually. CBC (periodically during the first 12 months). Fasting glucose, creatinine, and CPK periodically.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F141129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abeita (CL);",
"     </li>",
"     <li>",
"      Befizal (FR);",
"     </li>",
"     <li>",
"      Befizal LP (FR);",
"     </li>",
"     <li>",
"      Bezacur (AT, LU);",
"     </li>",
"     <li>",
"      Bezafibrat (DE, DK);",
"     </li>",
"     <li>",
"      Bezalip (AR, AT, CZ, FI, GB, GR, HK, HN, HU, IE, IN, IT, JP, MX, NL, NO, NZ, PK, PT, SE, TH, TW, VE, ZA);",
"     </li>",
"     <li>",
"      Bezalip Retard (EC, HK, IN, KP, MX, NZ, PE, PT, TW, UY);",
"     </li>",
"     <li>",
"      Bezamidin (CZ, HR, HU, PL);",
"     </li>",
"     <li>",
"      Bezamil (TH);",
"     </li>",
"     <li>",
"      Bezastad (PH);",
"     </li>",
"     <li>",
"      Bezatol SR (JP);",
"     </li>",
"     <li>",
"      Cedur (BE, BR, DE, LU);",
"     </li>",
"     <li>",
"      Cedur Retard (CH);",
"     </li>",
"     <li>",
"      Clofibral (PY);",
"     </li>",
"     <li>",
"      Decrilip (ID);",
"     </li>",
"     <li>",
"      Etifibrat (SV);",
"     </li>",
"     <li>",
"      Eulip (TW);",
"     </li>",
"     <li>",
"      Eulitop (ES);",
"     </li>",
"     <li>",
"      Evicta (TH);",
"     </li>",
"     <li>",
"      Fibalip (NZ);",
"     </li>",
"     <li>",
"      Lacromid (CY);",
"     </li>",
"     <li>",
"      Lipocin (MX);",
"     </li>",
"     <li>",
"      Lipocor (PK);",
"     </li>",
"     <li>",
"      Nimus (CN);",
"     </li>",
"     <li>",
"      Norlip (IL);",
"     </li>",
"     <li>",
"      Oralipin (CN);",
"     </li>",
"     <li>",
"      Oralipin Retard (PY);",
"     </li>",
"     <li>",
"      Polyzalip (TH);",
"     </li>",
"     <li>",
"      Zafibral (SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F141105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mechanism not definitely established; may increase VLDL catabolism by increasing lipoprotein and hepatic triglyceride lipase activities; attenuation of triglyceride biosynthesis by inhibition of acetyl-CoA carboxylase; decreased cholesterol biosynthesis by inhibition of 3-hydroxy-3-methyglutaryl-coenzyme A reductase",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F141122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~17 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 94% to 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (95%); feces (3%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bezalip&reg; SR product monograph, ACTAVIS Group PTC ehf, Iceland, May 2008",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ericsson CG, Nilsson J, Grip L, et al, &ldquo;Effect of Bezafibrate Treatment Over Five Years on Coronary Plaques Causing 20% to 50% Diameter Narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]),&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1997, 80(9):1125-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12933/abstract-text/9359536/pubmed\" id=\"9359536\" target=\"_blank\">",
"        9359536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12933/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Genest J, McPherson R, Frohlich J, et al, &ldquo;2009 Canadian Cardiovascular Society/Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease in the Adult &ndash; 2009 Recommendations,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2009, 25(10):567-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12933/abstract-text/19812802/pubmed\" id=\"19812802\" target=\"_blank\">",
"        19812802",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12933/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study. The BIP Study Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(1):21-7",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12933/abstract-text/10880410/pubmed\" id=\"10880410\" target=\"_blank\">",
"        10880410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8696 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-70BC344B75-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12933=[""].join("\n");
var outline_f12_40_12933=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141141\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141181\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141145\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617470\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649926\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141146\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617466\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076205\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217333\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141120\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141119\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141179\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141123\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141106\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141177\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141110\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141126\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141149\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141127\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141128\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141115\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141129\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141105\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141122\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8696\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8696|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/44/31428?source=related_link\">",
"      Bezafibrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_40_12934="Desloratadine: Drug information";
var content_f12_40_12934=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Desloratadine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/41/44692?source=see_link\">",
"    see \"Desloratadine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23765?source=see_link\">",
"    see \"Desloratadine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clarinex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aerius&reg;;",
"     </li>",
"     <li>",
"      Aerius&reg; Kids;",
"     </li>",
"     <li>",
"      Desloratadine Allergy Control",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F157732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F157705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Seasonal or perennial allergic rhinitis, chronic idiopathic urticaria:",
"     </b>",
"     Oral: 5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F157720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23765?source=see_link\">",
"      see \"Desloratadine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Perennial allergic rhinitis, chronic idiopathic urticaria:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-11 months: 1 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     12 months to 5 years: 1.25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-11 years: 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-5 years: 1.25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-11 years: 2.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F157706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F157707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Mild-to-severe impairment: 5 mg every other day.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F157708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Mild-to-severe impairment: 5 mg every other day.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarinex&reg;: 0.5 mg/mL (480 mL) [contains propylene glycol, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarinex&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarinex&reg;: 2.5 mg [DSC] [contains phenylalanine 1.4 mg/tablet; tutti frutti flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clarinex&reg;: 5 mg [DSC] [contains phenylalanine 2.9 mg/tablet; tutti frutti flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes syrup",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F157684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     RediTabs&reg; should be placed on the tongue; tablet will disintegrate immediately. Take immediately after removing from blister package. Allow tablet to dissolve completely before swallowing. May be taken with or without water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup: A commercially-available measuring dropper or syringe calibrated to deliver 2 mL or 2.5 mL should be used to administer age-appropriate doses in children.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F157683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR); treatment of chronic idiopathic urticaria (CIU)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7258803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Clarinex&reg; may be confused with Celebrex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F157730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency reported in children, unless otherwise noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (12% to 17%), headache (adults 14%), irritability (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (15% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (11% to 21%), cough (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (children 9%; adults 2%), insomnia (5%), fatigue (adults 2% to 5%), dizziness (adults 4%), emotional lability (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema (3%), maculopapular rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (adults 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (6%), anorexia (5%), nausea (children 3%; adults 5%), nausea (5%), appetite increased (3%), dyspepsia (adults 3%), xerostomia (adults 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (adults 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (children 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (6%), rhinorrhea (5%), pharyngitis (children 3% to 5%; adults 3% to 4%), epistaxis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Varicella infection (4%), parasitic infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Hepatitis (rare), hyperbilirubinemia; hypersensitivity reactions (including anaphylaxis, dyspnea, edema, pruritus, rash, urticaria); liver enzymes increased, palpitations, psychomotor hyperactivity, seizures, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F157687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to desloratadine, loratadine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F157673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) have been reported with use; discontinue therapy immediately with signs/symptoms of hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Slow metabolizers: Use with caution in patients known to be slow metabolizers of desloratadine (incidence of side effects may be increased).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F157699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Does not affect bioavailability.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F157679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F157690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies desloratadine as pregnancy category C. The use of antihistamines for the treatment of rhinitis during pregnancy is generally considered to be safe at recommended doses. Information related to the use of desloratadine during pregnancy is limited; therefore, other agents may be preferred. Desloratadine is the primary metabolite of loratadine; refer to the Loratadine monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F157711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12881344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Desloratadine is excreted into breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F157691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F157689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Clarinex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/mL (473 mL): $294.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Clarinex Reditabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $194.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $194.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Desloratadine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (30): $174.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $174.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Clarinex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $603.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Desloratadine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $501.83",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F157692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aerius (AR, AT, AU, BE, BG, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, MT, MY, NI, NL, NO, NZ, PA, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, VE);",
"     </li>",
"     <li>",
"      Aloret (PK);",
"     </li>",
"     <li>",
"      Aviant (MX);",
"     </li>",
"     <li>",
"      Azomyr (AR, AT, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, MX, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Campos (DO, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Claramax (AU, NZ);",
"     </li>",
"     <li>",
"      Delorat (UY);",
"     </li>",
"     <li>",
"      Denosin 5 (TW);",
"     </li>",
"     <li>",
"      Desalex (BR, CO);",
"     </li>",
"     <li>",
"      Deschu (TW);",
"     </li>",
"     <li>",
"      Deslogen (PH);",
"     </li>",
"     <li>",
"      Deslor (IN);",
"     </li>",
"     <li>",
"      Desloran (EC);",
"     </li>",
"     <li>",
"      Desora (TW);",
"     </li>",
"     <li>",
"      Despej (PE);",
"     </li>",
"     <li>",
"      Destina (PK);",
"     </li>",
"     <li>",
"      Letizia (PE);",
"     </li>",
"     <li>",
"      Loralergan (PE);",
"     </li>",
"     <li>",
"      Neoclaritine (CN);",
"     </li>",
"     <li>",
"      Neoclarityn (AT, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Supraler (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F157672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Desloratadine, a major active metabolite of loratadine, is a long-acting tricyclic antihistamine with selective peripheral histamine H",
"     <sub>",
"      1",
"     </sub>",
"     receptor antagonistic activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F157686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Desloratadine: 82% to 87%; 3-hydroxydesloratadine (active metabolite): 85% to 89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to active metabolite, 3-hydroxydesloratadine (specific enzymes not identified); subsequently undergoes glucuronidation. Decreased in slow metabolizers of desloratadine. Not expected to affect or be affected by medications metabolized by CYP with normal doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 27 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      McClellan K and Jarvis B, &ldquo;Desloratadine,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2001, 61(6):789-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12934/abstract-text/11398910/pubmed\" id=\"11398910\" target=\"_blank\">",
"        11398910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8472 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-422ACB6E1F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12934=[""].join("\n");
var outline_f12_40_12934=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157702\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157703\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157732\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157705\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157720\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157706\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157707\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157708\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157669\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157684\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157683\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7258803\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157730\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157687\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157673\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837880\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157677\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157699\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157679\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157711\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12881344\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157691\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157689\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157692\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157672\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157686\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8472\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8472|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/41/44692?source=related_link\">",
"      Desloratadine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/13/23765?source=related_link\">",
"      Desloratadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_40_12935="Azacitidine: Drug information";
var content_f12_40_12935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azacitidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24884?source=see_link\">",
"    see \"Azacitidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vidaza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14476760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vidaza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, DNA Methylation Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      MDS:",
"     </b>",
"     I.V., SubQ: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 7 days repeated every 4 weeks. Dose may be increased to 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day if no benefit is observed after 2 cycles and no toxicity other than nausea and vomiting have occurred. Treatment is recommended for at least 4 cycles; treatment may be continued as long as patient continues to benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Alternate (unlabeled) schedules (which have produced hematologic response) have been used for convenience in community oncology centers (Lyons, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (Mon-Fri), 2 days rest (Sat, Sun), then 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 2 days (Mon, Tues); repeat cycle every 28 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (Mon-Fri), 2 days rest (Sat, Sun), then 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (Mon-Fri); repeat cycle every 28 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days (Mon-Fri), repeat cycle every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      AML (unlabeled use):",
"     </b>",
"     SubQ: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 7 days repeated every 4 weeks (Sudan, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment based on hematology:",
"     </b>",
"     Adults: I.V., SubQ: MDS:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     For baseline WBC &ge;3.0 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, ANC &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, and platelets &ge;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nadir count: ANC &lt;0.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L or platelets &lt;25 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Administer 50% of dose during next treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nadir count: ANC 0.5-1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L or platelets 25-50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Administer 67% of dose during next treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nadir count: ANC &gt;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L or platelets &gt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Administer 100% of dose during next treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     For baseline WBC &lt;3 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, ANC &lt;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, or platelets &lt;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Adjust dose as follows based on nadir counts and bone marrow biopsy cellularity at the time of nadir, unless clear improvement in differentiation at the time of the next cycle:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC or platelet nadir decreased 50% to 75% from baseline and bone marrow biopsy cellularity at time of nadir 30% to 60%: Administer 100% of dose during next treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC or platelet nadir decreased 50% to 75% from baseline and bone marrow biopsy cellularity at time of nadir 15% to 30%: Administer 50% of dose during next treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC or platelet nadir decreased 50% to 75% from baseline and bone marrow biopsy cellularity at time of nadir &lt;15%: Administer 33% of dose during next treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC or platelet nadir decreased &gt;75% from baseline and bone marrow biopsy cellularity at time of nadir 30% to 60%: Administer 75% of dose during next treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC or platelet nadir decreased &gt;75% from baseline and bone marrow biopsy cellularity at time of nadir 15% to 30%: Administer 50% of dose during next treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC or platelet nadir decreased &gt;75% from baseline and bone marrow biopsy cellularity at time of nadir &lt;15%: Administer 33% of dose during next treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If a nadir defined above occurs, administer the next treatment course 28 days after the start of the preceding course as long as WBC and platelet counts are &gt;25% above the nadir and rising. If a &gt;25% increase above the nadir is not seen by day 28, reassess counts every 7 days. If a 25% increase is not seen by day 42, administer 50% of the scheduled dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment based on serum electrolytes:",
"     </b>",
"     The manufacturer recommends that if serum bicarbonate falls to &lt;20 mEq/L (unexplained decrease): Reduce dose by 50% for next treatment course",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F138164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Refractory AML (unlabeled use):",
"     </b>",
"     250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 4 and 5 every 4 weeks (Steuber, 1996)",
"     <b>",
"      or",
"     </b>",
"     300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 4 and 5 every 4 weeks (Hurwitz, 1995)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Due to the potential for decreased renal function in the elderly, select dose carefully and closely monitor renal function.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F138152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Not studied in patients with renal impairment; select dose carefully (excretion is primarily renal; consider dose reduction); monitor closely for toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4300621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not studied in patients with hepatic impairment; use caution. Contraindicated in patients with advanced malignant hepatic tumors.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F4300622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Renal toxicity:",
"     </b>",
"     If increases in BUN or serum creatinine (unexplained) occur, delay next cycle until values reach baseline or normal, then reduce dose by 50% for next treatment course.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vidaza&reg;: 100 mg [contains mannitol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F138131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: Premedication for nausea and vomiting is recommended. The manufacturer recommends equally dividing volumes &gt;4 mL into 2 syringes and injecting into 2 separate sites; however, policies for maximum SubQ administration volume may vary by institution; interpatient variations may also apply. Administer subsequent injections at least 1 inch from previous injection sites. Allow refrigerated suspensions to come to room temperature (up to 30 minutes) prior to administration. Resuspend by inverting the syringe 2-3 times and then rolling the syringe between the palms for 30 seconds. If azacitidine suspension comes in contact with the skin, immediately wash with soap and water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Premedication for nausea and vomiting is recommended. Infuse over 10-40 minutes; infusion must be completed within 1 hour of (vial) reconstitution.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F4300592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in LR, NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of myelodysplastic syndrome (MDS)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F138166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute myelogenous leukemia (AML)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       AzaCITIDine may be confused with azaTHIOprine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F138168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (7% to 19%), chest pain (16%), pallor (16%), pitting edema (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (30% to 52%), fatigue (13% to 36%), headache (22%), dizziness (19%), anxiety (5% to 13%), depression (12%), insomnia (9% to 11%), malaise (11%), pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (19% to 31%), petechiae (11% to 24%), erythema (7% to 17%), skin lesion (15%), rash (10% to 14%), pruritus (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (48% to 71%), vomiting (27% to 54%), diarrhea (36%), constipation (34% to 50%), anorexia (13% to 21%), weight loss (16%), abdominal pain (11% to 16%), abdominal tenderness (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (66% to 70%; grades 3/4: 58%), anemia (51% to 70%; grades 3/4: 14%), neutropenia (32% to 66%; grades 3/4: 61%), leukopenia (18% to 48%; grades 3/4: 15%), febrile neutropenia (14% to 16%; grades 3/4: 13%), myelosuppression (nadir: days 10-17; recovery: days 28-31)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (14% to 29%): Erythema (35% to 43%; more common with I.V. administration), pain (19% to 23%; more common with I.V. administration), bruising (5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (29%), rigors (26%), arthralgia (22%), limb pain (20%), back pain (19%), myalgia (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (11% to 30%), dyspnea (5% to 29%), pharyngitis (20%), epistaxis (16%), nasopharyngitis (15%), upper respiratory tract infection (9% to 13%), pneumonia (11%), crackles (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiac murmur (10%), hypertension (&le;9%), tachycardia (9%), hypotension (7%), syncope (6%), chest wall pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Lethargy (7% to 8%), hypoesthesia (5%), postprocedural pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Cellulitis (8%), urticaria (6%), dry skin (5%), skin nodule (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gingival bleeding (10%), oral mucosal petechiae (8%), stomatitis (8%), weight loss (&le;8%), dyspepsia (6% to 7%), hemorrhoids (7%), abdominal distension (6%), loose stools (6%), dysphagia (5%), oral hemorrhage (5%), tongue ulceration (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (8%), urinary tract infection (8% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hematoma (9%), postprocedural hemorrhage (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Pruritus (7%), hematoma (6%), rash (6%), granuloma (5%), induration (5%), pigmentation change (5%), swelling (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinorrhea (10%), rales (9%), wheezing (9%), breath sounds decreased (8%), pharyngolaryngeal pain (6%), pleural effusion (6%), postnasal drip (6%), rhinitis (6%), rhonchi (6%), nasal congestion (6%), atelectasis (5%), sinusitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Lymphadenopathy (10%), herpes simplex (9%), night sweats (9%), transfusion reaction (7%), mouth hemorrhage (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5% (Limited to important or life-threatening): Abscess (limb, perirectal), acute febrile neutrophilic dermatosis (Sweet&rsquo;s syndrome), agranulocytosis, anaphylactic shock, atrial fibrillation, azotemia, blastomycosis, bone marrow depression/failure, bone pain aggravated, cardiac failure, cardiorespiratory arrest, catheter site hemorrhage, cellulitis, cerebral hemorrhage, CHF, cholecystectomy, cholecystitis, congestive cardiomyopathy, dehydration, diverticulitis, eye hemorrhage, fibrosis (interstitial and alveolar), gastrointestinal hemorrhage, glycosuria, hemoptysis, hepatic coma, hypersensitivity reaction, hypophosphatemia, infection (bacterial), injection site infection, injection site necrosis, interstitial lung disease, intracranial hemorrhage, leukemia cutis, lung infiltration, melena, neutropenic sepsis, orthostatic hypotension, pancytopenia, pneumonitis, polyuria, pyoderma gangrenosum, renal failure, renal tubular acidosis, seizure, respiratory distress, sepsis, septic shock, serum bicarbonate levels decreased, serum creatinine increased, splenomegaly, systemic inflammatory response syndrome, toxoplasmosis, tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F138134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azacitidine, mannitol, or any component of the formulation; advanced malignant hepatic tumors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F138117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Neutropenia, thrombocytopenia, and anemia are common; may cause therapy delays and/or dosage reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: May be hepatotoxic, progressive hepatic coma leading to death has been reported (rare) in patients with extensive tumor burden, especially those with a baseline albumin &lt;30 g/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicities: Serum creatinine elevations, renal tubular acidosis, and renal failure have been reported with combination chemotherapy; decrease or withhold dose for unexplained elevations in BUN or serum creatinine, or reductions in serum bicarbonate to &lt;20 mEq/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Patients with hepatic impairment were excluded from clinical studies. Use is contraindicated in patients with advanced malignant hepatic tumors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dose adjustment may be required. Patients with renal impairment were excluded from clinical studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not FDA approved for use in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F138136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity, fetal death, and fetal abnormalities were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should be advised to avoid pregnancy during treatment. In addition, males should be advised to avoid fathering a child while on azacitidine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F138159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4300527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Vidaza Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $658.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F138125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, electrolytes, CBC with differential and platelets, renal function tests (BUN and serum creatinine) should be obtained prior to initiation of therapy. Electrolytes, renal function (BUN and creatinine), CBC should be monitored prior to each cycle and periodically as needed to monitor response and toxicity.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Vidaza (AR, AT, AU, BE, BR, CH, CN, CO, CR, CZ, DE, DK, DO, EE, FR, GB, GR, GT, HK, HN, IE, IL, KP, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, SE, SG, SV, TH, TR, TW, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F138116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antineoplastic effects may be a result of azacitidine's ability to promote hypomethylation of DNA leading to direct toxicity of abnormal hematopoietic cells in the bone marrow.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F138133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : I.V.: 76 &plusmn; 26 L; does not cross blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; hydrolysis to several metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: ~89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V., SubQ: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: SubQ: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50% to 85%); feces (minor)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adams CD, Szumita PM, Baroletti SA, et al, &ldquo;Azacitidine-Induced Interstitial and Alveolar Fibrosis in a Patient  With Myelodysplastic Syndrome,&rdquo;",
"      <i>",
"       Pharmacother",
"      </i>",
"      , 2006, 25(5):765-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hurwitz CA, Mounce KG, and Grier HE, &ldquo;Treatment of Patients With Acute Myelogenous Leukemia: Review of Clinical Trials of the Past Decade,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 1995, 17(3):185-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/7620918/pubmed\" id=\"7620918\" target=\"_blank\">",
"        7620918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jehn U, &ldquo;Long-Term Outcome of Postremission Chemotherapy for Adults With Acute Myeloid Leukemia Using Different Dose-Intensities,&rdquo;",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 1994, 15(1-2):99-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/7532060/pubmed\" id=\"7532060\" target=\"_blank\">",
"        7532060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kornblith AB, Herndon JE 2nd, Silverman LR, et al, &ldquo;Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(10):2441-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/12011121/pubmed\" id=\"12011121\" target=\"_blank\">",
"        12011121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kritz AD, Raptis G, Menendez-Botet C, et al, &ldquo;Pilot Study of 5-Azacytidine (5-AZA) and Carboplatin (CBDCA) in Patients With Relapsed/Refractory Leukemia,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 1996, 51(2):117-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/8579051/pubmed\" id=\"8579051\" target=\"_blank\">",
"        8579051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lyons RM, Cosgriff TM, Modi SS, et al, &ldquo;Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndrome,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(11):1850-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/19255328/pubmed\" id=\"19255328\" target=\"_blank\">",
"        19255328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Acute Myeloid Leukemia,&rdquo; Version 1, 2009. Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Myelodysplastic Syndromes,&rdquo; Version 2.2009. Available at  file://www.nccn.org/professionals/physician_gls/PDF/mds.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peterson BA, Collins AJ, Vogelzang NJ, et al, &ldquo;5-Azacytidine and Renal Tubular Dysfunction,&rdquo; Blood, 1981, 57(1):182-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/6160887/pubmed\" id=\"6160887\" target=\"_blank\">",
"        6160887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rees JK, Gray RG, and Wheatley K, &ldquo;Dose Intensification in Acute Myeloid Leukaemia: Greater Effectiveness at Lower Cost. Principal Report of the Medical Research Council's AML9 Study. MRC Leukaemia in Adults Working Party,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 1996, 94(1):89-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/8757514/pubmed\" id=\"8757514\" target=\"_blank\">",
"        8757514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverman LR, Demakos EP, Peterson BL, et al, &ldquo;Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(10):2429-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/12011120/pubmed\" id=\"12011120\" target=\"_blank\">",
"        12011120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverman LR, Holland JF, Weinberg RS, et al, &ldquo;Effects of Treatment With 5-Azacytidine on the",
"      <i>",
"       in vivo",
"      </i>",
"      and",
"      <i>",
"       in vitro",
"      </i>",
"      Hematopoiesis in Patients With Myelodysplastic Syndromes,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 1993, 7(Suppl 1):21-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/7683352/pubmed\" id=\"7683352\" target=\"_blank\">",
"        7683352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverman LR, McKenzie DR, Peterson BL, et al,&rdquo;Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(24):3895-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/16921040/pubmed\" id=\"16921040\" target=\"_blank\">",
"        16921040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steuber CP, Krischer J, Holbrook T, et al, &ldquo;Therapy of Refractory or Recurrent Childhood Acute Myeloid Leukemia Using Amsacrine and Etoposide With or Without Azacitidine: A Pediatric Oncology Group Randomized Phase II Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(5):1521-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/8622066/pubmed\" id=\"8622066\" target=\"_blank\">",
"        8622066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steuber CP, Holbrook T, Camitta B, et al, &ldquo;Toxicity Trials of Amsacrine (AMSA) and Etoposide &plusmn; Azacitidine (AZ) in Childhood Acute Nonlymphocytic Leukemia (ANLL): A Pilot Study,&rdquo;",
"      <i>",
"       Invest New Drugs",
"      </i>",
"      , 1991, 9(2):181-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/1714886/pubmed\" id=\"1714886\" target=\"_blank\">",
"        1714886",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sudan N, Rossetti JM, Shadduck RK, et al, &ldquo;Treatment of Acute Myelogenous Leukemia With Outpatient Azacitidine,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 107(8):1839-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/16967444/pubmed\" id=\"16967444\" target=\"_blank\">",
"        16967444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Volger WR, Weiner RS, Moore JO, et al, &ldquo;Long-Term Follow-up of a Randomized Postinduction Therapy Trial in Acute Myelogenous Leukemia (A Southeastern Cancer Study Group Trial),&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 1995, 9(9):1456-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/40/12935/abstract-text/7544851/pubmed\" id=\"7544851\" target=\"_blank\">",
"        7544851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8797 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12935=[""].join("\n");
var outline_f12_40_12935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138149\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14476760\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138170\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138150\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138164\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138151\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138152\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4300621\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4300622\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138127\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138114\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138131\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4300592\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138130\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138166\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401583\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138168\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138134\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138117\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298800\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218155\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138123\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138136\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138159\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4300527\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323005\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138125\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875313\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138116\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138133\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24884?source=related_link\">",
"      Azacitidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_40_12936="Evaluation of the immobile arm in children";
var content_f12_40_12936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the immobile arm in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/40/12936/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12936/contributors\">",
"     Sara Schutzman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/40/12936/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12936/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/40/12936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12936/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/40/12936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H356005530\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An immobile arm is a relatively common complaint in pediatrics evaluated in both the emergency department and primary care provider office. An infant or child is not moving the limb either due to current or recently resolved pain or weakness and can be considered to have an upper extremity equivalent of a &ldquo;limp&rdquo;. Since many of these children are preverbal and fearful of strangers, the evaluation may be challenging. Radial head subluxation (&ldquo;nursemaid&rsquo;s elbow&rdquo;) is by far the most common cause of arm immobility in children younger than six years of age, however, children with much more serious pathology may present with this complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12936/abstract/1\">",
"     1",
"    </a>",
"    ]. By using historical information, physical findings, selective radiologic studies, and laboratory tests, children with an immobile arm can be appropriately diagnosed and managed.",
"   </p>",
"   <p>",
"    This topic will discuss the approach to the child with an immobile arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005537\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An immobile arm most frequently results from radial head subluxation or an injury after a fall. The causes of an immobile arm are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef87861 \" href=\"UTD.htm?5/46/5868\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005545\">",
"    <span class=\"h2\">",
"     Life and limb-threatening causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although these causes of an immobile arm are presented first and should always be considered, other than trauma, they are quite rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005552\">",
"    <span class=\"h3\">",
"     Complicated fracture or dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with fractures or dislocations typically present with a history of trauma and have focal tenderness, swelling, or deformity. Although uncommon, associated neurovascular compromise or an open fracture may be present and require emergent intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42120?source=see_link\">",
"     \"Diagnosis and assessment of distal forearm fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30934?source=see_link\">",
"     \"Midshaft humeral fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link\">",
"     \"Evaluation and management of supracondylar fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87050670\">",
"    <span class=\"h3\">",
"     Child abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the preverbal child, the history of trauma may be absent either because it was unwitnessed or inflicted by a caretaker who is not forthcoming. Careful physical examination of the child often identifies other signs of inflicted trauma. In addition, inflicted fractures may have characteristic findings on radiographs. Identifying inflicted injuries is crucial to preventing further, potentially more serious injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005574\">",
"    <span class=\"h3\">",
"     Bone or joint infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone or joint infections are an uncommon cause of immobile arm. Patients often (but not uniformly) have associated history of fever. The onset of arm disuse is often less abrupt than with trauma. There is frequently associated paradoxical irritability (increased crying when being held), localized swelling, warmth and tenderness; infected joints usually have limited, painful range of motion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5832605\">",
"    <span class=\"h3\">",
"     Necrotizing cellulitis or fasciitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing soft tissue infections in children are most commonly caused by group A streptococcus; other agents include s. aureus and anaerobic organisms. Predisposing factors include skin trauma (eg, laceration, burn, surgery) and varicella, although skin may be intact. Children are usually febrile and toxic and the affected area is typically erythematous (without sharp borders), swollen, warm, shiny and exquisitely tender, often with pain out of proportion to the physical exam findings. Advanced cases may show blue-gray skin with cutaneous gangrene. Compartment syndrome and complicating myonecrosis may occur and CPK is often elevated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link&amp;anchor=H6762906#H6762906\">",
"     \"Necrotizing soft tissue infections\", section on 'Necrotizing fasciitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link&amp;anchor=H18#H18\">",
"     \"Necrotizing soft tissue infections\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005588\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stroke is a rare cause of arm weakness in children and typically presents with abrupt onset of hemiparesis (rather than isolated arm paresis). Although stroke may affect the arm more than the leg, suggesting a monoplegia, careful examination may reveal mild leg weakness, deep tendon reflex abnormalities or extensor plantar response. Stoke may also be associated with headache, seizure, altered mental status or speech difficulty. Children with sickle cell disease, structural cardiac disease, and coagulation disorders are predisposed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link&amp;anchor=H4#H4\">",
"     \"Ischemic stroke in children and young adults: Etiology and clinical features\", section on 'Etiologies and risk factors in children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005603\">",
"    <span class=\"h3\">",
"     Tumor or malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, a child with a neoplasm or malignancy may have decreased arm movement due to pain, either from tumors of bone, cartilage or muscle, or from neoplastic infiltration of the bone marrow. Associated pathologic fractures may be present. Typically less abrupt in onset, there may be a history of fever, malaise, or weight loss and localized tenderness or swelling may be present. With leukemia or neuroblastoma, abdominal mass, hepatosplenomegaly or pathologic adenopathy may be present. Rarely, tumors impinge on nerves or the brachial plexus, causing weakness (with or without pain) as the presenting symptom. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Bone and joint pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005610\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005618\">",
"    <span class=\"h3\">",
"     Radial head subluxation (nursemaid&rsquo;s elbow)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial head subluxation (RHS) is by far the most common cause of arm disuse and is a common elbow injury that is unique to young children, typically those younger than five years (peak incidence age two to three years). The classic mechanism involves a sudden pull of the arm (",
"    <a class=\"graphic graphic_figure graphicRef86688 \" href=\"UTD.htm?38/12/39108\">",
"     figure 1",
"    </a>",
"    ). However, almost half of injuries are caused by other mechanisms including falling and twisting, and it is not uncommon to have no history of trauma. The child with RHS typically holds the affected arm slightly flexed (often in the lap) with the forearm pronated and without spontaneous arm movement. The child is usually not distressed unless the elbow is moved (",
"    <a class=\"graphic graphic_figure graphicRef82235 \" href=\"UTD.htm?31/23/32127\">",
"     figure 2",
"    </a>",
"    ). There is typically no reproducible tenderness, warmth or swelling (best evaluated while distracting the child). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38532?source=see_link&amp;anchor=H4#H4\">",
"     \"Radial head subluxation (nursemaid's elbow)\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005632\">",
"    <span class=\"h3\">",
"     Fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture of the clavicle or arm may lead to arm disuse. In the neonate, this may be due to a difficult delivery. In the child there is typically a history of trauma with moderate to severe pain and examination reveals local swelling and tenderness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=see_link&amp;anchor=H29#H29\">",
"     \"Clavicle fractures\", section on 'Pediatric considerations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42120?source=see_link\">",
"     \"Diagnosis and assessment of distal forearm fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30934?source=see_link\">",
"     \"Midshaft humeral fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link\">",
"     \"Evaluation and management of supracondylar fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005639\">",
"    <span class=\"h3\">",
"     Soft tissue injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with soft tissue injuries usually present with a history of trauma and may have swelling, tenderness, or a contusion on exam. If obtained, radiographs show no bony abnormality. Rarely, direct neurologic injury may cause neurologic deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005674\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005682\">",
"    <span class=\"h3\">",
"     Hemoglobinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with sickle cell disease may present with decreased arm use because of stroke or vasoocclusive crisis, causing ischemia or infarction of bone marrow with acute bone pain. Long bones are commonly affected; however, young children frequently have involvement of the small bones of the hands and feet (dactylitis). Usually, no precipitating events are identified. The child typically has pain with localized tenderness and may have swelling of the involved areas. There may be associated warmth. If febrile, it is important to consider septic arthritis and osteomyelitis as children with sickle cell disease are susceptible to infection, and the clinical findings may overlap with bone infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Acute painful episodes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Cerebrovascular events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005689\">",
"    <span class=\"h3\">",
"     Inflammatory process",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonseptic arthritis may cause decreased arm use, and can be due to rheumatologic diseases, postinfectious causes, or, less commonly in the upper extremity, Lyme disease. In addition to a swollen, tender joint, children with inflammatory arthritis often have other findings of systemic disease including multiple joint involvement, rash, fever, adenopathy, heart murmur, hematuria or bloody stools. If the examination suggests an inflammatory arthritis but cannot exclude a septic process, then arthrocentesis is necessary for definitive diagnosis. Rarely, myositis (due to infection, injury, autoimmune or drug) can cause localized muscle tenderness and weakness leading to arm disuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14057?source=see_link\">",
"     \"Evaluation of the child with joint pain or swelling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5833237\">",
"    <span class=\"h3\">",
"     Congenital syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated infants with congenital syphilis may avoid movement of the upper extremities because of pain caused by osteochondritis or pathologic fracture (pseudoparalysis of Parrot) and typically present in the first months of life. Associated clinical findings may include hepatosplenomegaly, syphilitic rhinitis (&ldquo;snuffles&rdquo;), maculopapular rash, and generalized lymphadenopathy. Long bone films and serologic tests for syphilis can establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link&amp;anchor=H28809272#H28809272\">",
"     \"Congenital syphilis: Clinical features and diagnosis\", section on 'Early congenital syphilis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link&amp;anchor=H28809398#H28809398\">",
"     \"Congenital syphilis: Clinical features and diagnosis\", section on 'Approach to diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005696\">",
"    <span class=\"h3\">",
"     Bleeding disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with hemophilia or other bleeding disorder may have hemarthrosis or hematoma with minimal trauma. The child will typically have a history of a bleeding disorder (although not with the first presentation) and may or may not have a history of trauma. The affected joint is swollen and tender with limited range of motion but there is typically no fever or other systemic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of hemophilia\", section on 'Hemarthrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005703\">",
"    <span class=\"h3\">",
"     Conversion disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with weakness due to a conversion disorder are typically older children or adolescents and commonly demonstrate a notable lack of concern for their impairment. Their examination is often illogical both anatomically and physiologically. Discontinuous resistance during testing of power or give-way weakness may exist. Muscle wasting is absent, and reflexes are normal. Conversion disorder should be diagnosed only after organic causes have been ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005710\">",
"    <span class=\"h3\">",
"     Complex regional pain syndrome (reflex sympathetic dystrophy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with complex regional pain syndrome (CRPS) have pain to light touch and decreased movement that typically occurs in a single extremity (more commonly lower). There may or may not be history of preceding trauma. Onset of disuse and pain is usually less abrupt than with trauma, worsens over time and is unimproved or worsened by immobilization. Children with CRPS often have associated decreased skin temperature, edema and cyanosis, with some exhibiting hyperhidrosis. Erythema and fever are typically absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=see_link&amp;anchor=H10#H10\">",
"     \"Complex regional pain syndrome in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005717\">",
"    <span class=\"h3\">",
"     Other neurologic conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556738\">",
"    <span class=\"h4\">",
"     Todd paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Todd paralysis is a transient focal weakness that occurs after a seizure. The paralysis may be partial or complete. It is typically unilateral and although often a hemiparesis, it may be more prominent in one extremity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\", section on 'Behavior after the event'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005725\">",
"    <span class=\"h4\">",
"     Complex migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal motor deficits, usually hemiplegia, may occur during a classic migraine attack. The evolution of symptoms is variable but often includes scotomas, unilateral dysesthesias of the hand and mouth and unilateral weakness (may involve only the arm and face, sparing the leg). These non-headache symptoms may precede the headache by 30 to 60 minutes. Other features of migraine are often present, and typically include a throbbing frontotemporal headache contralateral to the affected hemisphere, as well as nausea and vomiting. The neurologic symptoms typically last less than 24 hours. First episodes of hemiplegic migraine should only be diagnosed after other causes of acute stroke have been excluded by brain imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=see_link&amp;anchor=H698850692#H698850692\">",
"     \"Classification of migraine in children\", section on 'Hemiplegic migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005746\">",
"    <span class=\"h4\">",
"     Brachial plexus pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachial plexus abnormalities are unusual causes of an immobile arm. Typical etiologies are determined by patient age as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neonatal brachial neuropathy",
"      </strong>",
"      &ndash; Brachial plexus injuries in the newborn are caused by excessive traction during delivery. Erb palsy involves the upper roots",
"      <span class=\"nowrap\">",
"       (C5/6),",
"      </span>",
"      causing the arm to be adducted and internally rotated, elbow extended, forearm pronated, and wrist flexed with preservation of hand movement. Klumpke palsy, an injury to the lower roots",
"      <span class=\"nowrap\">",
"       (C8/T1)",
"      </span>",
"      is much rarer, manifesting as isolated hand paralysis. Severe damage to all C5-T1 roots causes a flail arm and Horner syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H32#H32\">",
"       \"Brachial plexus syndromes\", section on 'Congenital brachial plexus palsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Postnatal brachial neuropathy",
"      </strong>",
"      &ndash; Although unusual, impairment of the brachial plexus is most often caused by trauma (traction or pressure), although tumor, inflammation or ischemia may rarely be responsible. Onset of symptoms may be acute or insidious and include weakness and pain, less commonly sensory loss. Examination may reveal weakness, atrophy, sensory loss, or diminished reflexes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=see_link&amp;anchor=H8#H8\">",
"       \"Brachial plexus syndromes\", section on 'Traumatic plexopathies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005772\">",
"    <span class=\"h4\">",
"     Mononeuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial, ulnar, or median nerve dysfunction causes weakness or sensory symptoms in the distal regions of innervation and is most commonly due to trauma (fracture or compression). Axillary neuropathy most commonly results from shoulder injury, direct trauma or pressure, and manifestations include numbness of the outer shoulder and deltoid weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556926\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005779\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive history helps narrow the extensive list of possible causes in the child with an immobile arm (",
"    <a class=\"graphic graphic_table graphicRef87861 \" href=\"UTD.htm?5/46/5868\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patient age",
"      </strong>",
"      &ndash; Patient age helps narrow the differential diagnosis as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neonates may present with birth complications (clavicle fracture, brachial plexus injury). If not from birth, arm disuse in this patient population and young infants up to one year of age is potentially concerning for significant pathology (eg, central nervous system abnormality, child abuse, septic arthritis, or osteomyelitis). It is important to note that infants may not mount a febrile response to infection and may only have nonspecific symptoms (eg, increased sleeping, lethargy, diminished feeding, irritability). Of note, congenital syphilis many cause pseudoparalysis in infants in the one to three month age range with or without fever.",
"     </li>",
"     <li>",
"      Children one to five years of age most commonly have radial head subluxation (RHS, nursemaid&rsquo;s elbow) or a fracture of the clavicle, humerus, or forearm bones, as the cause of an immobile arm.",
"     </li>",
"     <li>",
"      Children older than five years of age and adolescents typically have a fracture or soft tissue injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Onset",
"      </strong>",
"      &ndash; Acute arm immobility is usually due to trauma although acute onset may occur with some of the rare neurologic causes (eg, complex migraine, Todd paralysis, stroke). Subacute disuse is more typical of infection or a systemic disease such as an inflammatory arthritis, vasoocclusive crisis, or malignancy. If the patient is an infant, it should be determined whether the arm disuse began abruptly at birth, suggesting either brachial plexus injury or clavicle fracture sustained during a difficulty delivery, or more gradually in the first three months of life, as may be seen with pseudoparalysis of Parrot caused by congenital syphilis.",
"     </li>",
"     <li>",
"      <strong>",
"       Trauma",
"      </strong>",
"      &ndash; A history of a pull on the arm or trauma is typically present for children with RHS, fracture, or soft tissue injury. Details of the event may provide clues to the type of injury incurred: a fall onto an outstretched hand may cause soft tissue injury (eg, contusion, strain, or sprain) or an elbow, wrist or forearm fracture, whereas a sudden arm pull by a caregiver can cause RHS. It is important to note that many children with RHS may have a mechanism of injury other than traction.",
"     </li>",
"     <li>",
"      <strong>",
"       Pain",
"      </strong>",
"      &ndash; Pain is present for the majority of diagnoses but may be absent in RHS (if the arm is not moved) and with weakness due to rare neurologic processes. Location and duration of pain are important to elicit and can aid in diagnosing the etiology of the arm immobility.",
"     </li>",
"     <li>",
"      <strong>",
"       Other findings",
"      </strong>",
"      &ndash; Associated signs and symptoms can help suggest specific etiologies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fever, malaise, rash and weight loss can be seen in infectious, inflammatory or oncologic diseases.",
"     </li>",
"     <li>",
"      History of sickle cell disease, bleeding disorder, structural cardiac disease, or underlying inflammatory process (eg, rheumatologic disease) would suggest complications of the underlying illness as a possible etiology of arm disuse.",
"     </li>",
"     <li>",
"      Headache, seizure, paresthesias, or weakness would point to a neurologic cause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005821\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a full physical examination is important for evaluation of the child with arm disuse, examining a young child can prove challenging because they often cry when approached or touched by a stranger. Observation and inspection, sometimes from a distance of several paces, can provide information that might otherwise be unobtainable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       General appearance",
"      </strong>",
"      &ndash; Children with radial head subluxation typically appear comfortable as long as the arm is not moved. Significant pain at rest suggests fractures; or less commonly, arthritis, osteomyelitis, or sickle cell disease. Fever or ill appearance are concerning for an infectious cause.",
"     </li>",
"     <li>",
"      <strong>",
"       Examination of the affected arm",
"      </strong>",
"      &ndash; The following findings help in narrowing the differential diagnosis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Position",
"      </strong>",
"      &ndash; A child with RHS often holds the arm pronated and slightly flexed with obvious diminished movement although typically without apparent discomfort (",
"      <a class=\"graphic graphic_figure graphicRef82235 \" href=\"UTD.htm?31/23/32127\">",
"       figure 2",
"      </a>",
"      ). A child with neurologic abnormality may hold the arm limply at the side of the body. A child with a fracture may support the injured arm using the unaffected arm.",
"     </li>",
"     <li>",
"      <strong>",
"       Inspection",
"      </strong>",
"      &ndash; Evaluate for deformity, redness, swelling or bruising which may be evidence of localized trauma or inflammation.",
"     </li>",
"     <li>",
"      <strong>",
"       Palpation",
"      </strong>",
"      &ndash; The arm should be palpated from the sternoclavicular joint to the fingers to identify areas of warmth, swelling or tenderness (often best accomplished in the younger child while he or she is being distracted). Patients with RHS typically have no reproducible tenderness at rest but often have poorly localized pain with movement. The patient with no tenderness who does not have RHS yet is not moving the limb should be closely evaluated for neurologic impairment. For children in whom the examiner is unable to distinguish whether the reaction to palpation is secondary to pain as opposed to stranger anxiety, it may be helpful to have the parent palpate the arm while the examiner observes from across the room or the doorway.",
"     </li>",
"     <li>",
"      <strong>",
"       Joint exam",
"      </strong>",
"      &ndash; Joints should be assessed for focal warmth, redness, tenderness and range of motion; however, if a history of trauma is present manipulation can be deferred until an acute fracture has been excluded by radiograph.",
"     </li>",
"     <li>",
"      <strong>",
"       Neurovascular status",
"      </strong>",
"      &ndash; Careful assessment should be performed. Observation of the younger child&rsquo;s reach and grasp for an interesting object can provide information about active range of motion and neurologic function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       General examination",
"      </strong>",
"      &ndash; A thorough general exam, particularly for children without an obvious injury should be performed to assess for a rash, other joint abnormalities, hepatosplenomegaly, adenopathy, and neurologic findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005856\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005864\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with probable radial head subluxation (RHS) based upon a consistent history and physical examination and no features suggestive of another etiology do not require imaging for diagnosis or prior to attempted reduction as long as there is no focal tenderness present on palpation. Radiologic imaging is indicated only if other diagnoses are being considered. The procedure for reducing a RHS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38532?source=see_link&amp;anchor=H10#H10\">",
"     \"Radial head subluxation (nursemaid's elbow)\", section on 'Reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Plain radiograph",
"      </strong>",
"      &ndash; Plain radiographs of the arm may be helpful in the diagnosis of fracture, osteomyelitis, congenital syphilis, and bone tumors. The initial radiographs in children with Salter-Harris type I fractures, RHS, early osteomyelitis and septic arthritis are often normal. Comparison views should not routinely be obtained as two studies showed diagnostic accuracy was not improved by obtaining comparison views in children with elbow trauma. The decision to obtain comparison views should be individualized depending upon the clinician&rsquo;s experience and the diagnosis in question [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12936/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link&amp;anchor=H16#H16\">",
"       \"General principles of fracture management: Fracture patterns and description in children\", section on 'Salter I (Ogden IA-B)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38532?source=see_link&amp;anchor=H7#H7\">",
"       \"Radial head subluxation (nursemaid's elbow)\", section on 'Imaging'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link&amp;anchor=H138792840#H138792840\">",
"       \"Congenital syphilis: Clinical features and diagnosis\", section on 'Radiographic abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Ultrasonography",
"      </strong>",
"      &ndash; Ultrasound is an excellent technique for identifying joint effusions and could be considered if the diagnosis is in question or to guide joint aspiration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link&amp;anchor=H16#H16\">",
"       \"Bacterial arthritis: Clinical features and diagnosis in infants and children\", section on 'Radiologic evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Magnetic resonance imaging (MRI)",
"      </strong>",
"      &ndash; MRI of the involved extremity may be useful for diagnosing osteomyelitis, occult fractures infections, trauma of the soft tissues, or bone tumors. Brain MRI will aid in the diagnosis of central nervous system conditions.",
"     </li>",
"     <li>",
"      <strong>",
"       Radionuclide scan",
"      </strong>",
"      &ndash; Bone scintigraphy will reveal uptake at areas of increased metabolic activity before bony changes are visible on radiography and thus may be useful to localize bone pathology such as osteomyelitis or occult fracture. However, it is less sensitive and specific than MRI. It is thus most useful when MRI is not available and imaging other than plain radiography is needed to make the diagnosis; the area of suspected infection cannot be localized; or multiple areas of involvement are suspected.",
"     </li>",
"     <li>",
"      <strong>",
"       Computed tomography (CT)",
"      </strong>",
"      &ndash; CT is rarely required but can be useful to evaluate suspected acute central nervous system pathology, or to further delineate",
"      <span class=\"nowrap\">",
"       bony/soft",
"      </span>",
"      tissue pathology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005914\">",
"    <span class=\"h3\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of the child with immobile arm should be directed by the history and physical examination findings and is not indicated for the vast majority of children who have radial head subluxation or trauma as the cause of arm immobility.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Blood studies",
"      </strong>",
"      &ndash; Complete blood count (CBC), acute phase reactants (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) and blood culture and in young infants serologic studies for syphilis are useful when infection, inflammation, oncologic diseases or syphilis are possible causes of the immobile arm. Laboratory tests for sickle cell disease or bleeding disorders should be sent if these diagnoses are being considered and not yet diagnosed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical manifestations and diagnosis of hemophilia\", section on 'Diagnosis and detection of carriers'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Laboratory findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link&amp;anchor=H138792874#H138792874\">",
"       \"Congenital syphilis: Clinical features and diagnosis\", section on 'Laboratory abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Synovial fluid analysis",
"      </strong>",
"      &ndash; Joint aspiration is warranted if septic arthritis is suspected. Synovial fluid analysis should include white blood cell count, Gram stain, cultures and measurement of protein and glucose. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"       \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005930\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to a child with an immobile arm is described in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef88517 graphicRef88518 graphicRef88519 \" href=\"UTD.htm?29/48/30468\">",
"     algorithm 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005938\">",
"    <span class=\"h2\">",
"     Mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should first determine whether the arm became immobile after being pulled or other traumatic event specific traumatic event (or possible unwitnessed trauma). Site of injury (if possible) and neurovascular integrity should be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005953\">",
"    <span class=\"h3\">",
"     Classic radial head subluxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the history is classic for radial head subluxation (ie, the arm was pulled), the patient is holding the arm pronated and slight flexed, and there is not localized tenderness or swelling, then the clinician may attempt reduction (occasionally requires more than one attempt). If the child does not regain full use of the arm quickly, as in all other cases of trauma, radiographs should be obtained (",
"    <a class=\"graphic graphic_algorithm graphicRef88517 \" href=\"UTD.htm?22/25/22943\">",
"     algorithm 1A",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38532?source=see_link&amp;anchor=H8#H8\">",
"     \"Radial head subluxation (nursemaid's elbow)\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38532?source=see_link&amp;anchor=H9#H9\">",
"     \"Radial head subluxation (nursemaid's elbow)\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005960\">",
"    <span class=\"h3\">",
"     Trauma with arm tenderness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with a history of trauma and tenderness on physical examination of the arm should undergo plain radiographs (",
"    <a class=\"graphic graphic_algorithm graphicRef88517 \" href=\"UTD.htm?22/25/22943\">",
"     algorithm 1A",
"    </a>",
"    ). These images may reveal a fracture or dislocation. Normal plain radiographs often imply soft-tissue injury, but reproducible tenderness or swelling overlying the epiphysis implies a Salter-Harris I fracture. Not infrequently, a child with radial head subluxation may have an atypical clinical picture; if a child younger than four to five years has radiographs that exclude a fracture, but the patient is holding the arm in a characteristic position without focal tenderness, an attempt at reduction should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38532?source=see_link&amp;anchor=H9#H9\">",
"     \"Radial head subluxation (nursemaid's elbow)\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005981\">",
"    <span class=\"h2\">",
"     Neurologic abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although quite rare, a child not moving the arm who has no tenderness, full passive range of motion of all joints, and no evidence of radial heal subluxation is concerning for an underlying neurologic condition (",
"    <a class=\"graphic graphic_algorithm graphicRef88518 \" href=\"UTD.htm?23/25/23966\">",
"     algorithm 1B",
"    </a>",
"    ). Children with neurologic abnormalities should be evaluated urgently to localize the site and cause of the impairment (eg, central versus peripheral process) and to determine if they have an underlying predisposition for stroke (eg, sickle cell disease, hypercoagulable state, or congenital heart disease). Appropriate imaging and subspecialist consultation (eg, neurologist or neurosurgeon with pediatric expertise) should occur. The rare child or adolescent with neurologic findings that are illogical anatomically and physiologically may have a conversion disorder. In the neonate, distinguishing between findings from birth and those acquired post-natally is an important distinction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005988\">",
"    <span class=\"h2\">",
"     Evidence of localized inflammation or systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sickle cell disease or factor deficiency are likely to have a vasoocclusive crisis or hemarthrosis, respectively (",
"    <a class=\"graphic graphic_algorithm graphicRef88519 \" href=\"UTD.htm?41/62/42990\">",
"     algorithm 1C",
"    </a>",
"    ). Patients with fever or other findings of systemic inflammation warrant measurement of a complete blood count, blood culture, and inflammatory markers (eg, erythrocyte sedimentation rate, C-reactive protein) and plain radiographs (although occasionally some children may have fever from an unrelated source, eg, viral illness). Other laboratory studies may be indicated depending upon the clinical findings (eg, creatine phosphokinase in patients with possible myositis; serum lactate dehydrogenase and uric acid if concern for oncologic process). Based upon the history, physical examination, imaging and laboratory studies the child may have infection (eg, septic arthritis, osteomyelitis), malignancy, rheumatologic, or noninfectious inflammatory disease, for which the clinician can begin specific management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005995\">",
"    <span class=\"h2\">",
"     No trauma or concern for neurologic, infectious, or systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without a history of trauma and with no evidence for neurologic, infectious, or systemic disease should undergo plain radiographs to evaluate for bony abnormalities (eg, fracture, dislocation, tumor) (",
"    <a class=\"graphic graphic_algorithm graphicRef88517 \" href=\"UTD.htm?22/25/22943\">",
"     algorithm 1A",
"    </a>",
"    ). An attempt at reduction of a radial head subluxation (RHS) is warranted for children with normal radiographs who are younger than five years. If there is no improvement, then the diagnosis is most likely either a soft tissue injury or an unreduced RHS. These patients may be immobilized in a sling or splint and should undergo evaluation in one to two days.",
"   </p>",
"   <p>",
"    If radiographs are normal in the older child, he or she may have a soft tissue injury, complex regional pain syndrome, or conversion disorder.",
"   </p>",
"   <p>",
"    Regardless of age, an indolent pathologic process or occult fracture may be present in patients without a clear etiology. Obtaining blood work may be appropriate if occult infectious or inflammatory processes are suspected. In all such patients, close follow-up should be assured and clear instructions given to caretakers for reasons to return to the emergency department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356005945\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An infant or child who is not moving the limb either due to pain or weakness has an upper extremity equivalent of a &ldquo;limp&rdquo;. (See",
"      <a class=\"local\" href=\"#H356005530\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radial head subluxation (&ldquo;nursemaid&rsquo;s elbow&rdquo;) is by far the most common cause of arm immobility in children one to five years of age. However, children with much more serious pathology may present with this complaint. (See",
"      <a class=\"local\" href=\"#H356005537\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Correct diagnosis of the underlying cause for an immobile arm in a child depends upon a careful history, physical examination, and, in selected patients, imaging studies and laboratory testing. (See",
"      <a class=\"local\" href=\"#H556926\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The table and algorithm provide a list of conditions and an approach to evaluating a child with an immobile arm (",
"      <a class=\"graphic graphic_table graphicRef87861 \" href=\"UTD.htm?5/46/5868\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef88517 graphicRef88518 graphicRef88519 \" href=\"UTD.htm?29/48/30468\">",
"       algorithm 1A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H356005930\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12936/abstract/1\">",
"      Schutzman SA, Teach S. Upper-extremity impairment in young children. Ann Emerg Med 1995; 26:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12936/abstract/2\">",
"      Kissoon N, Galpin R, Gayle M, et al. Evaluation of the role of comparison radiographs in the diagnosis of traumatic elbow injuries. J Pediatr Orthop 1995; 15:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12936/abstract/3\">",
"      Chacon D, Kissoon N, Brown T, Galpin R. Use of comparison radiographs in the diagnosis of traumatic injuries of the elbow. Ann Emerg Med 1992; 21:895.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13884 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BFBE39938F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12936=[""].join("\n");
var outline_f12_40_12936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H356005945\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H356005530\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H356005537\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005545\">",
"      Life and limb-threatening causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005552\">",
"      - Complicated fracture or dislocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87050670\">",
"      - Child abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005574\">",
"      - Bone or joint infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5832605\">",
"      - Necrotizing cellulitis or fasciitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005588\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005603\">",
"      - Tumor or malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005610\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005618\">",
"      - Radial head subluxation (nursemaid&rsquo;s elbow)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005632\">",
"      - Fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005639\">",
"      - Soft tissue injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005674\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005682\">",
"      - Hemoglobinopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005689\">",
"      - Inflammatory process",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5833237\">",
"      - Congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005696\">",
"      - Bleeding disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005703\">",
"      - Conversion disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005710\">",
"      - Complex regional pain syndrome (reflex sympathetic dystrophy)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005717\">",
"      - Other neurologic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H556738\">",
"      Todd paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H356005725\">",
"      Complex migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H356005746\">",
"      Brachial plexus pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H356005772\">",
"      Mononeuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H556926\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005779\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005821\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005856\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005864\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005914\">",
"      - Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H356005930\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005938\">",
"      Mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005953\">",
"      - Classic radial head subluxation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H356005960\">",
"      - Trauma with arm tenderness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005981\">",
"      Neurologic abnormality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005988\">",
"      Evidence of localized inflammation or systemic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H356005995\">",
"      No trauma or concern for neurologic, infectious, or systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H356005945\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13884\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13884|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/25/22943\" title=\"algorithm 1A\">",
"      Immobile arm in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/25/23966\" title=\"algorithm 1B\">",
"      Immobile arm in children with neurologic deficits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/62/42990\" title=\"algorithm 1C\">",
"      Immobile arm in children with fever inflammation systemic signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13884|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/12/39108\" title=\"figure 1\">",
"      Nursemaids elbow PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/23/32127\" title=\"figure 2\">",
"      Radial head subluxation classic arm position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13884|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/46/5868\" title=\"table 1\">",
"      Causes of an immobile arm in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42327?source=related_link\">",
"      Classification of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12985?source=related_link\">",
"      Clavicle fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37768?source=related_link\">",
"      Complex regional pain syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=related_link\">",
"      Congenital syphilis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42120?source=related_link\">",
"      Diagnosis and assessment of distal forearm fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=related_link\">",
"      Evaluation and management of supracondylar fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14057?source=related_link\">",
"      Evaluation of the child with joint pain or swelling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=related_link\">",
"      Ischemic stroke in children and young adults: Etiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30934?source=related_link\">",
"      Midshaft humeral fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38532?source=related_link\">",
"      Radial head subluxation (nursemaid's elbow)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_40_12937="Gaucher disease: Initial assessment, monitoring, and clinical course";
var content_f12_40_12937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gaucher disease: Initial assessment, monitoring, and clinical course",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/40/12937/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12937/contributors\">",
"     Patrick Deegan, MD, MRCPI, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/40/12937/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12937/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/40/12937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12937/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/40/12937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaucher disease (GD) is an inborn error of metabolism that affects the recycling of cellular glycolipids. GD is the most common lysosomal storage disease. Glucocerebroside (also called glucosylceramide) and several related compounds that ordinarily are degraded to glucose and lipid components accumulate within the lysosomes of cells.",
"   </p>",
"   <p>",
"    GD is categorized into three clinical types. The disease involves the visceral organs, bone marrow, and bone in all affected patients. Type 1 (MIM #230800) is the most common. It is distinguished from type 2 (MIM #230900) and type 3 (MIM #231000) by the lack of characteristic involvement of the central nervous system.",
"   </p>",
"   <p>",
"    Additional resources for information about GD for patients and families are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef63615 \" href=\"UTD.htm?2/40/2699\">",
"     table 1",
"    </a>",
"    ). Guidelines for the evaluation and monitoring of children and adults with GD, based upon data from the International Collaborative Gaucher Group (ICGG) Registry (",
"    <a class=\"external\" href=\"file://www.gaucherregistry.com/\">",
"     www.gaucherregistry.com",
"    </a>",
"    ), and published data from international consensus panels are incorporated into the discussion in this topic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial assessment and routine monitoring of patients with GD will be discussed here. The pathogenesis, genetics, clinical manifestations, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=see_link\">",
"     \"Gaucher disease: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment must be tailored to the individual patient, because of the variability in the manifestations, severity, and progression of GD. Thus, each patient should undergo a comprehensive initial assessment of all potentially affected organ systems [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/8\">",
"     8",
"    </a>",
"    ]. A decision is made regarding whether enzyme replacement therapy is indicated after the extent of symptoms and rate of progression are established. Treatment is then individualized to achieve specific therapeutic goals (",
"    <a class=\"graphic graphic_table graphicRef75418 graphicRef54387 \" href=\"UTD.htm?7/28/7630\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=see_link\">",
"     \"Gaucher disease: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial assessment involves confirmation of deficiency of glucocerebrosidase (also known as glucosylceramide or acid beta-glucosidase, GBA), genotyping, and a complete family medical history if these were not part of the diagnostic process [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link&amp;anchor=H22#H22\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other aspects of the initial assessment that should be repeated at regular intervals throughout life include (",
"    <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"     table 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete physical examination",
"     </li>",
"     <li>",
"      Measurement of hemoglobin and platelet count",
"     </li>",
"     <li>",
"      Measurement of biomarkers",
"     </li>",
"     <li>",
"      Radiologic assessment of visceral and skeletal involvement",
"     </li>",
"     <li>",
"      Assessment of pain and patient-reported quality of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency with which this assessment should be repeated depends upon the treatment status and whether therapeutic goals have been achieved (",
"    <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"     table 3A-B",
"    </a>",
"    ). In addition, reassessment should be performed when the dose of enzyme therapy is changed if significant complications develop [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=see_link\">",
"     \"Gaucher disease: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The family history should include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Information about ethnicity and consanguinity",
"     </li>",
"     <li>",
"      Information about disease severity in parents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      affected siblings",
"     </li>",
"     <li>",
"      Information regarding a history of blood transfusions, splenectomy, pathologic fractures, bone pain, dyspnea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent chest infections (which may indicate undiagnosed GD)",
"     </li>",
"     <li>",
"      A family history of pulmonary hypertension (increases the risk of severe pulmonary hypertension)",
"     </li>",
"     <li>",
"      Parental heights (for prediction of adult height in skeletally immature patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination can provide important information regarding the severity, rate of progression, and response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/8\">",
"     8",
"    </a>",
"    ]. Important aspects of the examination include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/1,2,10\">",
"     1,2,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General appearance, demeanor, mood, and affect",
"     </li>",
"     <li>",
"      Weight, height, and head circumference percentiles, plotted on growth charts standardized for age and sex (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link\">",
"       \"Measurement of growth in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Examination of the skin for bruising, petechiae, pallor, and pigmentation",
"     </li>",
"     <li>",
"      Eye examination for pingueculae (small soft brownish patches of tissue on the sclerae, just beyond the iris) that are nonspecific findings, but commonly seen in adult GD patients",
"      <br/>",
"      <br/>",
"      The eye examination should also include evaluation for strabismus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormal extraocular movements. Additional ophthalmologic evaluation for patients who lack an N370S allele and are at risk for neuronopathic disease is discussed separately (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Neurologic'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Palpation of the abdomen for enlarged liver",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spleen; measurement of abdominal girth (the abdominal examination is supplemental to the radiologic evaluation) (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiology evaluation'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Gait, range of motion, muscle strength, and bone tenderness",
"     </li>",
"     <li>",
"      Assessment of pubertal status (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"       \"Normal puberty\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Evaluation for developmental delay (in children)",
"     </li>",
"     <li>",
"      Examination of the spine for kyphosis (including gibbus deformity, a particular form of kyphosis with a sharp angulation) and scoliosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78628 \" href=\"UTD.htm?0/0/4\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of neurologic complications has important implications for prognosis and treatment and should be determined as soon as possible after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thorough neurologic examination is critical for detecting evidence of neuronopathic disease in patients with suspect genotypes (ie, without an N370S allele) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/10\">",
"     10",
"    </a>",
"    ], neurologic symptoms, a sibling with proven neuronopathic GD,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    onset of severe systemic GD before two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children should undergo a thorough neurologic evaluation at baseline (",
"    <a class=\"graphic graphic_table graphicRef52960 \" href=\"UTD.htm?20/17/20764\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/4\">",
"     4",
"    </a>",
"    ]. This should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic examination, performed by a neurologist, preferably a pediatric neurologist",
"     </li>",
"     <li>",
"      Eye movement examination, preferably by an ophthalmologist since the signs of ocular involvement can be difficult to detect in young children",
"     </li>",
"     <li>",
"      Additional neuroophthalmologic investigation, including direct ophthalmoscopy or electrooculography",
"     </li>",
"     <li>",
"      Measurement of hearing (by otoacoustic emission audiometry [OAE]) in young children and pure tone-audiometry in older patients (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"       \"Evaluation of hearing impairment in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Brain imaging, preferably with magnetic resonance imaging (MRI), electroencephalography, and diagnostic brainstem-evoked responses",
"     </li>",
"     <li>",
"      Neurocognitive testing, with widely available protocols (eg, Wechsler Intelligence Scale for Children-III), ideally performed when the patient is sufficiently healthy to permit meaningful assessment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Psychosocial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the child's social and educational development may require the involvement of the child's school and teachers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/2\">",
"     2",
"    </a>",
"    ]. Detailed psychometric assessments (eg, IQ testing) should be conducted for patients at risk for developing neuronopathic disease. In addition, signs of depression should be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiopulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiopulmonary involvement is rare in children with type 1 GD, but should be excluded at baseline in symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/2\">",
"     2",
"    </a>",
"    ]. Risk factors for severe pulmonary hypertension in patients with GD include mutations other than N370S, a family history of pulmonary hypertension, angiotensin converting enzyme I gene polymorphism, asplenia, and female sex [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation in children may include chest radiograph, high-resolution CT thoracic imaging, electrocardiogram, echocardiogram, and pulmonary function tests (forced vital capacity and peak expiratory flow rates). In adults, pulmonary evaluation should include a Doppler echocardiogram to estimate right ventricular systolic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"     \"Overview of pulmonary function testing in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial laboratory evaluation should include measurement of hemoglobin concentration, platelet count, and biochemical markers (ie, chitotriosidase, angiotensin converting enzyme [ACE], tartrate-resistant acid phosphatase [TRAP],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high density lipoprotein [HDL]) (",
"    <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"     table 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/2,12-15\">",
"     2,12-15",
"    </a>",
"    ]. These biochemical markers can be used in monitoring disease progression. The absolute concentrations of these enzymes are not helpful, but serial increases may be an early indicator of clinical relapse and should prompt investigation of disease status and compliance with therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/16\">",
"     16",
"    </a>",
"    ]. Other biomarkers are under investigation for use in diagnosis and prediction of severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link&amp;anchor=H8074611#H8074611\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of biomarkers that may be of clinical use include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chitotriosidase, a chitinase, is a marker of &ldquo;alternative&rdquo; type macrophage activation that is overexpressed by the Gaucher cell. Its activity is increased in patients with GD and decreases in response to enzyme replacement therapy in conjunction with other indicators of clinical response [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/12,13,17\">",
"       12,13,17",
"      </a>",
"      ]. Measurement of chitotriosidase is recommended at baseline and periodically during therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/18\">",
"       18",
"      </a>",
"      ]. Activity of chitotriosidase is absent in six to eight percent of patients who have a mutation in the chitotriosidase gene [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/8\">",
"       8",
"      </a>",
"      ]; in such patients assessment of ACE or tartrate-resistant acid phosphatase (TRAP) can be substituted [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The chemokine CCL18 (pulmonary and activation-regulated chemokine, PARC) is another marker of alternatively activated macrophages that is elevated in Gaucher disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Concentrations of this protein correlate with several aspects of visceral and bony disease severity and respond to enzyme treatment in a similar manner to chitotriosidase [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased ratio of 16:0-glucosylceramide to 16:0-lactosylceramide and elevated plasma concentrations of lysosomal-associated membrane protein-1 (LAMP-1) and saposin C appear to be correlated with patient phenotype, but are generally not used clinically [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurement of glucocerebrosidase and genotyping should be performed if these were not part of the diagnostic process. Serum electrophoresis should be obtained at baseline and every 12 to 25 months, particularly in patients who are older than 50 years (because of an increased risk of multiple myeloma) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/24\">",
"     24",
"    </a>",
"    ]. Clonal gammopathies are frequent among GD patients and should be monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/6\">",
"     6",
"    </a>",
"    ]. Additional studies are recommended to monitor for other associated features, including B12 and vitamin D deficiency, iron overload, autoimmune disease, and platelet dysfunction (",
"    <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"     table 3A-B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Additional evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiology evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial radiology assessment should include various examinations to evaluate liver and spleen volume and the extent and severity of skeletal disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link&amp;anchor=H20909219#H20909219\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Radiologic findings'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. These studies may be helpful in determining whether enzyme replacement therapy is indicated and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volumetric computed tomography (CT) or magnetic resonance imaging (MRI) of the liver and spleen to help determine severity of hepatosplenomegaly, evaluate for cirrhosis or hepatic or splenic fibrosis, and assess response to therapy. Some centers use abdominal sonography to measure organomegaly [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/25\">",
"       25",
"      </a>",
"      ]. CT should only be used if the other modalities are unavailable or contraindicated to minimize radiation exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/3,26\">",
"       3,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI of the femoral head and lumbar spine to detect bone marrow infiltration, bone infarction, bone crises, and osteonecrosis (coronal T1- and T2-weighted scan) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/2,3,5\">",
"       2,3,5",
"      </a>",
"      ]. T1-weighted MRI is the most sensitive means of assessing marrow infiltration and T2-weighted MRI is the most sensitive method of detecting active bone infarcts. There are several systems to grade marrow infiltration in GD, among which the Bone Marrow Burden Score is most widely used [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/27\">",
"       27",
"      </a>",
"      ]. Bone marrow infiltration varies considerably from site to site within a patient [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/28\">",
"       28",
"      </a>",
"      ]. A nonhomogeneous pattern of bone marrow involvement (type B marrow morphology) and extensive marrow packing were associated with avascular necrosis of the femoral head in one study, suggesting that MRI may be a useful tool for identifying patients at high risk of this outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ischemia can be detected by technetium bisphosphonate bone scintigraphy early in the course of bone pain crises [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assessment of the skeletal age in children (according to the method of Greulich and Pyle) to assess growth retardation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antero-posterior view of the entire femora and lateral view of the spine [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/32\">",
"       32",
"      </a>",
"      ]; skeletal disease can occur without symptoms, particularly compression fractures of the spine and femoral head [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/3\">",
"       3",
"      </a>",
"      ]. These radiographs will provide information regarding old fractures, cystic bone changes, osteopenia, and other bone changes, such as the Erlenmeyer flask deformity of long bones.",
"     </li>",
"     <li>",
"      Radiographs of other skeletal sites to which the patient refers symptoms.",
"     </li>",
"     <li>",
"      Dual energy X-ray absorptiometry (DEXA) of the lumbar spine and nondominant femoral neck may be used to measure generalized osteopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/32-34\">",
"       32-34",
"      </a>",
"      ], although age-specific normative data for children are limited [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sedation may be necessary for younger children during MRI or CT scanning. The risk of sedation in these settings appears to be acceptably low when performed in accordance with published guidelines. As an example, in a series of 960 instances of pediatric sedation, there were no deaths or serious injuries when recommended procedures for conscious or deep sedation were followed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/36\">",
"     36",
"    </a>",
"    ]. Nevertheless, the requirement for sedation limits the general applicability of MRI for routine follow-up assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Functional health and well-being",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with GD are subject to the same psychosocial problems as any child with a chronic disease (anger, fear, insecurity, isolation) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/2\">",
"     2",
"    </a>",
"    ]. Visceromegaly, growth abnormalities, and delayed puberty may affect their body image and self-esteem. These feelings may be exacerbated by fatigue and restrictions on physical activity. Chronic pain, fatigue, and missed school may affect school performance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Psychosocial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Functional health and well-being can be assessed through a survey instrument such as the short form 36 Health Survey (SF-36), which is validated for individuals &ge;14 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/2\">",
"     2",
"    </a>",
"    ]. The younger patient and his or her parents should be questioned regarding the effects of GD on physical and social function, particularly with regard to pain and fatigue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=see_link\">",
"     \"Evaluation of health-related quality of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The occurrence and severity of pain (using a recognized pain assessment tool) should be monitored at each visit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. The use of a recognized pain assessment tool is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/8\">",
"     8",
"    </a>",
"    ]. In young children, pain severity may be assessed with a visual analogue scale, such as the faces pain scales [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/23,37\">",
"     23,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/15/44280?source=see_link\">",
"     \"Evaluation and management of pain in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=see_link\">",
"     \"Evaluation of chronic pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Information about GD for patients and families is available through the Gaucher Registry (",
"    <a class=\"external\" href=\"file://www.gaucherregistry.com/\">",
"     www.gaucherregistry.com",
"    </a>",
"    ) and other resources (",
"    <a class=\"graphic graphic_table graphicRef63615 \" href=\"UTD.htm?2/40/2699\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ROUTINE MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine monitoring of disease activity should be performed in all patients. Consensus minimum recommendations for effective monitoring of patients are provided by the ICGG (",
"    <a class=\"external\" href=\"file://www.gaucherregistry.com/\">",
"     www.gaucherregistry.com",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory and imaging studies are performed at baseline and then at recommended intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/1,38\">",
"     1,38",
"    </a>",
"    ]. The schedule is individualized according to the patient&rsquo;s clinical course, whether the patient is receiving treatment, and, if so, the response to therapy (",
"    <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"     table 3A-B",
"    </a>",
"    ). In addition, reassessment is performed when the dose of enzyme therapy is changed or if significant complications develop [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=see_link\">",
"     \"Gaucher disease: Treatment\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Laboratory evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Radiology evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neurologic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close neurologic monitoring is necessary for at-risk patients (ie, children without a c.1226A&gt;G mutation or with an allele associated with neuronopathic disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/3,39\">",
"     3,39",
"    </a>",
"    ]. Neurologic involvement is insidious in some patients, manifesting in late childhood or beyond [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurologic monitoring is reviewed in the table (",
"    <a class=\"graphic graphic_table graphicRef64752 \" href=\"UTD.htm?31/1/31772\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/1,4,40\">",
"     1,4,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional evaluation may be indicated in some patients at the time of the initial assessment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    during the clinical course if they fail to achieve their therapeutic goals. Patients who are unable to achieve their therapeutic goals should undergo evaluation for confounding factors (eg, poor compliance with therapy, development of comorbid conditions, or development of neutralizing antibody). The additional evaluation varies depending upon the manifestation of interest or the goal that is not achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional evaluation for anemia may include measurement of iron, iron-binding capacity, vitamin B12, white blood cell count, and serum immunoelectrophoresis. The incidence of vitamin B12 deficiency is increased among Ashkenazic Jews in Israel [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, a decline in hemoglobin concentration, whether acute or gradual, should prompt evaluation for blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of bleeding tendency at the time of diagnosis may require evaluation for a bleeding diathesis. Abnormalities of various coagulation factors and qualitative platelet deficits have been reported in Gaucher disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/5,42,43\">",
"     5,42,43",
"    </a>",
"    ], and it may be useful to look for these abnormalities of coagulation at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Evaluation may include measure of prothrombin time (PT) and activated partial thromboplastin time (PTT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hepatomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of liver function is indicated in patients with marked hepatomegaly or portal hypertension. This evaluation may include assessment of exposure to alcohol, hepatotoxic medications, blood products, sexually transmitted viral pathogens, and intravenous drug use. Measurement of aspartate aminotransferase (AST)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alanine aminotransferase (ALT), alkaline phosphatase, albumin, total protein, and total and direct bilirubin are routine in most clinical settings. Liver imaging by ultrasound (including Doppler assessment of portal blood flow) will determine whether gross scarring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    portal hypertension is present. Additional CT and MR imaging and liver biopsy may be necessary to reveal evidence of fibrosis or iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testing for viral hepatitis should be performed in patients who have a history of blood transfusion, intravenous or other parenteral illicit drug use, or who live in areas where infectious hepatitis is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Skeletal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum calcium, phosphorous, alkaline phosphatase, and concentrations of vitamin D and parathyroid hormone may be indicated to exclude other causes of bone disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Growth retardation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with GD who have severe stunting of stature also have severe visceral involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, other causes of growth retardation should be evaluated in otherwise mildly affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15486492\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course and life expectancy of GD type 1 is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/8\">",
"     8",
"    </a>",
"    ]. Severity may vary among siblings, even identical twins [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/47\">",
"     47",
"    </a>",
"    ]. The spectrum ranges from asymptomatic disease, discovered incidentally in elderly adults, to fulminant disease presenting in early childhood. The disease is usually progressive, but at different rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/48\">",
"     48",
"    </a>",
"    ]. In general, the disease has rapid progression in severely affected children, but has a more insidious course in more mildly affected adults. Thus, any rapid deterioration in adults requires evaluation for other causes. Stabilization of GD complications over time has been reported in untreated adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/49\">",
"     49",
"    </a>",
"    ], as has spontaneous regression of disease manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link&amp;anchor=H8#H8\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Type 1 (GD1)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The estimated average life expectancy at birth for a patient with GD type 1 was 68 years, based upon data from the Gaucher Registry, compared with 77 years in the standard United States population. Splenectomized and non-splenectomized patients had a life expectancy of 64 years and 72 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic patients may die prematurely from sequelae of splenectomy, severe bone disease, bleeding complications, infection, liver failure, or severe pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, patients with GD appear to have an increased risk of hematologic malignancy and multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/24,53\">",
"     24,53",
"    </a>",
"    ]. Review of data from 2742 patients in the International Gaucher Registry (92 percent with type 1, 81 percent treated with enzyme replacement therapy (ERT), median age in the third decade) indicates that the overall risk of cancer, including general hematologic malignancies, is not increased compared with the expected rate of individuals of the same age and sex in the United States population (relative risk [RR] 0.79, 95% CI 67-94) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the risk of multiple myeloma was increased (RR 5.9, 95% CI 2.9-10.8). All but one patient with multiple myeloma were older than 60 years. Multiple myeloma was reported in patients who had and had not been treated with ERT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GD types 2 and 3 are the neuronopathic forms. GD2 has the poorest prognosis of all types of GD. Patients have rapidly progressive neurologic deterioration and death usually occurs before the child reaches two years of age. The average age of death was 11.7 months in one review of 15 original cases along with published data on 104 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/54\">",
"     54",
"    </a>",
"    ]. GD type 3 usually is more severe and aggressive than GD1, but has a more variable course than GD2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link&amp;anchor=H19#H19\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Type 2 (GD2)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link&amp;anchor=H20#H20\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Type 3 (GD3)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15486686\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy can exacerbate the symptoms of Gaucher disease, particularly in women whose disease is not controlled by enzyme replacement therapy (ERT) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/18\">",
"     18",
"    </a>",
"    ]. The risks of bone crises peripartum and hemorrhage postpartum are increased. There is an emerging consensus that there are benefits to continuation of ERT in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/55\">",
"     55",
"    </a>",
"    ]; this option should be discussed by the clinician and patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=see_link\">",
"     \"Gaucher disease: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with GD can generally expect a good pregnancy outcome. A literature review found 24 citations between 1952 and 2001 describing 302 pregnancies in 190 untreated women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/56\">",
"     56",
"    </a>",
"    ]. The live birth rate was 87 percent. Postpartum bleeding was the most common serious complication (4 of 23 ERT treated patients and 4 of 43 untreated patients). Thus, these women should be considered at high risk, and blood and fresh frozen plasma should be available at delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gaucher disease (GD) is caused by deficiency of glucocerebrosidase, which results in abnormal accumulation of glycolipids within cellular lysosomes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment must be tailored to the individual patient, because of the variability in the manifestations, severity, and progression of GD. Thus, each patient should undergo a comprehensive initial assessment of all potentially affected organ systems (",
"      <a class=\"graphic graphic_table graphicRef75418 graphicRef54387 \" href=\"UTD.htm?7/28/7630\">",
"       table 2A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of neurologic complications has important implications for prognosis and treatment and should be determined as soon as possible after diagnosis. Neuronopathic disease can be excluded at the time of diagnosis through objective assessment of eye movements and audiologic testing. However, children should undergo a thorough neurologic evaluation at baseline if these specialized tests are not available. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Neurologic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine monitoring of disease activity should be performed in all patients. The schedule is individualized according to the patient&rsquo;s clinical course, whether the patient is receiving treatment, and, if so, the response to therapy (",
"      <a class=\"graphic graphic_table graphicRef57808 graphicRef68614 \" href=\"UTD.htm?25/61/26590\">",
"       table 3A-B",
"      </a>",
"      ). In addition, reassessment should be performed when the dose of enzyme therapy is changed or if significant complications develop [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Routine monitoring'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=see_link\">",
"       \"Gaucher disease: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Additional evaluation may be indicated in some patients at the time of the initial assessment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      during the clinical course if they fail to achieve their therapeutic goals (",
"      <a class=\"graphic graphic_table graphicRef75418 graphicRef54387 \" href=\"UTD.htm?7/28/7630\">",
"       table 2A-B",
"      </a>",
"      ). The additional evaluation varies depending upon the manifestation of interest or the goal that is not achieved. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Additional evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course and life expectancy of GD type 1 (GD1) is variable. The estimated average life expectancy at birth for a patient with GD1 is around 68 years. In contrast, most patients with type 2 GD (GD2) die within the first two years of life. GD type 3 (GD3) usually is more severe and aggressive than GD1, but has a more variable course than GD2. (See",
"      <a class=\"local\" href=\"#H15486492\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy can exacerbate the symptoms of Gaucher disease, particularly in women whose disease is not controlled by enzyme replacement therapy (ERT) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12937/abstract/18\">",
"       18",
"      </a>",
"      ]. The risks of bone crises peripartum and hemorrhage postpartum are increased. (See",
"      <a class=\"local\" href=\"#H15486686\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/1\">",
"      Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/2\">",
"      Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004; 163:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/3\">",
"      Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/4\">",
"      Vellodi A, Bembi B, de Villemeur TB, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/5\">",
"      Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/6\">",
"      Hughes D, Cappellini MD, Berger M, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 2007; 138:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/7\">",
"      Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/8\">",
"      Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/9\">",
"      Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005; 129:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/10\">",
"      Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 2003; 79:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/11\">",
"      Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002; 77:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/12\">",
"      Giraldo P, Cenarro A, Alfonso P, et al. Chitotriosidase genotype and plasma activity in patients type 1 Gaucher's disease and their relatives (carriers and non carriers). Haematologica 2001; 86:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/13\">",
"      Hollak CE, Maas M, Aerts JM. Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis 2001; 24 Suppl 2:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/14\">",
"      Lacerda L, Arosa FA, Lacerda R, et al. T cell numbers relate to bone involvement in Gaucher disease. Blood Cells Mol Dis 1999; 25:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/15\">",
"      Stein P, Yang R, Liu J, et al. Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. J Inherit Metab Dis 2011; 34:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/16\">",
"      Czartoryska B, Tylki-Szymaska A, Lugowska A. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 2000; 33:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/17\">",
"      Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994; 93:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/18\">",
"      Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008; 31:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/19\">",
"      Moran MT, Schofield JP, Hayman AR, et al. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000; 96:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/20\">",
"      Boot RG, Verhoek M, de Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004; 103:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/21\">",
"      Deegan PB, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 2005; 35:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/22\">",
"      Deegan PB, Pavlova E, Tindall J, et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 2011; 90:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/23\">",
"      Whitfield PD, Nelson P, Sharp PC, et al. Correlation among genotype, phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol Genet Metab 2002; 75:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/24\">",
"      Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105:4569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/25\">",
"      Patlas M, Hadas-Halpern I, Abrahamov A, et al. Spectrum of abdominal sonographic findings in 103 pediatric patients with Gaucher disease. Eur Radiol 2002; 12:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/26\">",
"      Grabowski GA. Recent clinical progress in Gaucher disease. Curr Opin Pediatr 2005; 17:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/27\">",
"      Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging--initial experience. Radiology 2003; 229:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/28\">",
"      Allison JW, James CA, Arnold GL, et al. Reconversion of bone marrow in Gaucher disease treated with enzyme therapy documented by MR. Pediatr Radiol 1998; 28:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/29\">",
"      Poll LW, Willers R, H&auml;ussinger D, et al. [MRI bone marrow findings in 63 patients with type I Gaucher disease]. Rofo 2010; 182:979.",
"     </a>",
"    </li>",
"    <li>",
"     Mariani G, Erba PA. Radionuclide evaluation of Gaucher disease. In: Gaucher disease, Futerman AH, Zimran A (Eds), CRC Press, Boca Raton 2006. p.287.",
"    </li>",
"    <li>",
"     Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist, Stanford University Press, Stanford 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/32\">",
"      Bembi B, Ciana G, Mengel E, et al. Bone complications in children with Gaucher disease. Br J Radiol 2002; 75 Suppl 1:A37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/33\">",
"      Maas M, Poll LW, Terk MR. Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol 2002; 75 Suppl 1:A13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/34\">",
"      Poll LW, Maas M, Terk MR, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 2002; 75 Suppl 1:A25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/35\">",
"      Crabtree NJ, Kibirige MS, Fordham JN, et al. The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 2004; 35:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/36\">",
"      Hoffman GM, Nowakowski R, Troshynski TJ, et al. Risk reduction in pediatric procedural sedation by application of an American Academy of Pediatrics/American Society of Anesthesiologists process model. Pediatrics 2002; 109:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/37\">",
"      Hicks CL, von Baeyer CL, Spafford PA, et al. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain 2001; 93:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/38\">",
"      Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 1998; 158:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/39\">",
"      Harris CM, Taylor DS, Vellodi A. Ocular motor abnormalities in Gaucher disease. Neuropediatrics 1999; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/40\">",
"      Davies EH, Mengel E, Tylki-Szymanska A, et al. Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool. J Inherit Metab Dis 2011; 34:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/41\">",
"      Gielchinsky Y, Elstein D, Green R, et al. High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population. Br J Haematol 2001; 115:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/42\">",
"      Billett HH, Rizvi S, Sawitsky A. Coagulation abnormalities in patients with Gaucher's disease: effect of therapy. Am J Hematol 1996; 51:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/43\">",
"      Seligsohn U, Zitman D, Many A, Klibansky C. Coexistence of factor XI (plasma thromboplastin antecedent) deficiency and Gaucher's disease. Isr J Med Sci 1976; 12:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/44\">",
"      Lachmann RH, Wight DG, Lomas DJ, et al. Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM 2000; 93:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/45\">",
"      Kauli R, Zaizov R, Lazar L, et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2000; 2:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/46\">",
"      Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in Type 1 Gaucher disease. J Bone Miner Res 1996; 11:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/47\">",
"      Lachmann RH, Grant IR, Halsall D, Cox TM. Twin pairs showing discordance of phenotype in adult Gaucher's disease. QJM 2004; 97:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/48\">",
"      Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, et al. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis 2000; 23:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/49\">",
"      Piran S, Roberts A, Patterson MA, Amato D. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations. Blood Cells Mol Dis 2009; 43:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/50\">",
"      Boomsma JM, van Dussen L, Wiersma MG, et al. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study. Blood Cells Mol Dis 2010; 44:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/51\">",
"      Weinreb NJ, Deegan P, Kacena KA, et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008; 83:896.",
"     </a>",
"    </li>",
"    <li>",
"     Lee RE. The pathology of Gaucher disease. In: Gaucher disease: A century of delineation and research, Desnick RJ, Gatt S, Grabowski GA (Eds), Alan R. Liss, New York 1982. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/53\">",
"      Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer 1993; 72:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/54\">",
"      Mignot C, Doummar D, Maire I, et al. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006; 28:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/55\">",
"      Zimran A, Morris E, Mengel E, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 2009; 43:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12937/abstract/56\">",
"      Elstein Y, Eisenberg V, Granovsky-Grisaru S, et al. Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol 2004; 190:435.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2921 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12937=[""].join("\n");
var outline_f12_40_12937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Psychosocial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiopulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiology evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Functional health and well-being",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ROUTINE MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neurologic monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hepatomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Skeletal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Growth retardation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15486492\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15486686\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2921\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2921|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/0/4\" title=\"diagnostic image 1\">",
"      Radiograph of gibbus deformity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2921|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/40/2699\" title=\"table 1\">",
"      Gaucher resources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/55/43900\" title=\"table 2A\">",
"      Gaucher treatment goals A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/7/121\" title=\"table 2B\">",
"      Gaucher treatment goals B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/43/23229\" title=\"table 3A\">",
"      Monitoring type1 GD A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/35/10813\" title=\"table 3B\">",
"      Monitoring type1 GD B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/17/20764\" title=\"table 4\">",
"      Initial assessment of primary neurologic involvement in GD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/1/31772\" title=\"table 5\">",
"      Neurologic follow-up in GD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/15/44280?source=related_link\">",
"      Evaluation and management of pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=related_link\">",
"      Evaluation of chronic pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=related_link\">",
"      Evaluation of health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10170?source=related_link\">",
"      Gaucher disease: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_40_12938="Communication in the ICU: Holding a family meeting";
var content_f12_40_12938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Communication in the ICU: Holding a family meeting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/40/12938/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12938/contributors\">",
"     Elizabeth Chaitin, DHCE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12938/contributors\">",
"     Gordon J Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12938/contributors\">",
"     Robert M Arnold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/40/12938/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12938/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12938/contributors\">",
"     Thomas L Schwenk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/40/12938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/40/12938/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/40/12938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family meetings facilitate communication between health care providers and families of patients in the intensive care unit (ICU). Effective communication improves family satisfaction, clinical decision-making, and the psychological well being of family members [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. As a result, research agendas and lists of quality indicators are increasingly recognizing the importance of good communication with families [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of communication and issues related to conducting a family meeting will be reviewed here. Throughout the discussion, \"family\" refers to any person of importance in the patient's life who might attend a conference related to the patient's care, whether they are related or not. Decision making by surrogates and informed consent are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26565?source=see_link\">",
"     \"Ethics in the intensive care unit: Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF COMMUNICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The receipt of honest, intelligible, and timely information is among the primary concerns of family members of patients in the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In addition, they need support, comfort, proximity, and reassurance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/14\">",
"     14",
"    </a>",
"    ]. Families want to feel that there is hope and they generally want to know the prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, the evidence indicates that communication with health care providers often leaves much to be desired [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/16\">",
"     16",
"    </a>",
"    ]. Observational studies have found that communication issues with clinicians are the number one source of complaints among families of deceased patients, with as many as 30 percent of family members feeling dissatisfied with communication in the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Contributing factors include inadequate time spent communicating with clinicians, lack of consistent information, and information provided by multiple health care providers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/20\">",
"     20",
"    </a>",
"    ]. Poor communication can affect family satisfaction, clinical decision-making, and the psychological outcomes of family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Family satisfaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family satisfaction corresponds to the degree to which the expectations of the family are met. This is affected by a number of factors related to providers, including the quality of communication, the quality of interactions, the level of empathy, and the degree to which family members feel isolated while visiting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional factors that have been associated with increased family satisfaction include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/22-29\">",
"     22-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Knowing the role of each health care provider",
"     </li>",
"     <li>",
"      Having junior clinicians give information",
"     </li>",
"     <li>",
"      Avoiding the perception that contradictory information is being provided",
"     </li>",
"     <li>",
"      Involvement of a primary care doctor",
"     </li>",
"     <li>",
"      Allocating sufficient time to provide information",
"     </li>",
"     <li>",
"      Clinician accessibility and continuity of care",
"     </li>",
"     <li>",
"      The clinician's ability to listen, encourage questions, provide emotional support, and pay attention to the patient's values",
"     </li>",
"     <li>",
"      The completeness of information provided to the family",
"     </li>",
"     <li>",
"      The feeling that the decision-maker was supported through the decision-making process",
"     </li>",
"     <li>",
"      Discussion of spiritual needs and satisfaction with spiritual care",
"     </li>",
"     <li>",
"      Withdrawing life support, especially when based on a clinician's recommendation",
"     </li>",
"     <li>",
"      Expression of the patient's wishes",
"     </li>",
"     <li>",
"      Allowing family members more opportunities to speak during a conference",
"     </li>",
"     <li>",
"      The use of empathic statements",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Family satisfaction is also improved by early and frequent interaction between family members and providers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/30\">",
"     30",
"    </a>",
"    ]. Such communication facilitates earlier recognition of how the illness is affecting the family unit and establishes a cooperative patient-focused style of care. It also offers an opportunity to correct any misunderstanding that the family may have about what is wrong with the patient.",
"   </p>",
"   <p>",
"    According to an observational study of 102 patients, only one-half of the families understood the patient's diagnosis, prognosis, or treatment after an initial meeting with an attending clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/31\">",
"     31",
"    </a>",
"    ]. Moreover, health care providers often do not recognize poor family comprehension and family members are frequently unaware of their own misunderstandings. In a study of 81 decision-makers, most reported excellent comprehension, but only one-half had a good understanding when objectively tested [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Addressing the needs of family members may have an even greater impact on family satisfaction than the medical outcome. In a survey of 539 family members of ICU patients, there were higher levels of satisfaction among the family members of patients who died than among those who survived [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/33\">",
"     33",
"    </a>",
"    ]. This difference was attributed to more family-centered care for patients who died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Decision-making",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of communication with families extends beyond its influence on satisfaction. Communication problems may also adversely affect clinical decision-making, since clinicians often need to rely on a family member to serve as a surrogate for the patient when trying to determine what care the patient would desire and how to proceed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Psychological impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Communication between clinicians and families may affect the psychological state of family members. Families of patients admitted to the ICU are understandably stressed. Qualitative and anecdotal studies have described the experience as being characterized by uncertainty, emotional turmoil, and stress. Families typically attempt to resolve the uncertainty by seeking both information about the medical condition and resources needed to cope with the event [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychological conditions are common among the family members of patients in the ICU. This was illustrated by a study of 920 family members, in which the prevalence of anxiety and depression was 69 percent and 35 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/23\">",
"     23",
"    </a>",
"    ]. In another report, approximately one-third of family members developed symptoms that suggested that they were at moderate to major risk of developing posttraumatic stress disorder (PTSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Families members who prefer a passive decision-making role may be more likely to be anxious and depressed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/38\">",
"     38",
"    </a>",
"    ]. In contrast, family members who are present at the time of death or who perceived that communication was inadequate are at increased risk for PTSD symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Additional risk factors for PTSD symptoms appear to include a young patient and discordance between the family member&rsquo;s preferred decision-making role and actual decision-making role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THE FAMILY MEETING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of a family meeting is to give health care providers an opportunity to meet the family, inform them of the patient's condition and treatment, answer questions, and include the patient's surrogates in the decision making process. The optimal method of conducting a family meeting is uncertain because there is a paucity of empirical evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/10,41\">",
"     10,41",
"    </a>",
"    ]. However, recognition that the skills necessary to conduct a family meeting can be taught has led to the development of methods to train clinicians to better communicate during family meetings. Such training tools are becoming increasingly available [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/42-45\">",
"     42-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Purpose of a meeting",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that family meetings can improve clinical outcomes for patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/1,4,46-48\">",
"     1,4,46-48",
"    </a>",
"    ]. One study compared outcomes before and after the institution of a strategy of early (within 72 hours of admission) multidisciplinary meetings plus follow-up meetings with families of patients whose goals were not being achieved with advanced supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/1\">",
"     1",
"    </a>",
"    ]. Length of stay decreased following the intervention, while mortality was unchanged. These effects persisted for four years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/47\">",
"     47",
"    </a>",
"    ]. A larger multicenter trial of this same communication structure, however, was ineffective at reducing length of stay [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/49\">",
"     49",
"    </a>",
"    ]. The authors cited multiple possible explanations for the negative result, the most significant of which may be the fact that the intervention only mandated a structure for when meetings should occur and what topics should be addressed, but did nothing to address the communication skills of the clinicians running the meetings. Observational studies have found that either ethics consultation or inclusion of a palliative care consultant in family meetings was associated with shorter ICU lengths of stay and unchanged mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/46,48\">",
"     46,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family meetings may also improve psychological outcomes for families [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/2,26,33\">",
"     2,26,33",
"    </a>",
"    ]. This was illustrated by a trial that randomly assigned 126 surrogates to receive either routine interactions with health care providers or interactions based upon a communication strategy called VALUE plus a bereavement brochure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/2\">",
"     2",
"    </a>",
"    ]. VALUE describes a communication system whose components include valuing and appreciating what surrogates communicate (V), acknowledging their emotions with reflective summary statements (A), listening carefully (L), understanding who the patient is as a person by asking open-ended questions (U), and eliciting questions (E). In the trial, the family members in the intervention group had less depression, anxiety, and PTSD symptoms.",
"   </p>",
"   <p>",
"    Some of the benefits derived from family meetings may be related to the opportunity that they provide for family members to express their feelings and concerns about the patient and the effect of the patient's illness on the family. This is important because families are less likely to experience conflict if they feel that the care provided was respectful and focused on the physical and emotional needs of the patient and the family. If care planning is viewed by the family as being patient-focused and if the family feels that all the planning was a cooperative effort between the family and the providers, it is more likely that the family will come away with a sense of certainty in the decisions that they made [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such opportunities for expression should not have to wait until a family meeting. Communication between providers and the family should be a continual process. Less formal meetings with individual family members can occur more frequently to ensure that the family is kept informed about the patient's condition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     When is a meeting appropriate?",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally worthwhile to schedule an initial family meeting within the first 72 hours after admission. Early discussions appear to increase family satisfaction, reduce the length of ICU stay, and increase the likelihood of achieving consensus between the providers and the family about when care should be limited or withdrawn. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Family satisfaction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Scheduling family meetings should not be dictated solely by the need to make an important health care decision. Family meetings may also be of value in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the patient is first admitted to the ICU",
"     </li>",
"     <li>",
"      When there is a change in the patient's medical status",
"     </li>",
"     <li>",
"      When conflict is present among family members, between the patient and family, or between the family and providers",
"     </li>",
"     <li>",
"      When the health care team believes that the goals should be transitioned to palliative care",
"     </li>",
"     <li>",
"      When the family requests a meeting or providers believe a meeting would be helpful",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Who should be invited?",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a previously competent patient expressed prior wishes that certain people not be included, these wishes should be honored. In the absence of such restrictions, the meeting generally should be open to all family members. Invitations to certain family members when there is a family conflict may be viewed as taking sides and may decrease the ability of providers to serve as impartial patient advocates. Moreover, having all family members hear the same information decreases misunderstandings. At the very least, the legal decision-maker (if there is one) and all family members who have visited or called should be offered the opportunity to attend. Family members should also be asked if there are any friends or religious counselors they would like to attend the meeting.",
"   </p>",
"   <p>",
"    It is important to invite all relevant health care providers to the family meeting. Both the primary care clinician and the ICU attending should be present, if possible. The evidence suggests that bad news is better received when it is delivered by the primary care clinician, unless the specialist has a prior relationship with the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/51\">",
"     51",
"    </a>",
"    ]. It is unclear whether this applies in an ICU where the critical care attending is involved in the day-to-day care of the patient and typically has more expertise with the patient's illness. However, involving a primary care clinician who knows the family and the patient has been shown to increase family satisfaction in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The nurse caring for the patient should always be invited to the meeting, since nurses frequently establish a close relationship with the family. The nurse can also reinforce information to the family between meetings.",
"   </p>",
"   <p>",
"    A social worker may be a valuable addition to a family meeting. Social workers can be helpful with issues of family dynamics and individual coping mechanisms. Discussions between providers and the social worker prior to the meeting may help the providers better understand the family relationships and beliefs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Meeting before the family meeting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family conferences bring together a number of different health care providers. It is important for the providers to be on the same page before the meeting as conflicting information can confuse families and leave family members feeling that the health care professionals are not communicating with each other. One study found that perceiving information as conflicting was an independent predictor of family dissatisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may be useful for the health care team to have a meeting before the family conference to discuss and come to agreement on the major medical facts, the prognosis, and possible treatment plans. Data collected by the social worker, chaplain, or nurse regarding how the family perceives information, their coping mechanisms, and any specific communication styles can be discussed at this time. When there is a language barrier and a translator is needed, it can be helpful to meet with the translator before the conference to discuss the appropriate balance of interpretation and cultural brokering [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/53\">",
"     53",
"    </a>",
"    ]. This may reduce the likelihood of serious mistranslations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncertainty is common in ICU care, as are differences of opinion about prognosis and what should be done for the patient. However, the appearance of provider consensus at a family meeting is usually an important aspect of achieving family satisfaction and family consensus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, all providers should strive to reach a consensus position that can be communicated to the family. Any differences of opinion about prognosis or management that persist should be communicated in a balanced and straightforward manner that shows respect for all of the providers.",
"   </p>",
"   <p>",
"    Clinicians need to consider their own emotional reactions to the patient and the family prior to the family meeting. The evidence suggests that clinicians' unacknowledged fears of loss and death are a barrier to emotional engagement with patients facing death and nearly all providers are uncomfortable discussing death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The longer that a clinician knows a patient, the more likely it is that the clinician will be overly optimistic and the less likely it is that therapies will be forgone. Self-awareness of these feelings may be a helpful way to keep this discomfort from affecting the family meeting.",
"   </p>",
"   <p>",
"    Finally, a facilitator should be chosen prior to the family meeting. Continuity of care is important for family satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/57\">",
"     57",
"    </a>",
"    ]. For this reason, one should attempt to have the same provider serve as the facilitator if there is more than one family meeting. No studies have compared physician facilitators with other health care providers, but usually the primary care clinician or the ICU attending serves in this role. All measures should be taken to ensure that the meeting is not interrupted, such as adjusting pagers to vibrate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Where should the meeting be held?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The meeting should be held in a comfortable, private room. Tissues should be available. Seating should be arranged to allow all family members to sit in the front row. An effort should also be made to spread providers throughout the room rather than having the providers and family on opposite sides of the room. Providers should be seated during the conference as this creates the impression that one has time to talk and listen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Understanding the family",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family meetings are similar to one-on-one clinician-patient interactions in some respects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/51,58\">",
"     51,58",
"    </a>",
"    ]. Providers should avoid medical jargon and explain the patient's condition and medical treatments to the family in a simple, straightforward manner. Written leaflets, videos, or other tools can be an effective way to provide information. One study found that families given an informational brochure during their first visit to the ICU were more likely to understand the patient's prognosis than those who had not received such information [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/59\">",
"     59",
"    </a>",
"    ]. Audio taping the family meeting and giving the family the tape to listen to at home may also be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, family meetings also differ from clinician-patient interactions in some respects. First, there is a group dynamic that needs to be considered. Second, such conferences involve families, which are unique systems with their own rules of interaction and their own style of decision-making. A lot can be learned about the family system in advance of the meeting by talking to a social worker or a primary care clinician who knows the family. Paying careful attention to the family during the conference may also yield important clues about how the family interacts and the roles that particular family members play:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Note where family members sit. The person who sits closest to the clinician may be the informal family spokesperson. Family members who deliberately sit apart may harbor old grudges. How the family negotiates who stands and who sits if there are not enough seats may provide clues about the family hierarchy.",
"     </li>",
"     <li>",
"      Observe whether the family members talk about themselves, whether the conversation is respectful, and whether questions focus on a single topic. Notice who is involved in the conversation and who keeps talking when there are interruptions.",
"     </li>",
"     <li>",
"      Note whether the family is empathic or dismissive when a family member becomes emotional.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While insight into a family's dynamics can help providers understand family reactions, it is crucial that providers not try to correct what they believe are dysfunctional family dynamics. Similarly, providers should stay neutral in family disputes. The family dynamics predate the patient's illness and reflect lifelong patterns of interaction. While these interactions may seem dysfunctional to health care providers, they may serve useful functions within the family system that are not immediately apparent to those outside of the system [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/52\">",
"     52",
"    </a>",
"    ]. It is unlikely that a clinician who is meeting the family for the first time can influence these patterns of behavior, especially in such a stressful situation. Attempts to do so are likely to be viewed as intrusive, since the family did not request counseling. In the case of disputes, it is reasonable to say something like, \"I can see that you all have some disagreements on a number of issues. I wonder if you could put these aside for now, so that we could try to focus on what is going on with your mother.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Starting a meeting",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to introduce all of the providers and family members at the start of a family meeting. Introductions should include name, position, role, and the level of involvement in the patient's care. This is particularly important in teaching hospitals where it is hard to distinguish between medical students, residents, fellows, and attendings on the basis of dress or age. Knowing clinicians' roles correlates with family satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After making sure that everyone is comfortably seated and that all the relevant family members are at the meeting, the meeting's goals should be clarified. As an example, the facilitator might say on the first hospital day, \"I want to spend some time talking with all of you about how your dad is doing. I also wanted to make sure that you all understand what we are doing for him and what we will be watching for over the next couple of days. Are there any other things that you want to discuss?\" Providers should allow family members adequate time to speak during the meeting and not dominate the discussion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sharing clinical information",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is helpful to ask family members what they already know prior to explaining the patient's condition. Understanding the family's level of knowledge, emotional state, and degree of education allows for more efficient discussions. Sample questions that can be used to start a conversation include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"What have the other doctors told you is going on with your father?\"",
"     </li>",
"     <li>",
"      \"What do you think is going on with your mother?\"",
"     </li>",
"     <li>",
"      \"To make sure we are on the same page, can you tell me what your understanding of this disease is?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Clinical situation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step is to describe the situation to the family. It is essential for health care providers to have reviewed the medical record and test results prior to presenting information to the family.",
"   </p>",
"   <p>",
"    The types of information to be discussed generally include diagnosis, prognosis, and therapy. Such information will reduce uncertainty about what is happening or is likely to happen, increase the family's ability to act as the patient's surrogates in making decisions, and strengthen the relationship with the family [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/62\">",
"     62",
"    </a>",
"    ]. It is important that the provider ensure that the information is understood by the family. It is recommended that information be provided at a ninth grade level using as little jargon as possible. Providers should modify the way in which they are conveying information based upon a family's understanding and communication style. Given that family members are under stress, their ability to understand large chunks of information at one time is diminished. A rule of thumb is not to give more than three pieces of information without stopping and checking comprehension. Pictures often help convey information and increase understanding.",
"   </p>",
"   <p>",
"    Multiple short meetings may be better than one long meeting. At the first meeting, it may be enough to provide an idea of what is wrong with the patient and the plans for therapeutic interventions. The next meeting may focus on progress since the last meeting and prognosis. A following meeting might address the possibility of transitioning to palliative care if things are going badly. While some discussion of medical details may help reassure the family regarding the medical team's competency, detailed pathophysiologic information is unlikely to increase a family's understanding of the clinical situation. Long and detailed discussions regarding urine output, ventilator settings, and pressors may confuse the family or lead to a situation where they focus on details to the exclusion of the bigger picture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most families feel that clinicians are obligated to discuss prognosis and should not try to protect families from the truth. Such information helps families support the patient and prepare emotionally and logistically for the possibility of the patient's death. Most surrogates do not feel that prognostic information affects their ability to maintain hope [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Families occasionally do not want prognostic information, or they may desire more information than the patient wants. Unfortunately, there is no simple way to identify who wants information or how much. Experienced clinicians suggest asking how much information people want before giving information. One might say, \"I want to give you as much information as you want about the future, but not overwhelm you. Some people want to hear about what I think may happen, while others do not want this information. Which kind of person are you?\" It is important to check in with different family members if there is more than one person at the meeting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite its importance, many clinicians do not like discussing prognosis because they worry that it will decrease surrogates' hopefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/66\">",
"     66",
"    </a>",
"    ]. Discussion of prognosis is especially difficult in the ICU because of uncertainty and the rapidity with which the clinical situation can change. This may explain why prognosis for survival is not discussed in more than one-third of ICU family conferences about major end-of-life treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/67\">",
"     67",
"    </a>",
"    ]. Most prediction models focus on prognosis for survival, but discussing the patient's likely functional outcome if they do survive may be equally important [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Families tend to be more optimistic about prognosis than clinicians. This was demonstrated by two studies. In the first study of 169 surrogate decision-makers, one out of five surrogates estimated that the patient&rsquo;s prognosis was more than 20 percent more favorable than that estimated by the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/70\">",
"     70",
"    </a>",
"    ]. Concordance was equally bad whether the clinician used numeric or qualitative terms to describe the prognosis. A greater degree of discordance was associated with less trust in the clinician. In the second study, 88 percent of surrogate decision-makers doubted the clinician's ability to prognosticate accurately, although all of the surrogates still found the information valuable for informing decisions and preparing for poor outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/71\">",
"     71",
"    </a>",
"    ]. Other factors that may impact a family member&rsquo;s estimation of prognosis include their estimation of the patient&rsquo;s strength of character and life history [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The uncertainty that exists in describing prognosis is best dealt with by being open [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/73\">",
"     73",
"    </a>",
"    ]. Discussions of uncertainty need to accomplish three tasks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Explain that uncertainty exists",
"     </li>",
"     <li>",
"      Explain the factors that will help decrease the uncertainty",
"     </li>",
"     <li>",
"      Give an estimate of when more will be known about prognosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To deal with uncertainty early in the ICU course, one might say, \"Your father is very sick. As we discussed, we are doing everything we can to help his body recover from the infection. Unfortunately, this is not always enough. The next 48 hours are going to be really important regarding how he does. The kinds of things we are looking for are whether his blood pressure gets better, how his kidneys are doing, and whether he wakes up.\"",
"   </p>",
"   <p>",
"    It may also be helpful to discuss both the best and worst situations with the family. A phrase that may help the family look at both sides is, \"hoping for the best and preparing for the worst\" [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/74\">",
"     74",
"    </a>",
"    ]. This phrase emphasizes that the providers understand the family's hope that the patient will survive the hospitalization, while planting the seed that the patient may not survive. The importance of including negative predictions is supported by a study of 141 patients with advanced cancer who communicated with 51 oncologists [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/75\">",
"     75",
"    </a>",
"    ]. While optimistic statements of prognosis were common, only pessimistic statements were associated with an increased likelihood that patients would agree with their oncologist's estimated chance of cure. To ascertain the family's fears and concerns, it may be helpful to ask if family members have thought about what might be done if the patient does not improve. This conversation may also lead to a discussion of when it is appropriate to change the treatment to less aggressive care or to palliative care.",
"   </p>",
"   <p>",
"    Taking a minute at the end of the first meeting to foreshadow possible outcomes and normalize common reactions may help, especially since the rapidity with which a patient's status can change in the ICU is hard for families to comprehend (eg, \"But he was doing so well just this morning\"). An example might be, \"I have tried to describe to you what is likely to happen in the ICU. Unfortunately, when people are really sick, like your mom, things may change very rapidly. Your time here may well feel like a roller coaster. That is normal. It is why we try not to get too caught up in each and every lab test but try to see how your mom is doing overall. We will try to point out to you when the changes are something to worry about or when they are just bumps in the road that do not change her prognosis. We will get hold of you if there is an important change in her status.\"",
"   </p>",
"   <p>",
"    The literature stresses the importance of maintaining hope while remaining truthful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/76\">",
"     76",
"    </a>",
"    ]. The desired balance of hope and prognosis is variable, but can be balanced in a number of ways [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/77\">",
"     77",
"    </a>",
"    ]. First, while providing prognostic information, clinicians should acknowledge its limitations in individual cases. Second, even if one believes the family's goals are unrealistic, providers should acknowledge them and express their sorrow that they are unlikely to be fulfilled. Wish statements (eg, \"I wish I could tell you that your mom is going to pull through\") are a particularly powerful way to do this. Finally, providers can gently inquire about other goals. For most families, the initial hope is that the patient recovers and returns to his or her previous baseline. If this is not possible, families must be given time to understand and grieve the loss. Chaplains or other religious counselors may be particularly helpful in this process. The family can then turn to discussing what the patient's new goals might be. This might mean staying alive until all family can get into town, living until a fiftieth wedding anniversary, or dying in a dignified, peaceful manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Therapeutic plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical to describe what is going to be done to improve the patient's situation. Precise medical details are only important if they convince the family of the competence of the ICU team. It is more important that the family understands what the therapy means for the patient (eg, \"a tube needs to be placed in a large blood vessel to give your father blood\" or \"he is going on the kidney machine today to help out his kidneys, which are not working\"). Common complications can be mentioned with an offer to answer any other questions the family might have.",
"   </p>",
"   <p>",
"    The discussion should focus on what the family believes the patient's goals are, rather than asking the family to choose specific treatments. Clinicians have the technical expertise to determine the most efficacious way to achieve the patient's goals and should make recommendations about specific treatments that can achieve the patient's goals. As an example, there should be an explicit discussion about what will be done to keep the patient comfortable and what tradeoffs may exist between interventions that improve comfort and interventions that improve prognosis.",
"   </p>",
"   <p>",
"    How success or failure of the therapeutic plan will be measured should also be discussed. As an example, for a patient who is septic and requiring vasopressors, the following might be said to the family: \"The blood pressure is low because of the infection in his blood. We're giving him antibiotics to fight the infection and medicines to raise the blood pressure. If one more day passes and we are still unable to stop the medicines which are artificially raising the blood pressure, that will tell us that the antibiotics are not working. That would mean that this infection might not be treatable. Let's meet again tomorrow to see if we have been able to stop the blood pressure medicines.\" This is referred to as a time-limited trial and the various measures that are examined are termed clinical milestones [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/1,78\">",
"     1,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Families are generally reassured by knowing that a large team is caring for the patient and that the patient is receiving multiple therapies in the hopes of improvement. Explaining all of the therapies being undertaken is a subtle way of reinforcing the seriousness of the situation. Paradoxically, it is even more important to stress the team's efforts when you think the discussion should focus on end-of-life topics. Families of critically ill patients often worry about giving up too early. Emphasizing the efforts that were taken may reassure them that the health care team wants the patient to improve and is trying all reasonable interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     End-of-life issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family meetings are an opportunity to foreshadow end-of-life discussions, allowing family members to psychologically prepare themselves for bad news. End-of-life conversations tend to be less jarring for families when they occur during a family meeting because they appear to be part of the natural progression of dialogue about the course of an illness. In contrast, waiting to raise the notion of palliative care until there is nothing more to be done may seem cold or disheartening to families.",
"   </p>",
"   <p>",
"    When ICU interventions are unlikely to accomplish the patient's goals, it is appropriate to raise the issue of transitioning to palliative care. Family members of patients who die in the ICU report a higher quality of dying and death when the ICU team held a family conference and discussed the patient's wish to withdraw life support during that conference [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/79\">",
"     79",
"    </a>",
"    ]. Factors to be considered in making a decision to withdraw support are the patient's premorbid quality of life, the likelihood of survival, the likelihood of returning the patient to an acceptable post-ICU quality of life, and the pain and suffering that may result from ICU interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Such conversations frequently occur later in the patient's illness than may be appropriate, a belief that is supported by the observation that do-not-resuscitate (DNR) orders are typically written only three days before death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Discussion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Talking to surrogates about end-of-life issues raises unique concerns. Clinicians first need to operationalize the ethical principle underlying surrogate decision-making: family members should be guided by what they believe the patient would want if he or she could speak. This may be helpful to surrogates who feel as if they are being asked to make life and death decisions for their loved one. Rather than asking, \"What do you think we should do next?\" the clinician might say, \"If your dad was sitting here and could hear what we have said about his condition, what would he say?\" or \"What do you think your mom's opinion on this would be?\" Specific questions such as, \"Have you ever talked to your mom about what her wishes would be if she became critically ill?\" may also be helpful. Empirical evidence suggests that wording the question this way results in the family member being better able to predict what the patient would want [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Family members may find these questions difficult. A common response is, \"My dad would never have wanted to be like this, but I can't tell you to stop.\" This answer gives the providers two important pieces of information. First, one knows that the ethically appropriate treatment plan is the one that is consistent with the patient's goals. Second, the answer emphasizes that the family members feel like they are being asked to make a life and death decision, which makes them feel uncomfortable. In end-of-life decision-making, we believe it is important to take the decision-making burden away from the family by presenting a recommendation based upon a synthesis of the medical facts and the patient's values. Such value-centered recommendations have been incorporated into most guidelines for making decisions with families [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/84-86\">",
"     84-86",
"    </a>",
"    ], although there is conflicting evidence about whether such recommendations are preferred by families [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/28,87\">",
"     28,87",
"    </a>",
"    ]. Given the variability of decision-making preferences, negotiation of roles can be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible response to the above statement using a value-centered recommendation would be, \"I would never ask you to make the decision to stop. That is a horrible thing to ask a son to think about doing for his father. What I needed you to do was to tell me what your dad would have said so that I could tell you the best way to respect his goals and values. And you have done that.\" After determining that the patient would never want to be kept alive if he could not hunt and fish, one might say, \"Given these values, I think we should focus our goals on keeping your dad comfortable.\" At this point, keeping the patient comfortable should be described. Finally, one might say, \"If he gets sicker, I do not think we should put him on machines to prolong his dying process.\"",
"   </p>",
"   <p>",
"    It is important to ensure that decisions to forgo a particular treatment are not viewed as withdrawing care. Abandonment is a critical issue for dying patients and their families [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/89\">",
"     89",
"    </a>",
"    ]. Families need to be assured that the patient will receive appropriate, competent care regardless of the stage of his or her illness.",
"   </p>",
"   <p>",
"    Providers should pay attention to family dynamics throughout the process, since families typically make end-of-life decisions based on consensus even if there is a durable power of attorney. The legally appointed decision-maker still needs to get along with other family members after the patient dies. As result, providers need to ensure that all opinions can be voiced and discussed in family meetings. It also may be helpful to leave the room and let the family members talk among themselves, since they may not wish to disagree in front of a stranger.",
"   </p>",
"   <p>",
"    Family satisfaction with the care provided at the end of life is associated with the degree to which the decisions made were patient-centered and collaborative [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/30\">",
"     30",
"    </a>",
"    ]. While shared decision-making is generally favored and associated with increased satisfaction, it is uncommon. In one study, only 2 percent of decisions met all of the criteria for shared decision-making [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Types of statements from clinicians that are associated with family satisfaction include assurances that the patient will not be abandoned before death, assurances that the patient will be comfortable and will not suffer, and support for the family's decisions about end-of-life care, whether the decision was to withdraw or not withdraw life support [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are some phrases that might be helpful when discussing end-of-life issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"If your father were sitting here at the table, what would he say?\"",
"     </li>",
"     <li>",
"      \"Sometimes what you want is different from what your mother would want. I really respect your ability to focus on her wishes.\"",
"     </li>",
"     <li>",
"      \"I do not want you to feel like you are making medical decisions; that is my job. You can help greatly by telling me what your dad would have wanted if he were here.\"",
"     </li>",
"     <li>",
"      \"The goal of all this planning is so that you can stand as a family and have no regrets no matter what happens.\"",
"     </li>",
"     <li>",
"      \"I want you to be able to look back on this six months from now and be sure you did what your mom wanted.\"",
"     </li>",
"     <li>",
"      \"Your father went to some trouble to make sure we knew his views regarding this form of treatment. We need to respect this decision like we would anything else he told us to do.\"",
"     </li>",
"     <li>",
"      \"There are no more life and death decisions to be made, just type of death decisions.\"",
"     </li>",
"     <li>",
"      \"How are you doing? What can we do for you?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Family emotions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families may react to these difficult conversations in a number of ways. Psychophysiologic responses include the fight or flight response (leading some family members to need to get up and walk around) and the parasympathetic response (leading some family members to become quiet, numb, and withdrawn). One may also see a variety of emotional reactions to impending death, including sadness, anger, grief, guilt, fear, and anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of these reactions are normal. Launching into a biomedical discussion or providing false reassurance will convey to family members that providers are uncomfortable with their emotions. Supportive reactions include active listening and letting family members know that health care providers are present and can deal with their strong emotions. For the family members, knowing that someone understands what they are going through may be psychotherapeutic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two mnemonics have been developed that can guide clinicians during their interaction with surrogates and help manage the emotional impact of the interaction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NURSE describes how a clinician can be empathic when surrogates express strong emotions [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/94\">",
"       94",
"      </a>",
"      ]. Its components include naming (N), understanding (U), respecting (R), supporting (S), and exploring (E), as described in the table (",
"      <a class=\"graphic graphic_table graphicRef75046 \" href=\"UTD.htm?13/3/13371\">",
"       table 1",
"      </a>",
"      ). The use of more empathic statements has been associated with higher family satisfaction with communication [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      VALUE describes a communication system that can promote harmony between providers and surrogates. Its components include valuing and appreciating what surrogates communicate (V), acknowledging their emotions with reflective summary statements (A), listening carefully (L), understanding who the patient is as a person by asking open-ended questions (U), and eliciting questions (E) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/2,95\">",
"       2,95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Health care providers often miss opportunities to address family emotions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/96\">",
"     96",
"    </a>",
"    ]. In one study, clinicians did not make any empathic statements in one-third of family meetings [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/22\">",
"     22",
"    </a>",
"    ]. This appears to be especially problematic when clinicians are meeting with families with limited English proficiency. In meetings requiring a translator, clinicians made fewer supportive statements such as valuing the family&rsquo;s input, easing emotional burdens, and active listening [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/97\">",
"     97",
"    </a>",
"    ]. Some providers hesitate to address emotions because they fear that it will take too much time, but this concern may be unfounded. Studies of clinician-patient interactions show that addressing emotions shortens outpatient visits, reduces patient anxiety, and promotes satisfaction with the meeting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/22,98,99\">",
"     22,98,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Conflict",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicts between families and health care providers regarding end-of-life decisions are common. In one study, over one-third of clinicians reported conflicts with families, of which 63 percent involved decision-making at the end of life [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/100\">",
"     100",
"    </a>",
"    ]. In another study, 46 percent of families reported conflict with providers, most commonly regarding communication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/18\">",
"     18",
"    </a>",
"    ]. Conflict is also common between members of the clinical team [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When conflicts occur, clinicians may feel that their competence or judgment is not trusted. This may lead them to redouble their effort to convince the family that they are wrong, or they may begin to question the family's competence or intentions. Families may feel isolated, misunderstood, or abandoned. In addition, they may feel pressured to give up or they may doubt the health care team's commitment to the patient's well being. What should be a cooperative effort to achieve treatment goals can quickly turn into frustration and distress.",
"   </p>",
"   <p>",
"    A strategy for dealing with conflict is to attempt to understand why the family is choosing therapies that the providers believe are unlikely to work [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Approaching the problem as a differential diagnosis helps ensure that all of the possible explanations for the disagreement are carefully considered. A list of possible reasons why families may disagree with providers' recommendations and potential responses are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef73237 \" href=\"UTD.htm?2/57/2972\">",
"     table 2",
"    </a>",
"    ). It is also important to acknowledge the emotions that underlie the conflict. The underlying issue is often sadness or frustration over the patient's dying [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/78\">",
"     78",
"    </a>",
"    ]. Social work interventions to help address such issues improve decision-making in families that are at high risk for conflict [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another strategy is to use time-limited trials and clinical milestones, as discussed above. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Therapeutic plan'",
"    </a>",
"    above.) It is often easier to withdraw an intervention when certain criteria are not met if the family understands the criteria that the team uses to determine the success of an intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two issues that frequently underlie the conflict. First, families may need time to come to grips with end-of-life decisions. Family members are not familiar with the course of life-limiting illnesses and, early in the course of the illness, they may have been told to remain hopeful or that the ICU was where the patient was most likely to get better. Allowing a family a day or two to think about new information that they received may be enough for them to acknowledge a patient's terminal condition. A family may sometimes need to have small changes made over time, as illustrated by a study that found that withdrawal of all life-sustaining interventions took more than a day in over one-half of patients and that such stuttering withdrawal was associated with increased satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/40/12938/abstract/106\">",
"     106",
"    </a>",
"    ]. Second, having a family member in the ICU is stressful and this may interfere with decision-making. One way to build a relationship with family members is to acknowledge the stress that they are under and to offer to help. Many families live far from the hospital and it may be helpful if the social worker can arrange for closer accommodations or less expensive parking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Wrap up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to finishing up the family meeting, the major issues discussed should be summarized. If the discussion focused on giving news, summarize the major issues. Giving family members a written summary may increase their knowledge and understanding of what was emphasized within the meeting. Another option is to ask the family to summarize the conversation. This allows the providers to make sure that the family has heard the major points.",
"   </p>",
"   <p>",
"    The summary should focus both on consensus decisions and areas of disagreement. There should be a discussion about what will happen next. Always ask the family if they have questions, especially since it is likely that the family will forget many of the topics discussed.",
"   </p>",
"   <p>",
"    Finally, clinicians must ensure that there is an adequate follow-up plan. This includes a family spokesperson for less formal conversations who can then communicate with other family members (particularly for large families), a way for the family to contact the providers if questions or issues arise, and a clear plan regarding when the next family meeting will take place. The plan can be a time or the criteria that will guide the occurrence of a next meeting. Given the importance of continuity, family members should be informed if a follow-up meeting will not occur and should be given an explanation so that they do not feel abandoned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family meetings facilitate communication between health care providers and families of patients in the intensive care unit (ICU). Effective communication improves family satisfaction, clinical decision-making, and the psychological well being of family members. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Importance of communication'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Purpose of a meeting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is generally worthwhile to schedule an initial family meeting within the first 72 hours after admission. Scheduling family meetings should not be dictated solely by the need to make an important health care decision. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'When is a meeting appropriate?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a previously competent patient expressed prior wishes that certain people not be included, these wishes should be honored. In the absence of such restrictions, the meeting generally should be open to all family members. Family members should also be asked if there are any friends or religious counselors they would like to attend the meeting. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Who should be invited?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Family conferences may bring together a number of different providers. It may be useful for the providers to meet before the family conference so that conflicting information is not presented. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Meeting before the family meeting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All providers and family members should be introduced at the beginning of a family meeting. Family members should be asked what they already know about the patient's condition and then the clinical situation should be described. The types of information to be discussed generally include diagnosis, prognosis, and therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Starting a meeting'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Sharing clinical information'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Family meetings are an opportunity to foreshadow end-of-life discussions, allowing family members to psychologically prepare themselves for bad news. When ICU interventions are unlikely to accomplish the patient's goals, it is appropriate to discuss other goals that are achievable. These may include comfort, dignity, and family member peace with the decision-making process. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'End-of-life issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/1\">",
"      Lilly CM, De Meo DL, Sonna LA, et al. An intensive communication intervention for the critically ill. Am J Med 2000; 109:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/2\">",
"      Lautrette A, Darmon M, Megarbane B, et al. A communication strategy and brochure for relatives of patients dying in the ICU. N Engl J Med 2007; 356:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/3\">",
"      Curtis JR, Treece PD, Nielsen EL, et al. Integrating palliative and critical care: evaluation of a quality-improvement intervention. Am J Respir Crit Care Med 2008; 178:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/4\">",
"      Mosenthal AC, Murphy PA, Barker LK, et al. Changing the culture around end-of-life care in the trauma intensive care unit. J Trauma 2008; 64:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/5\">",
"      Rubenfeld GD, Curtis JR, End-of-Life Care in the ICU Working Group. End-of-life care in the intensive care unit: a research agenda. Crit Care Med 2001; 29:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/6\">",
"      Mularski RA, Curtis JR, Billings JA, et al. Proposed quality measures for palliative care in the critically ill: a consensus from the Robert Wood Johnson Foundation Critical Care Workgroup. Crit Care Med 2006; 34:S404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/7\">",
"      Nelson JE, Mulkerin CM, Adams LL, Pronovost PJ. Improving comfort and communication in the ICU: a practical new tool for palliative care performance measurement and feedback. Qual Saf Health Care 2006; 15:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/8\">",
"      Clarke EB, Curtis JR, Luce JM, et al. Quality indicators for end-of-life care in the intensive care unit. Crit Care Med 2003; 31:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/9\">",
"      Nelson JE, Puntillo KA, Pronovost PJ, et al. In their own words: patients and families define high-quality palliative care in the intensive care unit. Crit Care Med 2010; 38:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/10\">",
"      Curtis JR, Patrick DL, Shannon SE, et al. The family conference as a focus to improve communication about end-of-life care in the intensive care unit: opportunities for improvement. Crit Care Med 2001; 29:N26.",
"     </a>",
"    </li>",
"    <li>",
"     Managing Death in the ICU. The Transition from Cure to Comfort, Curtis JR, Rubenfeld GD (Eds), Oxford University Press, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/12\">",
"      Hickey M. What are the needs of families of critically ill patients? A review of the literature since 1976. Heart Lung 1990; 19:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/13\">",
"      Henrich NJ, Dodek P, Heyland D, et al. Qualitative analysis of an intensive care unit family satisfaction survey. Crit Care Med 2011; 39:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/14\">",
"      Leske JS. Overview of family needs after critical illness: from assessment to intervention. AACN Clin Issues Crit Care Nurs 1991; 2:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/15\">",
"      Phillips RS, Wenger NS, Teno J, et al. Choices of seriously ill patients about cardiopulmonary resuscitation: correlates and outcomes. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Am J Med 1996; 100:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/16\">",
"      Levy MM. End-of-life care in the intensive care unit: can we do better? Crit Care Med 2001; 29:N56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/17\">",
"      Hanson LC, Danis M, Garrett J. What is wrong with end-of-life care? Opinions of bereaved family members. J Am Geriatr Soc 1997; 45:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/18\">",
"      Abbott KH, Sago JG, Breen CM, et al. Families looking back: one year after discussion of withdrawal or withholding of life-sustaining support. Crit Care Med 2001; 29:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/19\">",
"      Baker R, Wu AW, Teno JM, et al. Family satisfaction with end-of-life care in seriously ill hospitalized adults. J Am Geriatr Soc 2000; 48:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/20\">",
"      Ahrens T, Yancey V, Kollef M. Improving family communications at the end of life: implications for length of stay in the intensive care unit and resource use. Am J Crit Care 2003; 12:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/21\">",
"      Azoulay E, Pochard F. Communication with family members of patients dying in the intensive care unit. Curr Opin Crit Care 2003; 9:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/22\">",
"      Selph RB, Shiang J, Engelberg R, et al. Empathy and life support decisions in intensive care units. J Gen Intern Med 2008; 23:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/23\">",
"      Pochard F, Azoulay E, Chevret S, et al. Symptoms of anxiety and depression in family members of intensive care unit patients: ethical hypothesis regarding decision-making capacity. Crit Care Med 2001; 29:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/24\">",
"      Curtis JR, Wenrich MD, Carline JD, et al. Understanding physicians' skills at providing end-of-life care perspectives of patients, families, and health care workers. J Gen Intern Med 2001; 16:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/25\">",
"      Heyland DK, Cook DJ, Rocker GM, et al. Decision-making in the ICU: perspectives of the substitute decision-maker. Intensive Care Med 2003; 29:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/26\">",
"      Wall RJ, Engelberg RA, Gries CJ, et al. Spiritual care of families in the intensive care unit. Crit Care Med 2007; 35:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/27\">",
"      McDonagh JR, Elliott TB, Engelberg RA, et al. Family satisfaction with family conferences about end-of-life care in the intensive care unit: increased proportion of family speech is associated with increased satisfaction. Crit Care Med 2004; 32:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/28\">",
"      Gries CJ, Curtis JR, Wall RJ, Engelberg RA. Family member satisfaction with end-of-life decision making in the ICU. Chest 2008; 133:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/29\">",
"      Stricker KH, Kimberger O, Schmidlin K, et al. Family satisfaction in the intensive care unit: what makes the difference? Intensive Care Med 2009; 35:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/30\">",
"      Kirchhoff KT, Song MK, Kehl K. Caring for the family of the critically ill patient. Crit Care Clin 2004; 20:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/31\">",
"      Azoulay E, Chevret S, Leleu G, et al. Half the families of intensive care unit patients experience inadequate communication with physicians. Crit Care Med 2000; 28:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/32\">",
"      Rodriguez RM, Navarrete E, Schwaber J, et al. A prospective study of primary surrogate decision makers' knowledge of intensive care. Crit Care Med 2008; 36:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/33\">",
"      Wall RJ, Curtis JR, Cooke CR, Engelberg RA. Family satisfaction in the ICU: differences between families of survivors and nonsurvivors. Chest 2007; 132:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/34\">",
"      Brock DW. What is the moral authority of family members to act as surrogates for incompetent patients? Milbank Q 1996; 74:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/35\">",
"      Levine C, Zuckerman C. Hands on/hands off: why health care professionals depend on families but keep them at arm's length. J Law Med Ethics 2000; 28:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/36\">",
"      Levine C, Zuckerman C. The trouble with families: toward an ethic of accommodation. Ann Intern Med 1999; 130:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/37\">",
"      Azoulay E, Pochard F, Kentish-Barnes N, et al. Risk of post-traumatic stress symptoms in family members of intensive care unit patients. Am J Respir Crit Care Med 2005; 171:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/38\">",
"      Anderson WG, Arnold RM, Angus DC, Bryce CL. Passive decision-making preference is associated with anxiety and depression in relatives of patients in the intensive care unit. J Crit Care 2009; 24:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/39\">",
"      Gries CJ, Engelberg RA, Kross EK, et al. Predictors of symptoms of posttraumatic stress and depression in family members after patient death in the ICU. Chest 2010; 137:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/40\">",
"      Kross EK, Engelberg RA, Gries CJ, et al. ICU care associated with symptoms of depression and posttraumatic stress disorder among family members of patients who die in the ICU. Chest 2011; 139:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/41\">",
"      Swigart V, Lidz C, Butterworth V, Arnold R. Letting go: family willingness to forgo life support. Heart Lung 1996; 25:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/42\">",
"      Lorin S, Rho L, Wisnivesky JP, Nierman DM. Improving medical student intensive care unit communication skills: a novel educational initiative using standardized family members. Crit Care Med 2006; 34:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/43\">",
"      Chipman JG, Beilman GJ, Schmitz CC, Seatter SC. Development and pilot testing of an OSCE for difficult conversations in surgical intensive care. J Surg Educ 2007; 64:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/44\">",
"      Back AL, Arnold RM, Baile WF, et al. Faculty development to change the paradigm of communication skills teaching in oncology. J Clin Oncol 2009; 27:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/45\">",
"      Schmitz CC, Chipman JG, Luxenberg MG, Beilman GJ. Professionalism and communication in the intensive care unit: reliability and validity of a simulated family conference. Simul Healthc 2008; 3:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/46\">",
"      Dowdy MD, Robertson C, Bander JA. A study of proactive ethics consultation for critically and terminally ill patients with extended lengths of stay. Crit Care Med 1998; 26:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/47\">",
"      Lilly CM, Sonna LA, Haley KJ, Massaro AF. Intensive communication: four-year follow-up from a clinical practice study. Crit Care Med 2003; 31:S394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/48\">",
"      Norton SA, Hogan LA, Holloway RG, et al. Proactive palliative care in the medical intensive care unit: effects on length of stay for selected high-risk patients. Crit Care Med 2007; 35:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/49\">",
"      Daly BJ, Douglas SL, O'Toole E, et al. Effectiveness trial of an intensive communication structure for families of long-stay ICU patients. Chest 2010; 138:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/50\">",
"      Forrow L, Arnold RM, Parker LS. Preventive ethics: expanding the horizons of clinical ethics. J Clin Ethics 1993; 4:287.",
"     </a>",
"    </li>",
"    <li>",
"     Fischer GS, Tulsky JA, Arnold RM. Communicating a Poor Prognosis. In: Topics in Palliative Care, Portenoy R, Bruera E (Eds), Oxford University Press, New York 2000. Vol 5, p.75.",
"    </li>",
"    <li>",
"     Bowen M. Family Therapy in Clinical Practice, Aronson Publications, New Jersey 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/53\">",
"      Norris WM, Wenrich MD, Nielsen EL, et al. Communication about end-of-life care between language-discordant patients and clinicians: insights from medical interpreters. J Palliat Med 2005; 8:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/54\">",
"      Pham K, Thornton JD, Engelberg RA, et al. Alterations during medical interpretation of ICU family conferences that interfere with or enhance communication. Chest 2008; 134:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/55\">",
"      Curtis JR. Communicating about end-of-life care with patients and families in the intensive care unit. Crit Care Clin 2004; 20:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/56\">",
"      Kvale J, Berg L, Groff JY, Lange G. Factors associated with residents' attitudes toward dying patients. Fam Med 1999; 31:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/57\">",
"      Johnson D, Wilson M, Cavanaugh B, et al. Measuring the ability to meet family needs in an intensive care unit. Crit Care Med 1998; 26:266.",
"     </a>",
"    </li>",
"    <li>",
"     Lipkin M, Putnam S, Lazare A. The medical interview, Springer-Verlag, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/59\">",
"      Azoulay E, Pochard F, Chevret S, et al. Impact of a family information leaflet on effectiveness of information provided to family members of intensive care unit patients: a multicenter, prospective, randomized, controlled trial. Am J Respir Crit Care Med 2002; 165:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/60\">",
"      Butow PN, Dunn SM, Tattersall MH, Jones QJ. Patient participation in the cancer consultation: evaluation of a question prompt sheet. Ann Oncol 1994; 5:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/61\">",
"      Tattersall MH, Butow PN, Griffin AM, Dunn SM. The take-home message: patients prefer consultation audiotapes to summary letters. J Clin Oncol 1994; 12:1305.",
"     </a>",
"    </li>",
"    <li>",
"     Cassell EJ. Talking with patients: The theory of doctor-patient communication and Clinical Technique, The MIT Press, Cambridge 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/63\">",
"      Apatira L, Boyd EA, Malvar G, et al. Hope, truth, and preparing for death: perspectives of surrogate decision makers. Ann Intern Med 2008; 149:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/64\">",
"      Back AL, Arnold RM. Discussing prognosis: \"how much do you want to know?\" talking to patients who are prepared for explicit information. J Clin Oncol 2006; 24:4209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/65\">",
"      Back AL, Arnold RM. Discussing prognosis: \"how much do you want to know?\" talking to patients who do not want information or who are ambivalent. J Clin Oncol 2006; 24:4214.",
"     </a>",
"    </li>",
"    <li>",
"     Christakis NA. Death foretold: prophecy and prognosis in medical care, The University of Chicago Press, Chicago 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/67\">",
"      White DB, Engelberg RA, Wenrich MD, et al. Prognostication during physician-family discussions about limiting life support in intensive care units. Crit Care Med 2007; 35:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/68\">",
"      Lloyd CB, Nietert PJ, Silvestri GA. Intensive care decision making in the seriously ill and elderly. Crit Care Med 2004; 32:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/69\">",
"      Douglas SL, Daly BJ, Lipson AR. Neglect of quality-of-life considerations in intensive care unit family meetings for long-stay intensive care unit patients. Crit Care Med 2012; 40:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/70\">",
"      Lee Char SJ, Evans LR, Malvar GL, White DB. A randomized trial of two methods to disclose prognosis to surrogate decision makers in intensive care units. Am J Respir Crit Care Med 2010; 182:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/71\">",
"      Zier LS, Burack JH, Micco G, et al. Doubt and belief in physicians' ability to prognosticate during critical illness: the perspective of surrogate decision makers. Crit Care Med 2008; 36:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/72\">",
"      Boyd EA, Lo B, Evans LR, et al. \"It's not just what the doctor tells me:\" factors that influence surrogate decision-makers' perceptions of prognosis. Crit Care Med 2010; 38:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/73\">",
"      Evans LR, Boyd EA, Malvar G, et al. Surrogate decision-makers' perspectives on discussing prognosis in the face of uncertainty. Am J Respir Crit Care Med 2009; 179:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/74\">",
"      Back AL, Arnold RM, Quill TE. Hope for the best, and prepare for the worst. Ann Intern Med 2003; 138:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/75\">",
"      Robinson TM, Alexander SC, Hays M, et al. Patient-oncologist communication in advanced cancer: predictors of patient perception of prognosis. Support Care Cancer 2008; 16:1049.",
"     </a>",
"    </li>",
"    <li>",
"     Back AL, Arnold RM, Tulsky JA. Mastering communication with seriously ill patients: Balancing honesty with empathy and hope, Cambridge University Press, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/77\">",
"      Curtis JR, Engelberg R, Young JP, et al. An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer. J Palliat Med 2008; 11:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/78\">",
"      Back AL, Arnold RM. Dealing with conflict in caring for the seriously ill: \"it was just out of the question\". JAMA 2005; 293:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/79\">",
"      Glavan BJ, Engelberg RA, Downey L, Curtis JR. Using the medical record to evaluate the quality of end-of-life care in the intensive care unit. Crit Care Med 2008; 36:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/80\">",
"      Tomlinson T, Brody H. Ethics and communication in do-not-resuscitate orders. N Engl J Med 1988; 318:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/81\">",
"      Quill TE. Perspectives on care at the close of life. Initiating end-of-life discussions with seriously ill patients: addressing the \"elephant in the room\". JAMA 2000; 284:2502.",
"     </a>",
"    </li>",
"    <li>",
"     Buchanan AE, Brock DW. Deciding for others, Cambridge University Press, Cambridge 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/83\">",
"      Tomlinson T, Howe K, Notman M, Rossmiller D. An empirical study of proxy consent for elderly persons. Gerontologist 1990; 30:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/84\">",
"      Quill TE, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med 1996; 125:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/85\">",
"      Weissman DE. Decision making at a time of crisis near the end of life. JAMA 2004; 292:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/86\">",
"      Rabow MW, Hauser JM, Adams J. Supporting family caregivers at the end of life: \"they don't know what they don't know\". JAMA 2004; 291:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/87\">",
"      White DB, Evans LR, Bautista CA, et al. Are physicians' recommendations to limit life support beneficial or burdensome? Bringing empirical data to the debate. Am J Respir Crit Care Med 2009; 180:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/88\">",
"      White DB, Malvar G, Karr J, et al. Expanding the paradigm of the physician's role in surrogate decision-making: an empirically derived framework. Crit Care Med 2010; 38:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/89\">",
"      Quill TE, Cassel CK. Nonabandonment: a central obligation for physicians. Ann Intern Med 1995; 122:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/90\">",
"      White DB, Braddock CH 3rd, Bereknyei S, Curtis JR. Toward shared decision making at the end of life in intensive care units: opportunities for improvement. Arch Intern Med 2007; 167:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/91\">",
"      Stapleton RD, Engelberg RA, Wenrich MD, et al. Clinician statements and family satisfaction with family conferences in the intensive care unit. Crit Care Med 2006; 34:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/92\">",
"      McAdam JL, Dracup KA, White DB, et al. Symptom experiences of family members of intensive care unit patients at high risk for dying. Crit Care Med 2010; 38:1078.",
"     </a>",
"    </li>",
"    <li>",
"     Soelle D. Suffering, Fotress Press, Philadelphia 1975.",
"    </li>",
"    <li>",
"     Smith RC. The Patient's Story: Integrated patient-doctor interviewing, Lippincott-Raven, Boston 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/95\">",
"      Lilly CM, Daly BJ. The healing power of listening in the ICU. N Engl J Med 2007; 356:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/96\">",
"      Curtis JR, Engelberg RA, Wenrich MD, et al. Missed opportunities during family conferences about end-of-life care in the intensive care unit. Am J Respir Crit Care Med 2005; 171:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/97\">",
"      Thornton JD, Pham K, Engelberg RA, et al. Families with limited English proficiency receive less information and support in interpreted intensive care unit family conferences. Crit Care Med 2009; 37:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/98\">",
"      Levinson W, Gorawara-Bhat R, Lamb J. A study of patient clues and physician responses in primary care and surgical settings. JAMA 2000; 284:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/99\">",
"      Fogarty LA, Curbow BA, Wingard JR, et al. Can 40 seconds of compassion reduce patient anxiety? J Clin Oncol 1999; 17:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/100\">",
"      Breen CM, Abernethy AP, Abbott KH, Tulsky JA. Conflict associated with decisions to limit life-sustaining treatment in intensive care units. J Gen Intern Med 2001; 16:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/101\">",
"      Azoulay E, Timsit JF, Sprung CL, et al. Prevalence and factors of intensive care unit conflicts: the conflicus study. Am J Respir Crit Care Med 2009; 180:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/102\">",
"      Goold SD, Williams B, Arnold RM. Conflicts regarding decisions to limit treatment: a differential diagnosis. JAMA 2000; 283:909.",
"     </a>",
"    </li>",
"    <li>",
"     Stone D, Patton B, Heen S. Difficult conversations: how to discuss what matters most, Penguin Group, New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/104\">",
"      Zier LS, Burack JH, Micco G, et al. Surrogate decision makers' responses to physicians' predictions of medical futility. Chest 2009; 136:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/105\">",
"      Burns JP, Mello MM, Studdert DM, et al. Results of a clinical trial on care improvement for the critically ill. Crit Care Med 2003; 31:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/40/12938/abstract/106\">",
"      Gerstel E, Engelberg RA, Koepsell T, Curtis JR. Duration of withdrawal of life support in the intensive care unit and association with family satisfaction. Am J Respir Crit Care Med 2008; 178:798.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1643 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12938=[""].join("\n");
var outline_f12_40_12938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPORTANCE OF COMMUNICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Family satisfaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Decision-making",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Psychological impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THE FAMILY MEETING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Purpose of a meeting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      When is a meeting appropriate?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Who should be invited?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Meeting before the family meeting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Where should the meeting be held?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Understanding the family",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Starting a meeting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sharing clinical information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Clinical situation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Therapeutic plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      End-of-life issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Discussion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Family emotions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Conflict",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Wrap up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/3/13371\" title=\"table 1\">",
"      NURSE acronym",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/57/2972\" title=\"table 2\">",
"      Diff dx disagreements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/60/26565?source=related_link\">",
"      Ethics in the intensive care unit: Informed consent",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_40_12939="OI prophylaxis in AIDS";
var content_f12_40_12939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prophylaxis against opportunistic infections in patients with AIDS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Infection",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preferred drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Indications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pneumocystis carinii pneumonia",
"      </td>",
"      <td>",
"       Trimethoprim-sulfamethoxazole (double-strength tablet daily)",
"      </td>",
"      <td>",
"       CD4 count &lt;200 cells/microL; thrush; unexplained fever for more than two weeks; history of PCP",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Toxoplasmosis",
"      </td>",
"      <td>",
"       Trimethoprim-sulfamethoxazole (double-strength tablet daily)",
"      </td>",
"      <td>",
"       CD4 count &lt;100 cells/microL and Toxoplasma sero-positive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterium avium complex",
"      </td>",
"      <td>",
"       Azithromycin (1200 mg weekly)",
"      </td>",
"      <td>",
"       CD4 count &lt;50 cells/microL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Histoplasmosis",
"      </td>",
"      <td>",
"       Itraconazole (200 mg daily)",
"      </td>",
"      <td>",
"       CD4 count &lt;100 cells/microL and lives in an endemic area",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12939=[""].join("\n");
var outline_f12_40_12939=null;
var title_f12_40_12940="Association of CVS migraines";
var content_f12_40_12940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Profile of symptoms in cyclic vomiting syndrome, abdominal migraine, and migraine headaches",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Percentage of patients with symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        CVS",
"       </td>",
"       <td class=\"subtitle2\">",
"        Abdominal migraine",
"       </td>",
"       <td class=\"subtitle2\">",
"        Migraine headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Core symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vomiting",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        39 to 72",
"       </td>",
"       <td>",
"        40 to 69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal pain",
"       </td>",
"       <td>",
"        3 to 81",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        10 to 55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Headache",
"       </td>",
"       <td>",
"        38 to 59",
"       </td>",
"       <td>",
"        31 to 50",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Associated symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lethargy",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pallor",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        90 to 100",
"       </td>",
"       <td>",
"        23 to 88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anorexia",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        91 to 98",
"       </td>",
"       <td>",
"        13 to 93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nausea",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        73 to 91",
"       </td>",
"       <td>",
"        46 to 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Photophobia",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        1 to 42",
"       </td>",
"       <td>",
"        27 to 81",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Li BU, Balint JP. Cyclic vomiting syndrome: Evolution in understanding of a brain-gut disorder. Adv Pediatr 2000; 47:117.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12940=[""].join("\n");
var outline_f12_40_12940=null;
var title_f12_40_12941="Causes of back pain in children";
var content_f12_40_12941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of back pain in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Musculoskeletal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nonspecific musculoskeletal back pain",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Spondylolysis/spondylolisthesis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Scoliosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Scheuermann disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Disc degeneration and/or prolapse",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Other:",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Intervertebral disc calcification",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Congenital absence of pedicle",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Vertebral apophyseal fracture",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Aneurysmal bone cyst",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Sacroiliac joint stress reaction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Idiopathic juvenile osteoporosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Infectious",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Discitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vertebral osteomyelitis, including tuberculosis (Pott disease)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Epidural abscess",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sacroiliac joint infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Nonspinal infection:",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Paraspinous muscle abscess",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Pyelonephritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Pneumonia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Pelvic inflammatory disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Endocarditis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Viral myalgias",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Inflammatory",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ankylosing spondylitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Psoriatic arthritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          IBD-associated arthritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Reactive arthritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neoplastic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Osteoid osteoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Leukemia or lymphoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Solid malignancy, primary or metastatic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Other benign tumor:",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Neurofibroma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Vascular malformation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Other",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Appendicitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sickle cell pain crisis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Syringomyelia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cholecystitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pancreatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chronic recurrent multifocal osteomyelitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Psychosomatic illness",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nephrolithiasis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ureteropelvic junction obstruction",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IBD: Inflammatory bowel disease.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12941=[""].join("\n");
var outline_f12_40_12941=null;
var title_f12_40_12942="Carboplatin plus pemetrexed for non-small cell lung cancer";
var content_f12_40_12942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Carboplatin plus pemetrexed for non-small cell lung cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: Every 21 days for a maximum of four cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Carboplatin",
"        </strong>",
"       </td>",
"       <td>",
"        AUC* = 5 mg/mL x min IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS)",
"        <sup>",
"         &Delta;",
"        </sup>",
"        and administer over 30 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pemetrexed",
"        </strong>",
"       </td>",
"       <td>",
"        500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 100 mL NS and administer over 10 minutes. Do not administer with calcium-containing IV fluids such as Lactated Ringer's solution.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for skin rashes:",
"        </strong>",
"        Premedication with dexamethasone (4 mg orally twice daily for three days starting the day before drug administration) is recommended to reduce cutaneous toxicity",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Carboplatin is an irritant. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infectious prophylaxis:",
"        </strong>",
"        The incidence of neutropenic infections was 8 percent but may be higher in patients 75 years of age and older",
"        <sup>",
"         [1]",
"        </sup>",
"        . The decision to use primary prophylaxis with a hematopoietic growth factor should be individualized according to current guidelines. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Avoid use of pemetrexed if creatinine clearance is &lt;45 mL/min. Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula*. There are recommendations for avoidance of NSAIDs in the days prior to and immediately following each dose of pemetrexed in patients with mild to moderate renal dysfunction (CrCl 45 to 79 mL/min) because of the potential for decreased clearance of pemetrexed. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", and \"Pemetrexed: Drug information\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vitamin supplementation:",
"        </strong>",
"        Vitamin supplementation with folic acid and B12 is recommended prior to administration of pemetrexed and during treatment to reduce both hematologic and nonhematologic side effects",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count before each treatment and once midcycle between days 10 to 14.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Electrolytes, renal, and liver function before each cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity",
"        <sup>",
"         &loz;",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Chemotherapy should be delayed for one week if the ANC is &lt;1000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and/or the platelet count is &lt;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        prior to the start of each cycle. Doses for subsequent cycles are reduced by 25 percent if the ANC is 1000 to 1499 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets are 75,000 to 99,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        on day 22 after the preceding cycle, or if the nadir ANC was &lt;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        . A 50 percent dose reduction should be considered if the platelet nadir is less than 50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . Consider discontinuing therapy if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days. Dose reductions should be maintained for subsequent cycles",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Nonhematologic toxicity",
"         <sup>",
"          &sect;",
"         </sup>",
"         :",
"        </strong>",
"        Creatinine clearance should be &ge;45 mL/min, and grade 3 and 4 toxicities should be resolved prior to beginning therapy. A delay in therapy by one week should be considered if toxicities are not resolved or the creatinine clearance &le;45 mL/min. It is recommended that subsequent cycles be dose reduced by 25 percent if the patient has grade 3 or 4 toxicity (excluding grade 3 or 4 mucositis, for which a 50 percent dose reduction is warranted) and discontinued if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days. Dose reductions should be maintained for subsequent cycles",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; NSAIDs: nonsteroidal anti-inflammatory drugs; CrCl: creatinine clearance; CBC: complete blood count; ANC: absolute neutrophil count; GFR: glomerular filtration rate.",
"     <br/>",
"     * AUC (area under the concentration X time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) x (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"     <br/>",
"     &Delta; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Dose adjustments in the study may differ slightly from that recommended by the manufacturer. The manufacturer's recommendations can be found in the FDA approved package insert",
"     <sup>",
"      [2,3]",
"     </sup>",
"     .",
"     <br/>",
"     &sect; Toxicity was graded using the Common Terminology Criteria of Adverse Events version 3.0.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Gronberg BH, et al. J Clin Oncol. 2009; 27:3217.",
"      </li>",
"      <li>",
"       Alimta (pemetrexed disodium) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).",
"      </li>",
"      <li>",
"       Carboplatin injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 9, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12942=[""].join("\n");
var outline_f12_40_12942=null;
var title_f12_40_12943="Neuropathy and glycemic control I";
var content_f12_40_12943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70914%7ENEURO%2F50952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70914%7ENEURO%2F50952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glycemic control prevents diabetic neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 274px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence of the development of clinically evident diabetic neuropathy at five years in patients with type 1 diabetes treated with conventional or intensive insulin therapy. Glycemic control was beneficial in both the primary prevention (no retinopathy) and secondary intervention (background retinopathy) cohorts. Patients with confirmed clinical neuropathy at baseline were excluded from the study. This comprised 3.5 percent of patients in the primary prevention cohort and 9.4 percent in the secondary intervention cohort.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Diabetes Control and Complications Research Group, N Engl J Med 1993; 329:977.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glycemic control prevents diabetic neuropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 285px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prevalence of clinically evident diabetic neuropathy (abnormal neurologic examination), abnormal autonomic function, or abnormal nerve conduction in patients with type 1 diabetes who had no neuropathy at baseline and who received either intensive or conventional therapy for five years. Patients treated with intensive insulin had a lower rate of development of neuropathy by all three evaluations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Diabetes Control and Complications Trial Research Group, N Engl J Med 1993; 329:977.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_40_12943=[""].join("\n");
var outline_f12_40_12943=null;
